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ABSTRACT 
Adoptive cell transfer (ACT) using T cell receptor (TCR) gene-modified T cells is an 
exciting and rapidly evolving field. Numerous basic science and clinical studies have 
demonstrated various levels of feasibility, safety, and efficacy using TCR-engineered T 
cells to treat cancer and viral infections. Although evidence suggests their use can be 
effective, how effective and how to improve these therapeutics are still remaining 
questions.  
Because TCR affinity is thought to play the central role in defining T cell 
specificity and sensitivity, the field has adopted the theory that creating affinity-
enhanced TCRs creates better functioning T cells; but, enhanced affinity creates the 
opportunity for cross-reactivity. TCR cross-reactivity against off-tumor/on-target or off-
target antigens has caused serious adverse events, including death, in recent clinical 
trials using high affinity TCR-engineered T cells. However, the use cross-reactive TCRs 
could offer therapeutic benefit for diseases where targeted antigens are susceptible to 
mutation via genomic instability.  
The proper choice and design of therapeutic TCRs mandate a broader 
understanding of the basic principles governing antigen recognition by a T cell. In light of 
what is known about TCRs and T cell function, numerous factors still need to be 
addressed. These include: (1) what kinetic or cellular parameters are most important in 
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facilitating antigen recognition; (2) how is T cell function affected by alterations in TCR- 
peptide-major histocompatibility complex (pMHC) interactions; (3) how can we 
structurally rationalize the cross-reactivity of a TCR; and (4) how might the cross-
reactivity of a TCR augment or inhibit therapeutic efficacy.  These biologic questions 
addressed in this dissertation utilize traditional and novel approaches to characterize 
TCR gene-modified T cells harboring an HLA-A2-restricted TCR cross-reactive against 
naturally occurring mutant HCV NS3:1406-1415 epitopes, serving as a model to study 
antigen recognition. 
Overall, contrary to what is generally accepted in the field, we found that TCR-
pMHC affinity is not necessarily the most important factor dictating antigen recognition. 
Other cellular parameters, including ligand density, TCR density, and co-receptor 
signaling greatly influenced recognition of altered pMHC ligands. Modifying any of these 
parameters changed functional responses, sometimes independent of affinity. 
Additionally, we found that the field’s interpretation of antigen recognition may be 
narrowed and misguided when evaluation of T cell function is limited to a single 
cytokine. Functional phenotypes by seven-parameter flow cytometry revealed that T cell 
functional profiles are more complex than were previously believed. Evaluation of a 
single functional phenotype, such as IFNγ, did not accurately reflect the functional 
behavior of a T cell culture.  Combining functional studies with structural analysis of the 
TCR-pMHC interface helps bring clarity to these unexpected results.  
In summary, we have established a new working model highlighting the 
previously unappreciated and complex relationship between kinetic, cellular, and 
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structural parameters governing antigen recognition and T cell function. Together, our 
data suggest the field is oversimplifying the biology of T cells and the fundamentals of 
antigen recognition. This enhanced understanding will not only help steer rational, 
structure-guided design of TCRs to generate better functioning T cells for ACT, but will 
also impact the way in which we study other immune cell and receptor types, approach 
epitope discovery, and evaluate vaccine design. In this way, we have provided a new 
foundation in which to evaluate the design and implementation of novel 
immunotherapies.  
 
 
 
 
1 
CHAPTER ONE  
REVIEW OF LITERATURE 
Introduction 
 Immunotherapy is one of the most promising and innovative approaches to treat 
cancer, viral infections, and other immune-modulated diseases. Adoptive 
immunotherapy using gene-modified T cells is an exciting and rapidly evolving field.  
Exploiting knowledge of basic T cell biology and immune cell receptors has fostered 
innovative approaches to modify immune cell function. Novel and more efficient 
technologies have been developed to redirect T cell specificity by introducing designed 
receptors. The ability to engineer T cells to manifest desired phenotypes and functions is 
now a thrilling reality. 
 TCR-transduced T cells offer the ability to target a wide variety of self and 
nonself targets through the normal biology of a T cell. But to produce an optimally 
functioning gene-modified T cell, a firm understanding of the basic principles governing 
antigen recognition is required. Yet, many diseases targeted by such immunotherapies 
are genetically unstable, leading to immune escape. Investigation into how a T cell might 
be limited by changes in its target, affecting therapeutic efficacy, is also essential.  
A potential solution to immune escape by antigen mutation is the use of cross-
reactive TCRs given their ability to recognize a spectrum of related antigens. But the 
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potential for unwanted off-target reactivity, leading to adverse events in the clinic, 
warrants a closer examination into what factors govern T cell specificity. Conventionally, 
antigen recognition is thought to be dictated by the affinity between the TCR-pMHC 
interaction [1], but recent evidence suggests traditionally measured affinity interactions 
may not fully explain the complex relationship between T cell specificity and T cell 
reactivity [2]. Furthermore, current strategies used to randomly enhance the affinity of 
TCRs, hoping to improve their therapeutic efficacy [3, 4], may be too blinded. Thus, a 
greater understanding of antigen recognition by TCR-gene modified T cells may help lay 
the groundwork for more optimal therapeutic strategies.  
The studies discussed in this dissertation explore structure-function relationships 
between a T cell receptor (TCR) and its peptide major histocompatibility complex 
(pMHC) ligand using hepatitis C virus (HCV) mutant epitopes as a model for genomic 
instability. A more complete appreciation of how altered TCR-pMHC affinity influences 
antigen recognition in light of genomic instability may aid in the rational design of TCRs 
for safer and more effective TCR-based immunotherapies. 
TCR-Mediated Antigen Recognition 
T cells play a central role in mediating cellular immunity.  These multi-functional 
effector cells protect us from disease throughout our entire lives with their ability to 
recognize bacterial, viral, and cancer-associated antigens. The specificity of a T cell is 
mediated by the TCR, a cell surface heterodimer that facilitates target cell recognition 
[5].  There are two types of T cells, which can be distinguished by the TCRs expressed on 
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their surface. αβ T cells express a highly variable αβTCR whereas γδ T cells express a 
highly conserved γδTCR [6, 7]. TCRs mediate recognition of foreign or self-peptides 
bound to MHC molecule displayed by other cells [8-13].  This interaction between the 
TCR and its pMHC ligand plays a crucial role in determining the specificity and reactivity 
of an individual T cell. For the purpose of these studies, we will focus on αβ T cells/TCRs. 
Cell surface expression of the TCR requires its association with the CD3 complex 
[14-19]. Upon TCR-pMHC engagement, a cascade begins with the initiation of a series of 
signaling events starting with the phosphorylation of ITAM’s on the CD3 ζ chain, leading 
to full T cell activation and function [20]. The CD4 and CD8 co-receptors play a critical 
role in T cell activation and function by enhancing the binding of the TCR to the pMHC 
[21-24] and promoting the signaling by localizing lck to the TCR/CD3 complex [21, 25, 
26] (Fig. 1).  Consequently, a specific TCR-pMHC interaction (thought to be primarily 
driven by affinity) translates into a signaling cascade to facilitate functional recognition 
of the presence of pathogens or transformed cells. This complex process ultimately 
leads to target cell killing, or the secretion of pro-inflammatory cytokines that recruit 
and support other immune effectors, described in a later section. There are many 
important factors involved in antigen recognition and T cell function which should be  
thoroughly evaluated when considering how to generate the most effective anti-tumor 
T cells by introducing a foreign TCR. 
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Figure 1. TCR-mediated target cell recognition. Depicted is the structure of an MHC 
class I-restricted TCR interacting with a tumor or virus-infected cell. TCR α and β chains 
are specific to both MHC and presented antigenic peptide. The TCR complexes with 
various CD3 components on the cell surface, and the CD8 co-receptor stabilizes the TCR-
pMHC interaction while recruiting lck to facilitate TCR signaling. ITAMs are denoted as 
colored octagons. Lck = lymphocyte-specific protein tyrosine kinase; ZAP70 = zeta-chain-
associated protein kinase 70; P=phosphate group; Black arrows=downstream signaling. 
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TCR Diversity 
All higher vertebrates maintain a large and diverse repertoire of T cells capable 
of recognizing most of the pathogens we will ever encounter.  This tremendous diversity 
is due to the extreme variability of the TCR expressed by each T cell.  Each TCR chain 
consists of a variable (V) gene segment, a joining (J) region, a diversity (D) region in the β 
chain only, and a constant (C) region [27].  In the thymus, the different TCR α and β 
chains are generated randomly by germline rearrangements which bring together one 
of many Vα genes with one of many Jα regions for the TCRα chain or one of many Vβ 
genes, one of the two Dβ regions, and one of the thirteen Jβ regions for the TCRβ chain 
[28, 29]. The numerous arrangements of elements in each TCR chain together with the 
combinations of α and β chain pairing contribute to some of the TCR diversity observed 
in nature [7].  However, the majority of the diversity in TCRs expressed by mature T cell 
results from the addition and deletion of bases at the Vα-Jα, Vβ-Dβ, and, Dβ-Jβ junctions 
(known as N-region substitutions) which occurs during TCR gene rearrangement [7].  
This hypervariable region of the TCR α chain or TCR β chain is the third complementarity 
determining region (CDR3).  The TCR α and β chain CDR3s are considered to be the most 
important regions of the TCR for antigen recognition due to their length and sequence 
diversity. This combinatorial rearrangement of the TCR gene segments combined with 
N-region substitutions provides a theoretical estimate for 1015 different αβ TCRs in the T 
cell repertoire [27]. 
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The random TCR rearrangements that lead to such a large potential TCR 
repertoire suggests we should have T cell immunity against most pathogenic peptides 
presented by MHC as well as self and nonself peptides presented by allo-MHC.  Positive 
selection enables developing thymocytes expressing TCRs capable of binding 
antigen/self-MHC molecules in the thymus with the “correct” affinity to be protected 
from programmed cell death (positive selection). These positively selected T cells then 
complete T cell development resulting in a pool of mature T cells restricted only by self-
MHC. In contrast, thymocytes expressing TCRs whose affinity for the host pMHC is too 
low (death by neglect) or too high (negative selection) are not protected from 
programmed cell death and do not complete T cell development, eliminating them from 
the pool of mature T cells [30].  The net effect of thymic selection is to save 
“immunologic space” for T cells that are beneficial to the host by eliminating T cells that 
are not self-MHC restricted and those that have the potential for autoimmunity.  These 
are important factors to consider for TCR gene transfer studies given that most human 
tumor reactive T cells recognize normal, non-mutated self-antigens [31-33].  
Given the extreme TCR diversity, two critical questions initially raised by the field 
are: (1) do we have a choice in TCRs that target a single pMHC, and (2) if we have a 
choice, does it matter which TCR we select to use for a given target.  Early studies aimed 
to address these questions focused on the diversity of the TCR repertoire against a 
single target pMHC by testing the concept of restricted TCR V gene usage [34-39]. 
Because of clonal selection theory, it would make sense that our immune system would 
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select for one or a limited number of TCR rearrangements that “best” recognize a given 
peptide [40]. Using TCRs reactive against melanoma antigen MART-1 as a model, 
multiple studies found that the TCR diversity among MART-1 reactive T cell clones to be 
very high [35, 36]. More importantly, individual MART-1-reactive T cells clones 
recognized different subsets a panel of peptides with homology to the MART-1 peptide 
[41].  Furthermore, peptides recognized commonly by the different MART-1 reactive T 
cell clones were recognized by each clone with different efficiencies [41]. Diversity of 
TCR V gene usage is not a property unique to MART-1-reactive T cells [42]. Such findings 
indicate that each TCR can recognize a single antigen differently. Ultimately, how a T cell 
recognizes its target might make a difference in the effectiveness and the safety (cross-
reactivity) of the resulting TCR gene-modified T cells in vivo. 
TCR Affinity 
TCR affinity has been traditionally thought to play a significant, if not the most 
important, role in determining the sensitivity of a T cell to antigen recognition[1] .  
Generally, the affinity of TCR for pMHC is lower than antibody/antigen interactions and 
generally occur between 1-100 µM [11, 30, 43]. As discussed earlier, TCRs have different 
affinities for the pMHC, the range of which is tightly regulated by thymic selection. 
There are several important facts to consider regarding the relationship between TCR 
affinity and T cell function.  Contrary to the predictions of thymic selection, T cells 
reactive with self-antigens are not always deleted in the thymus since many are found in 
the periphery.  In both animal and human systems, self-reactive T cells can be induced 
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to mediate tumor rejection and in some cases, autoimmunity.  These T cells are 
generally CD8-dependent meaning they express TCRs with relatively low affinity for 
pMHC. Their anti-self-reactivity is generally limited until their physiology or the host 
environment is altered.  Another key observation is that T cells derived from a single T 
cell clone can have varied T cell function [44]. Under certain circumstances, T cells can 
be very antigen reactive whereas in other circumstances they are weakly antigen 
reactive [44, 45]. Therefore, it is likely that the biology of a given T cell can dictate 
function and TCR affinity plays a less important role than previously thought.  
There are several mechanisms, which can explain how the function of a T cell is 
influenced by its environment, regardless of the affinity of the TCR-pMHC interaction.  It 
is well known that T cells become refractory to immune function resulting from the level 
of immune suppression in the tumor-bearing host [46-52].  Furthermore, reactive 
oxygen and nitrogen species in the tumor-bearing host can promote T cell death [53-
58].  Interesting, none of these suppressive mechanisms require changes in TCR affinity 
to reduce immune function of a T cell. However, there are examples of immune 
suppression mechanisms that do seem to impact on TCR affinity.  We know that one key 
role of CD8 is to stabilize the TCR-pMHC complex.  It has been observed that the spatial 
relationship of the TCR and CD8 on the surface of a T cell can vary leading to differences 
in the relative stability of the TCR-pMHC complex [59].  Similarly, the ratio of the high 
affinity form of CD8 (CD8αβ) versus the low affinity form of CD8 (CD8αα) can vary on 
each T cell expressing the same TCR [60].  CD8αβ induces a higher functional avidity 
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than CD8αα, which translates to higher anti-tumor activity. Finally, myeloid-derived 
suppressor cells (MDSCs) have been shown to modify the TCR proteins by nitration of 
tyrosine residues leading to weaker binding to pMHC [61]. In all these suppressive 
mechanisms, the function of a T cell expressing a high affinity TCR could be as easily 
overcome as the function of a T cell expressing a low affinity TCR.  The studies described 
in this dissertation aim to help shed light on this inconsistency. 
T Cell Signaling and Function 
As mentioned earlier, engagement of the TCR/CD3 complex with its pMHC ligand 
at the immunological synapse initiates a radiating and branching network of signaling 
cascades leading to T cell activation and function [62]. Precisely how the engagement of 
the TCR with its pMHC target tips the signaling balance in favor of T cell activation is still 
a matter of debate. Traditionally, TCR engagement is thought to promote lck-dependent 
phosphorylation of ITAMs of CD3ζ chains, resulting in recruitment and activation of ζ-
chain associated protein 70 (ZAP70), which induces the assembly of the signal 
diversification and regulation components [63] (Fig. 1). Subsequent signaling events 
facilitate the hallmarks of T cell activation, including Ca2+ release, actin polymerization, 
integrin activation, proliferation, mobilization of transcription factors, cytokine 
secretion, and degranulation [62]. 
 Ultimately, signal propagation results in a functional response, which can vary 
depending on the subset of T cell activated. When a naïve T cell is activated by an 
antigen presenting cell (APC), they acquire effector functions while differentiating into 
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various subtypes. Differentiation is often influenced by the cocktail of cytokines present 
in the milieu during antigen presentation [64]. These T cell subsets are subsequently 
identified by cell surface markers, transcription factors, and cytokine secretion profiles.  
A well-characterized example of this is the Th1/Th2 dichotomy, where these 
CD4+ T helper cell subpopulations are distinguished by their cytokine profiles. Th1 cells 
express transcription factor T-bet, produce mainly IFNγ, IL-2, and TNFα, and have 
functional importance in pro-inflammatory cell-mediated immunity, delayed-type 
hypersensitivity, and immune responses against certain protozoa. Conversely, Th2 cells 
express transcription factor GATA-3, secrete IL-4, -5, -6, -10, and -13, and promote non-
inflammatory immediate immune responses and are essential in promoting B cell-
mediate immunity. It is thought that these developmental routes and cytokine profiles 
of Th1 and Th2 are mutually antagonistic, giving rise to the model of polarization of the 
immune response [64]. 
 Interestingly, a growing spectrum of additional T cell subset lineages has been 
defined by transcription factor expression and signature cytokine secretion. These 
include, but are not limited to, Th17 (ROR-γt+; IL-17A and -22 secreting), Treg (Foxp3+; IL-
10 and TGF-β secreting), and Th9 (IL-9 secreting) subsets [64]. CD8+ cytotoxic 
lymphocytes (Tc) are similarly categorized into subsets based on cytokine profiles (Tc1, 
Tc2, Tc17, etc.). These CD8+ subsets are hallmarked by cell-mediated killing by 
perforin/granzyme-mediated or Fas/Fas-ligand-mediated apoptosis. In this way, the 
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field generally accepts that T cells are functionally restricted by the subset into which 
they differentiate [64]. 
 The impact of TCR-pMHC affinity on TCR signaling remains debated. One 
argument, the kinetic proofreading model [65], proposes that the TCR signaling cascade 
serves as a biochemical clock. This models predicts that very slight discrepancies in 
ligand engagement can cause time delays between successive steps of activation, 
resulting in a distinct kinetic attenuation. Because of the intricate radiation and 
branching of downstream pathways in TCR signaling, kinetic attenuation can produce 
different ratios of downstream signaling molecules, leading to substantially different 
cellular functions. Factors that influence this biochemical clock (unique to a given TCR-
pMHC interaction) are thought to include TCR-pMHC dissociation rates, TCR clustering, 
and co-receptor accumulation in the immunological synapse [65, 66].  
 Overall, TCRs exhibit an enormous breadth of diversity, allowing for immune 
surveillance over countless self and nonself targets. Antigen recognition dictated by TCR 
specificity to its pMHC ligand initiates a complex, and not entirely understood, signaling 
pathway resulting in a host of cellular responses. Although TCR affinity plays a major 
role in dictating its specificity, the effect of slight alterations in TCR-pMHC interactions is 
not always reconciled with changes in T cell reactivity. An enhanced understanding of 
basic T cell biology will ultimately help improve the design of TCR-based therapeutics. 
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Adoptive Cell Therapy 
In light of T cell-mediated immune surveillance, unfortunately most viruses and 
tumors have developed various mechanisms to evade the host immune system. Immune 
evasion can lead to weak or ineffective immune responses, resulting in chronic 
infections or malignancies. To address ineffective immune responses towards cancer, 
many therapeutic approaches are aimed at optimizing the anti-tumor potential of T 
cells. Immune-modulating strategies include directly promoting a T cell immune 
response by administration of IL-2 which is used in treatment against melanoma and 
renal cell carcinoma [67]. Conversely, other therapies lift restraints on T cell activation, 
known as checkpoint blockade. These tactics include targeting inhibitory receptors 
CTLA-4 or PD-1 with antagonist antibodies ipilimumab [68-70] and pembrolizumab [71, 
72], respectively, which are currently approved to treat melanoma. Despite their recent 
success, cytokine administration and checkpoint blockade are not 100% effective; thus, 
combinatorial or novel therapeutic strategies need to be evaluated to improve cancer 
and viral immunotherapies. 
One such novel immunotherapy known as adoptive cell transfer (ACT) involves 
the transfer of ex vivo activated and expanded antigen-reactive T cells or genetic 
modification to redirect their specificity prior to transfer. ACT gained its first success 
using lymphokine activated killer (LAK) cells [73] and later tumor infiltrating 
lymphocytes (TIL) [74, 75] or antigen stimulated autologous peripheral blood 
lymphocytes (PBL) [76-79]. The most promising of these early approaches utilized TIL 
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following harvest from tumor and short term ex vivo expansion and were pioneered by 
the Rosenberg group at the Surgery Branch of the National Cancer Institute. Animal 
models and studies in patients with melanoma demonstrated that TIL maintained tumor 
reactivity in vitro, having the capability to lyse tumor cells and secrete cytokines, such as 
IL-2, IFNγ, and TNFα [80, 81]. These cells also mediated objective clinical responses 
when grown ex vivo and infused back into patients [82].   
Despite these promising but preliminary clinical results, for a variety of reasons 
TIL has not been a universal approach for ACT. For example, TIL production is a 
logistically and technically demanding process. Oftentimes primary tumors harboring TIL 
are previously resected as part of cancer treatment or are inaccessible depending on the 
tumor type and location. Additionally, the time it takes or the inability to expand 
available TIL to therapeutic numbers calls for an alternative cell-based approach for 
treating cancer or chronic viral infections [83, 84]. 
Recent technological advances have facilitated efficient expression of transgenes 
in T cells allowing for normal circulating PBL to be redirected targeting desired antigens.  
Genetically engineering T cells with chimeric antigen receptors (CARs), TCRs, and other 
receptor types have been shown to successfully redirect the specificity of T cells [85]. 
However, the ability to redirect a T cell to recognize a specific antigen is not enough to 
guarantee an effective immunotherapy. Antigen recognition needs to be coupled with 
efforts to ensure a T cell’s functionality is specific, limiting off-target or off-tumor 
recognition. T cells should also be able to functionally persist long-term and be able to 
14 
 
 
traffic to and accumulate at the target site. Additionally, optimal gene-modified T cells 
should exhibit robust, multi-functional immune responses and resist mechanisms of 
anergy, exhaustion and immunosuppression. They should also be amenable to deletion 
on demand to diminish potential toxicity issues. While T cell engineering strategies show 
promise at the bench and have shown some clinical success at the bedside, many 
aspects of this type of therapy must be resolved before these effectors are safe and 
effective enough to become the standard of care. 
CAR Gene Therapy 
CAR design. CARs, the first class of antigen receptors we will discuss, have been 
widely examined for the use of redirecting T cell specificity. A CAR is simply described as 
combining the antigen binding capability of an antibody with the intracellular signaling-
associated component of a TCR (Fig. 2). This unique juxtaposition allows for high affinity, 
three-dimensional epitope recognition by an immunoglobulin to be linked to the helper 
or effector responses of a T cell [86]. Specifically, the extracellular antigen-recognizing 
domain is generally derived from the antigen-binding fragment (Fab) of mouse 
monoclonal antibodies (mAbs) that have high affinity for specific antigens.  Unlike the 
normal structure of the Fab fragment of a mAb, the Fab fragment in a CAR exists as a 
single-chain variable fragment (scFv) [86]. The scFv is linked via hinge and 
transmembrane domains to an intracellular signaling domain. This couples antigen 
recognition to immune cell signal transduction by phosphorylation of immunoreceptor 
tyrosine-based activation motifs (ITAMs). The first CAR, described by Eshhar and  
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Figure 2. CAR-mediated target cell recognition. Structure of a 2nd generation CAR 
interacting with a  tumor cell. A CAR consists of a single-chain variable fragment (scFv) 
composed of variable light (VL) and heavy (VH) chains linked via hinge, transmembrane 
domains, and intracellular signaling domains containing at least the γ chain of the FcR or 
the ζ chain of the TCR/CD3 complex. Specificity of the scFv region dictates MHC-
independent recognition of a surface antigen. ITAMs of CD3ζ are denoted in blue 
octagons. 
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colleagues, linked the scFv to the signaling components of the FcRγ chain [87]. 
Subsequent CARs, however, have replaced FcRγ with ζ chain of the TCR/CD3 complex 
[88] to enhance signaling potential as the CD3ζ signaling domain contains three ITAMs 
as opposed to FcRγ’s single ITAM. Overall, CARs’ structural configuration allows for 
essentially any mAb to be engineered into a CAR. For targets where generating 
conventional antibodies in mice or other species is difficult, other techniques, including  
phage display, have been useful in generating the antigen-binding portion of the CAR 
[89, 90]. 
The use of a mAb as a ligand receptor facilitates recognition of intact proteins, 
carbohydrates, and lipids, alleviating the need for target antigens to be processed and 
presented by MHC molecules [86]. This would allow for CAR-mediated target 
recognition despite HLA downregulation or aberrant antigen processing mechanisms. 
Non-MHC-restriction also allows CAR to be used in patients of all HLA types [91]. This 
provides a distinct advantage compared to TCR-engineered T cells, which will be 
discussed in a later section.   CAR function is also independent of many of the signaling 
molecules or co-receptors required for TCR signaling and do not require association with 
the CD3 complex for T cell activation and function [92]. As such, CARs contain all the 
minimal elements necessary to bind antigen and activate the T cell. Additionally, as a 
single chain construct, CAR are compact in relatively small vectors allowing it easy to 
make high titer virus for transduction. Furthermore, single chain CARs are not subject to 
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chain pairing competition or mispairing, unlike when introducing exogenous TCRs, 
described later [93].  
However, there are some limitations using CAR-engineered T cells [94]. For 
example, CARs target surface antigens, rendering them ineffective against any 
intracellular target that would otherwise be processed and presented by MHC. Also, the 
mAb-antigen interaction is much stronger than a TCR-antigen interaction, which may 
negatively impact T cell function [95]. Additionally, used of murine-derived scFv cause 
concern for potential immunogenicity of these chimeric receptors [96], although efforts 
to reduce immunogenicity have been used by humanizing murine-derived scFv or 
generating scFv from human scFv phage display libraries [97]. Overall, CARs offer a 
unique approach to re-direct the specificity of T cells combining the antigen recognition 
capabilities of an antibody with T cell signaling components. 
Generations of CARs. Over time, the design of CARs has been refined to provide 
better antigen recognition and a more efficient transfer of cellular signaling for T cell 
function and persistence. As mentioned previously, the signaling domain of FcRγ was 
swapped with that of CD3ζ because CD3ζ included a greater number of ITAMs (Fig. 3) 
leading to enhanced T cell function [88]. Additionally, the single chain antibody can be 
substituted for other receptors or a ligand of a receptor expressed on tumor cells. Such 
approaches include substituting the scFv region of a CAR for heregluin (a ligand for Her3 
or Her4 receptors) [98], VEGF (anti-VEGFR2) [99], NKp30 (targeting B7-H6) [100] or the  
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Figure 3. Generations of CARs. Comparison of co-stimulatory domains included in first 
(left), second (middle), or third (right) generation of CARs. ITAMs are denoted as colored 
octagons. 
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 NKG2D receptor [101-103]. Moreover, multiple signaling domains have been added to 
the CD3ζ or FcRγ domains to augment activation and co-stimulation mimicking 
immunologic signal 2 during physiologic T cell activation [104]. Addition of co-
stimulatory domains has led to subsequent “generations” of CARs.  
“Second generation” CARs (Fig. 3) utilize one additional cytoplasmic domain of a 
co-stimulatory receptor, such as CD28, 4-1BB, DAP10, OX40, or ICOS, providing greater 
strength of signaling and persistence to the T cells [51, 105-117]. For example, one study 
investigating the requirements of CAR signaling cassettes found that in a mouse CEA+ 
colorectal tumor xenograft model, CEA CAR-engineered T cells containing both CD3ζ and 
CD28 enhanced proliferation and IFNγ secretion compared to CD3ζ-only containing  
CARs [106]. The presence of CD28 was also required for efficient IL-2 secretion. 
Additionally, one group found that CD19-specific CARs containing CD3ζ and co-
stimulatory cassette 4-1BB provided enhanced anti-leukemic efficacy and prolonged 
survival in tumor bearing mice compared to CD3ζ- or CD3ζ/CD28-containing CARs [113]. 
Together, these data suggest that the addition of co-stimulatory cassettes, including 
CD28 and 4-1BB, is required for complete T cell activation and that second generation 
CARs may provide enhanced therapeutic benefit. 
A third generation of CARs (Fig. 3) were also developed using two co-stimulatory 
domains with an activating domain, conferring an even greater potency to redirected T 
cells [51, 115, 117-121]. For example, use of an ERBB2 CAR containing 4-1BB, CD28, and 
CD3ζ signaling moieties exhibited greater transgene persistence, increased cytokine 
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secretion, and enhanced lytic activity in vitro compared to ERBB2 CARs containing only 
CD3ζ and CD28 signaling cassettes [117]. Moreover, the third generation CAR better 
suppressed tumor growth in a xenogeneic mouse model compared to the second 
generation CAR. In light of enhanced performance by third generation CARs, it is unclear 
whether such strong co-stimulation would always be advantageous. One clinical report 
highlighting this point used a third generation trastuzumab-based CAR containing CD3ζ, 
CD28, and 4-1BB signaling moieties. Administration of anti-Her-2 third generation CAR-
transduced autologous T cells was lethal in one patient after cytokine storm and fatal 
respiratory distress due to recognition of low levels of Her-2 on lung epithelia [122]. 
Thus, optimization of how many and which types of signaling domains included in CARs 
are necessary. Only then can we determine which combination is best for augmenting 
activation, sustained function and survival while minimizing anergy, premature death, 
and rapid exhaustion. Additionally, further efforts examining how antigen location and 
density, as well as CAR binding moiety, affinity, and sensitivity affect it T cell function 
may also optimize CAR design. 
CAR targets. The first clinical trials using CARs targeted folate binding protein 
(FBP) for patients with ovarian cancer [123] and carbonic anhydrase IX (CAIX) for 
patients with renal cell carcinoma (RCC) [124]. Both CARs were first generation 
containing the FcRγ signaling domain. In both of these trials, no objective clinical 
responses were seen, nor were the gene-modified T cells able to persist long term. 
However, the potential for adverse events using CAR therapy was first recorded. In the 
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trial targeting CAIX+ RCC, the phenomenon described as on-target/off-tumor effects was 
clearly evident. Patients treated with the CAIX CAR gene-modified T cells experienced 
grade 2-4 liver toxicity because the transduced cells recognized CAIX antigen expressed 
on the epithelial cells of the bile duct [124]. These results indicated administration of 
CAR T cells was feasible but could have unwanted off-tumor effects. 
As subsequent generations of CARs were developed and more specific CAR 
targets were identified, we observed greater clinical success using CARs. Efforts 
targeting the pan-B cell antigen CD19 are the best examples of the proof-of-concept for 
CAR therapy. Initial trials targeting CD19-associated with relapsed indolent non-
Hodgkin’s lymphomas (NHL) and chronic lymphocytic leukemia (CLL) [125-131] 
demonstrated the safety of CAR T cells and modest clinical benefit. Later, patients with 
B cell acute lymphoblastic leukemia (B-ALL) receiving CD19-targeted CAR T cell 
treatment resulted in positive clinical outcomes with robust anti-tumor efficacy in two 
independent trials [132, 133].  
The success of CD19-targeting CARs has relied on CD19’s near universal 
expression on B cell malignancies and its limited expression on B cells. Its absence on 
bone marrow stem cells also limits off-target potential. Outcomes from this CD19 model 
additionally provided the practical limitations of initial CAR design and fostered the 
development of subsequent generations of CARs. Recently, a clinical trial using a second 
generation CD19-reactive CAR treated both children and young adults with 
chemotherapy-resistant B-precursor acute lymphoblastic leukemia [134]. In this trial, 
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CD19 CARs exhibited potent anti-leukemic activity and all grade 3 and 4 toxicities were 
reversible, suggesting second generation CARs can be relatively safe and effective. Other 
studies, however, have seen serious neurotoxicity associated with administration of 
CD19 CAR T cells [135], highlighting the remaining challenges in maximizing both the 
efficacy and safety with the use of CARs. 
Although less serious than aforementioned on-target/off-tumor events, another 
drawback of the highly effective CD19 CAR campaign targeting B cell malignancies is the 
prolonged elimination of normal B lymphocytes and, thus, impairment of humoral 
immunity [125, 128, 130]. Although this can be mitigated by intravenous administration 
of gammaglobulin, B cell aplasia and hypogammaglobulinemia should still be recognized 
as on-target adverse events. 
While CD19-targeted B cell malignancies have been the poster child advocating 
for CAR therapy, it is important to acknowledge another CAR target that has exhibited 
mixed clinical results. As mentioned earlier, the use of a third generation CAR based on 
the widely used mAb trastuzumab targeting Her-2 induced respiratory distress resulting 
in death in one treated patient with metastatic colon cancer [122]. It was discovered 
that low level Her-2 expression on normal lung epithelia caused this fatal side effect, 
characterized as a much more serious on-target/off-tumor adverse event than B cell 
aplasia. With this is mind, a modified CAR-based approach targeting Her-2 led to a more 
successful recent trial [136]. In this report, a dose-escalation study using a second-
generation Her-2-specific CAR with a different scFv was used in patients with 
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recurrent/refractory Her-2+ sarcomas. This study also differed in that it did not use co-
administration of high-dose IL-2 or lymphodepleting chemotherapy prior to transfusion. 
Transduced cells persisted for 6 weeks and trafficked to tumor sites without any evident 
toxicities. Some patients even exhibited stable disease or partial response. The stark 
contrast between these two trials highlights the importance of mAb and co-stimulatory 
cassette selection, target distribution, and host conditioning can have on the positive 
and negative outcomes in CAR clinical trials. 
A wide variety of other CARs have been designed to target an array of antigens 
showing promise as potential cancer immunotherapies. Other targets evaluated in vitro 
and in vivo include but are not limited to EGFRvIII [137] for glioblastoma, GD2 [138, 139] 
for neuroblastoma, GD3 [140, 141], MAGE-1 [142], and HMW-MAA [143] for melanoma 
, CD20 [115, 119, 144-147], CD23 [148], CD30 [149-151] and others for hematologic 
malignancies, PSMA [107, 152] for prostate cancer, MUC-1 [120], Her-2 [19, 153], and 
CEA [154-156] for breast cancer, EGP-40 [157] for colorectal cancer, VEGF-R2 [99, 158] 
and KDR [159] for tumor neovasculature, and MUC16 [160] for ovarian cancer. Table 1 
lists a sampling of active clinical trials using CARs and their respective targets. 
CAR summary. Overall, CARs provide MHC-independent recognition of a variety 
of extracellular target types with a compact, single chain construct containing all the 
minimal elements necessary for T cell activation. For better or for worse, the design of 
CARs prevents any chance of receptor mispairing but circumvents the natural processes 
of T cell activation and dysregulation. While documentation of on-target/off-tumor   
24 
 
 
Table 1. Active clinical trials using CAR-engineered T cells. 
Target 
Antigen 
Associated  
Malignancy 
CAR 
Generation 
Clinical 
Trial ID# 
CD19 Acute lymphoblastic 
leukemia 3
rd
 (CD28:4-1BB) NCT02186860 
CD133 Various malignancies 1
st
 NCT02541370 
CD171 Neuroblastoma 
2
nd
 (4-1BB) and 3
rd
 (CD28: 
4-1BB); transgene includes 
truncated EGFR 
NCT02311621 
CEA CEA
+
 adenocarcinomas 2
nd
 (CD28) NCT01723306 
EGFR EGFR
+
 solid tumors 1
st
 and 2
nd
 (4-1BB) NCT01869166 
GD2 Neuroblastoma 3
rd
 (CD28:OX40); 
transgene includes iC9 
NCT02439788 
GD2 GD2
+
 sarcomas 3
rd
 (CD28-OX40); 
transgene includes iC9 
NCT01953900 
Her-2 Breast cancer 2
nd
 (CD28) NCT02547961 
Her-2 Glioblasoma multiforme 2
nd
 (CD28) NCT01109095 
Mesothelin Pancreatic, ovarian, and 
mesothelioma 2
nd
 (4-1BB) NCT02159716 
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effects is well noted, off-target effects are not as readily seen because the antigen 
binding regions of CARs are generally derived from well-characterized monoclonal 
antibodies. However, several groups conducting clinical trials with CARs have recorded 
other serious adverse events including tumor lysis syndrome [130] and cytokine storm  
[128, 161, 162]. Overall, the majority of CAR studies have shown much promise for their 
clinical use. Continuing efforts are ongoing to improve clinical outcomes while 
minimizing adverse events. 
TCR Gene Therapy 
As the focus of these dissertation studies, we now introduce the concept, 
success, and limitations of TCR-gene modified T cells. These discussions serve as a 
prelude to identify what approaches can help us better understand antigen recognition 
by a T cell in order to improve TCR-based ACT. A schematic of TCR engineering of T cells 
for ACT (detailed in the following sections) is provided in Figure 4.  Over the past 20 
years, a myriad of TCRs have been cloned and characterized that recognize antigens, 
including but not limited to, EBV [163], gp100 [44, 164], HCV [165, 166], HPV [167], 
MART-1 [15, 34, 168], tyrosinase [169, 170], and unknown antigen reactivity [171]. To 
date, TCRs investigated for ACT have been limited to mostly MHC-I-restricted 
candidates. Although, more recent identification of direct tumor-recognizing MHC-II-
restricted CD4+ T cells [172] have provided the opportunity to generated MHC-II-
restricted TCR-transduced T cells [173]. The sections below describe the design, use,   
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Figure 4. Adoptive cell transfer using TCR gene-modified T cells. Viral or cancer antigen-
reactive T cell clones are isolated and expanded from TIL or peripheral blood to identify 
a therapeutic TCR candidate. TCR genes are identified and cloned into retroviral vectors. 
Packing and producer cell lines are engineered with this retroviral construct to produce 
high titer retrovirus used to transduce activated PBMC from an HLA-matched antigen 
positive patient. Transduced cells are expanded ex vivo with cytokine support and 
infused back into the patient. These autologous T cells with re-directed specificity 
provide new anti-viral or anti-tumor immunity. 
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success, and limitations of TCR-engineered T cells used in ACT. They provide a 
foundation for the biologic questions addressed in this dissertation. 
TCR design. An important factor influencing the effectiveness of 
immunotherapeutic use of TCRs is the relationship between TCR-pMHC affinity and T 
cell function [1]. Antigen recognition depends on a productive interaction between a 
TCR and pMHC, and lower affinity interactions generally require the presence of the CD8 
co-receptor to facilitate antigen recognition [2]. Thus, it might be predicted that T cells 
engineered with high affinity TCRs are better effectors than T cells engineered with 
lower affinity TCRs [15, 168, 169]. Various CD8-independent TCRs have been 
characterized that can transfer antigen recognition to CD4+ cells in an MHC-I-restricted 
manner, providing helper cytokine support and enhanced tumor regression [165, 166, 
169, 170, 174-181]. Naturally occurring high affinity, CD8-independent TCRs are 
relatively rare, however, and thus difficult to find. Rather than screening for such high 
affinity TCRs, various methods have been developed to affinity-enhance already 
characterized TCRs. These approaches are discussed in a later section.  It is important to 
recognize, however, that T cells harboring higher affinity TCRs are more likely to 
undergo activation induced cell death (AICD) upon antigen encounter [182, 183], or 
induce off-tumor/on-target and off-tumor/off-target reactivity [184-186], 
counterproductive to their therapeutic intention.  
It is also important to acknowledge that MHC-restriction of TCRs limits the 
number of patients that can be treated using a single TCR, and engineered T cells would 
28 
 
 
need to be HLA matched to patients. HLA class I expression has a tendency to be 
downregulated on tumor cells [187, 188], however, which may also serve as a barrier to 
effective therapy. Additionally, because TCRs require interaction with the CD3 complex, 
a TCR’s expression and functionality is limited by available CD3 complex components. 
Competition for the CD3 complex with endogenous TCR limits functional transgene 
expression, although strategies discussed below may allow for improved association 
with CD3 by the introduced TCR.  
TCR chain pairing. Because TCRs exist as heterodimers, TCR gene-modified T 
cells require two different genes, or chains, to be expressed to redirect specificity. 
Because expression of two individual genes may result in non-uniform chain expression, 
various approaches have been developed to address this. For example, the addition of 
viral 2A self-cleavage peptide sequences between the α and β chains within retroviral 
constructs allows for more uniform chain expression [189-191]. Additionally, codon 
optimization of the construct facilitates increased TCR expression [192, 193]. Both these 
approaches help augment introduced TCR expression without altering the TCR sequence 
itself. 
Additionally, the presence of an endogenous TCR can induce chain mispairing 
between endogenous and introduced α and β chains. These interactions reduce the 
level of expression of functional introduced TCR [168, 194] and could lead to novel and 
unpredictable self-reactive TCRs  (false pairing) with serious adverse events. Such off-
target/off-tumor adverse events have been reported as a result of high affinity TCRs 
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recognizing unanticipated epitopes or as a result of TCR chain mispairing. Two recent 
studies demonstrate undesirable reactivity propagated from TCR mispairing between 
endogenous and introduced TCR α and β chains. One study recorded graft-versus-host-
disease (GVHD) in a mouse model in five different TCR systems [195]. Another 
demonstrated the ability of engineered human T cells to develop MHC class I and II-
restricted allo- and auto-reactivity through TCR chain mispairing [196]. However, to 
date, no evidence of GVHD has been seen in over 100 patients treated with this gene 
therapy approach [197]. 
A handful of approaches have been developed to address potential for TCR chain 
mispairing. One main strategic effort involves a host of modifications to the TCR 
construct, summarized in Figure 5. As mentioned previously, codon optimization of the 
TCR α and β genes can help promote efficient translation and surface assembly of the 
introduced receptor without altering the TCR sequence itself [192, 193]. Introduction of 
cysteine residues in the α and β constant regions has been shown to promote inter-
chain disulfide bridge formation to limit mispairing [176]. Other approaches to help 
improve pairing, expression, and function of the introduced TCRs include the addition of 
leucine zippers at the end of the intracellular tails [174] and altering the glycosylation of 
the TCR [177]. Substituting human constant regions with portions of or the entire mouse 
constant regions also promotes proper pairing and enhanced surface expression [170, 
198-202].  Specifically, elements of the murine constant regions do not efficiently 
interact with the human constant regions [200]. Additionally, the murine constant   
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Figure 5. TCR modifications to limit mispairing and improve cell surface expression and 
function. Modifications of WT TCR structure (far left) include codon optimization, 
introduction of a disulfide bridge, addition of leucine zipper, modification of 
glycosylated residues, substitution with murine constant regions, or use of single chain 
Vα-Vβ-Cβ with a Cα chain. WT, wildtype; V, variable; C, constant. 
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region has a higher affinity for human CD3, which can favor the murinized receptor 
associating with limited surface CD3 [198]. Receptors with murine constant regions 
were also found to mediate higher levels of cytokine secretion in vitro [198, 199]. This 
technique poses additional problems, however, including immunogenicity and clearance 
of the engineered T cells as they express potentially antigenic domains in the transgene 
[199].  
Another novel approach to alleviate mispairing was demonstrated by recent 
reports using single chain TCRs [200, 203]. One group engineered a recombinant TCR 
consisting of a single chain Vα-Vβ-Cβ and a Cα chain, which only paired with each other 
and not the endogenous TCR [200]. Another group used a stabilized Vα-Vβ single chain 
TCR linked to intracellular signaling domains (lck, CD28), which elicited functional 
activation of T cells in the absence of either the CD3 complex or co-receptors and 
circumvented mispairing with endogenous TCRs [203]. Efforts to limit mispairing have 
also focused on downregulating the endogenous TCR by via small interfering RNA 
(siRNA) [204] or using designer zinc-finger nucleases [205]. All of these alternate 
strategies share the same goal to reduce competition for the CD3 complex, allow for 
stable pairing of the introduced TCR, and minimize adverse events due to false pairing.  
TCR targets. More than 20 years after TCR gene-modified T cells were first used 
to redirect T cell specificity in mice [206] this technology was first evaluated in humans 
targeting melanoma-associated antigens. TCR engineered T cells’ first use in the clinic 
targeted HLA-A2+/MART-1+ melanoma [207, 208]. These initial clinical studies 
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demonstrated that TCR gene-modified T cells were generally safe, well tolerated, and 
had the potential to be therapeutic in cancer patients. A later study targeting melanoma 
antigens MART-1 and gp100 demonstrated further clinical benefit using TCR-transduced 
T cells but highlighted the potential for adverse events [184]. Of note, the gp100-
reactive TCR in this study was high affinity and of mouse origin, and many patients 
treated with this TCR exhibited toxicities in the eye and inner ear, displaying destruction 
of normal melanocytes. This well-characterized example of on-target/off-tumor effects 
first cautioned the use of high affinity TCRs. Fortunately, in this case such toxicities 
resolved naturally or with administration of topical steroids in almost all patients. These 
earliest studies suggested TCR gene-modified T cells were feasible with clinical benefit, 
but that the choice of TCR may be important to limit toxicities. 
Since these early studies, however, identification of numerous TCR genes 
capable of recognizing tumor-associated antigens and improvements in TCR gene 
transfer technology have allowed for specificity redirection to target of a variety of 
other antigens and malignancies. These include, but not limited to, carcinoembryonic 
antigen (CEA), cancer-testis antigen (CTA) family members, and viral protein family 
members. Examples using TCR gene-modified T cells to target these families of antigens 
are described below. 
CEA is overexpressed in a many epithelial cancers, allowing CEA-reactive TCRs to 
target a wide variety of malignancies.  In fact, a recent clinical trial TCR gene-modified T 
cells to target CEA+ colorectal cancer noted objective clinical response in a patient 
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bearing metastatic disease [186]. However, on-target/off-tumor adverse events, 
including inflammatory colitis, were documented in numerous patients as CEA has 
shared expression on normal tissues, including the colon. This example highlights 
therapeutic benefit as well as safety concerns using TCR-gene modified T cells targeting 
CEA. 
The CTA family of antigens, including NY-ESO-1 and MAGE, are expressed by the 
normal testis and a host of human cancers including breast, bladder, colon, lung, 
melanoma, head and neck, gastric, ovarian, thyroid, neuroblastoma, synovial cell 
sarcoma, and prostate [209]. Clinical studies have shown T cells redirected to recognize 
NY-ESO-1 provided objective clinical response in patients with synovial cell sarcoma and 
melanoma without any evidence of previously reported adverse events [210]. A pair of 
clinical trials targeting another widely expressed CTA, MAGE-A3, recorded much more 
mixed results. The first clinical trial used a mouse-derived, high avidity TCR that was 
further modified by site directed mutagenesis in its CDR3 [211]. Targeting MAGE-A3, it 
cross-recognized MAGE-A9/A12. Although five out of nine patients experienced clinical 
regression of their cancers, one third of the patients experienced neurological toxicity. 
Two patients even died due to these adverse events. T cells cross-reactive against 
unknown expression of MAGE-A12 in the brain are believed to have caused this toxicity. 
Another clinical trial using an affinity-enhanced TCR targeting MAGE-A3 resulted in 
cardiogenic shock and death of the first two patients treated [212, 213]. While no 
MAGE-A3 expression was detected in cardiac tissue at autopsy, it was determined the 
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TCR designed with affinity-enhancing mutations in α and β CDR2s exhibited an 
unpredicted cross-reactivity to titin, a sarcomeric protein expressed in striated muscle. 
Interestingly, the parental TCR from which the engineered TCR was derived from was 
isolated from a patient without cardiac toxicity. This might attribute the adverse events 
in the clinical trial to the intentionally induced CDR2 mutations. Taken together, these 
studies are encouraging that TCR gene-modified T cells under the right circumstances 
can provide clinical benefit but also highlight the importance of TCR and target selection 
to minimize cross-reactivity by modified TCRs. 
Viral proteins expressed on tumors compose a third family of antigens targeted 
by TCR-engineered T cells. Several groups have TCR-engineered T cells to target 
antigens, including CMV [214, 215], EBV [163, 216, 217], HIV [218-221], HCV [165, 166, 
222], HPV [167, 223], and others. No clinical reports have yet been published testing 
virus-reactive TCR-transduced T cells in humans, however. Table 2 lists some of the 
active clinical trials using TCRs and their respective targets. 
Use of high affinity TCRs in ACT. Discussed earlier, thymic selection generally 
excludes high affinity TCRs against tumor (self) antigens to occur normally in the 
periphery. But engineering T cells with high affinity TCRs circumvents normal thymic 
limitation and can generate high avidity tumor-reactive T cells.  There are clear 
advantages to using a high affinity TCRs to engineer T cells for ACT.  The ability to 
generate tumor-reactive MHC class I-restricted CD4+ T cells is one major benefit using 
high affinity TCRs [169].  CD4+ T cells’ ability to produce helper cytokines upon antigen   
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Table 2. Active clinical trials using TCR-engineered T cells. 
Target  
Antigen 
Associated  
Malignancy 
MHC  
Restriction 
Clinical 
Trial ID# 
gag HIV HLA-A2 NCT00991224 
gp100 Melanoma HLA-A2 NCT00509288 
HPV E6 
HPV-associated 
cancers 
HLA-A2 NCT02280811 
MAGE-A3 
Various 
malignancies 
HLA-A1 NCT02153905 
MAGE-A3 
Various 
malignancies 
HLA-DP04 NCT02111850 
NY-ESO-1 
Various 
malignancies 
HLA-A2 NCT02457650 
Thyroglobulin Thyroid cancer HLA-A2 NCT02390739 
Tyrosinase Melanoma HLA-A2 NCT01586403 
WT1 
Myelodysplastic 
syndrome, AML 
HLA-A2 NCT02550535 
WT-1 
Non-small cell 
lung cancer, 
mesothelioma 
HLA-A2 NCT02408016 
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stimulation offers the opportunity to provide MHC I-restricted T cell help at the tumor 
site [169, 224, 225].  Therefore, TCR transduced CD4+ T cells might facilitate cross-
priming or epitope spreading, leading to broad systemic anti-tumor immunity.  Another 
application for a high affinity TCR involves engineering CD4+ regulatory T cells [226].  
Like helper T cells, MHC I-restricted regulatory T cells could help reduce the severity of 
autoimmune diseases [226]. Thus, the ability to use high affinity TCRs to target novel 
classes of MHC-I-restricted T cell subsets is a very attractive concept. 
However, T cells expressing TCRs with extremely high affinity for pMHC can 
undergo activation-induced cell death (AICD) upon antigen encounter. AICD could lead 
to the destruction of the very effector cells that were intended to destroy a patient’s 
cancer or virally infected cells [182, 183].  Additionally, high affinity TCRs are better at  
detecting low levels of antigen [227], and have even exhibited cross-reactivity to related 
antigens causing death in a clinical trial previously discussed [211]. T cells expressing 
high affinity TCRs can also lead to autoimmunity as observed in one transgenic mouse 
model [185] and two clinical trials [184, 186].  Given these observations, the proper use 
of high affinity TCR sfor effective anti-tumor immunity remains unresolved.  Approaches 
used to design high affinity TCRs are discussed in a later section. 
Other T cell Engineering Approaches 
Other receptor types.  While the use of CARs and TCRs to redirect the specificity 
of a T cell have been well documented, ongoing efforts to design other receptor types 
for gene modification hold therapeutic potential as well. For example, engineering T 
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cells to express the NKG2D receptor allows T cells acquire the reactivity of natural killer 
(NK) cells [101-103]. Another NK cell receptor that has been investigated for T cell 
engineering is NKp30, which recognizes the tumor-prone antigen B7-H6. A recent study 
combined the specificity of NKp30 and the signaling capability of CARs, designing a novel 
NKp30-based CAR replacing the scFv domain with the ligand-binding domain of NKp30 
[100]. Adoptive transfer of the NKp30-CAR T cells allowed for non-MHC-restricted 
recognition of B7-H6 expressing RMA, a murine lymphoma, in vivo. Interestingly, NKp30-
CARs T cells provided protection against subsequent challenge with wildtype (WT) RMA 
tumor cells. Similar efforts are examining the feasibility of replacing the scFV domain of 
CARs with other ligands or ligand-binding receptors described earlier. Exploring other 
approaches to engineer T cells with novel antigen receptors may help optimize the use 
of gene-modified T cells for ACT. 
Another unique approach under investigation is dual-receptor-engineering of T 
cells. This strategy engineers T cells to co-express complementary CARs, TCRs or other 
receptors, each specific to a distinct target. This approach is thought to optimize T cell 
homing and tumor specificity while reducing toxic potential. Dual-specificity may also 
provide synergistic signaling as well as a means to combat downregulation or mutation 
of antigens in immune escape. One study validated this tactic by generating T cells co-
expressing CARs reactive to MUC1 and ERBB2 targeting breast cancer cells in vitro [228]. 
They found that dual-targeted T cells killed ERBB2+ targets efficiently, but T cell 
proliferation required engagement with both MUC1 and ERBB2 antigens because CARs 
38 
 
 
contained either CD3ζ or CD28 for ERBB2 and MUC1 specificity, respectively. 
Additionally, IL-2 production was modest in dual-CAR expressing cells compared to CAR 
T cells engineered with a single second generation CAR containing both CD3ζ and CD28. 
These data suggest generating dual-receptor engineered T cells is feasible but requires 
optimization to enhance T cell function. 
Additionally, recent work has highlighted anti-specific inhibitory chimeric antigen 
receptors (iCARs) linked to a powerful acute inhibitory signaling domain, such as CTLA-4 
and PD-1 [229]. T cells engineered with these iCARs were selectively limited in cytokine 
secretion, cytotoxicity, and proliferation compared to those engineered with an 
activating CAR targeting the same antigen. This dual-receptor approach provides an 
attractive opportunity to limit unwanted off-target responses.  
Cytokine production. Another approach to modify or enhance the potency of 
receptor-engineered T cells is to further genetically modify T cells to secrete pro-
inflammatory or pro-proliferative cytokines. This approach not only provides autocrine 
support to enhance T cell function, proliferation, and/or persistence, but also favorably 
alters the tumor microenvironment. This would enhance innate and cognate immune 
effector recruitment while limiting the systemic toxicity of exogenously delivered 
cytokines. For example, engineering melanoma-reactive T cells to express IL-2 resulted 
in continued cell growth in the absence of exogenous IL-2, which may a viable approach 
to help T cell persistence post-adoptive transfer [230]. A similar tactic demonstrated T 
cells modified to express IL-12 exhibited enhanced anti-tumor function and were better 
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able to resist immunosuppression by regulatory T cells [231, 232]. Similarly, engineering 
T cells to secrete IL-12 transformed myeloid cell within tumors from immunosuppressive 
to immunosupportive [233]. This strategy was even used in a recent phase I clinical trial 
where IL-12 secreting MUC-16 (ecto)-targeting CAR T cells were infused into patients 
with recurrent ovarian cancer [234]. In summary, the ability to additionally modify 
receptor-engineered T cells to provide cytokine support is an attractive approach that 
still needs more clinical validation to become mainstream. 
Chemokine recognition. In addition to cytokine-engineered T cells, modifying 
them to express chemokine receptors can aid in migration patterns, increasing the 
efficiency of trafficking to and infiltration of tumors. Transferring genes encoding CCR4, 
CCR2B, or CXCR2, enabled T cells to home towards CCL17, CXCL1, and macrophage 
chemoattractant proteins [149, 235, 236].  Also, VEGFR-2-engineered T cells allowed T 
cells to find tumor-associated neovasculature in one study [237]. Additional efforts to 
improve T cell homing may include engineering T cells with certain integrins or their 
ligands [238] or by blocking inhibitors of migration like endothelin [239]. Further 
investigation is necessary, however, to prove clinical benefit. 
Ways to Optimize Gene-Modified T cells.  
Host conditioning. Lymphodepletion prior to ACT has been a point of interest to 
improve long-term persistence and function of transferred T cells. This host pre-
conditioning strategy is thought to create space for the transferred T cells and eliminate 
competition for cytokines [240], remove competition at the surfaces of antigen 
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presenting cells [241, 242], and withdraw immunosuppressive regulatory T cells [243]. 
This evidence came from preliminary mouse studies that were followed up in the clinic 
by the Rosenberg group. They first noted that persistence and antitumor activity of 
transferred T cells in vivo was greatly increased with non-myeloablative 
lymphodepleting treatment using cyclophosphamide and fludarabine before adoptive 
transfer [244]. It is believed these changes in the host may lead to induction of a 
memory phenotype and enhance effector function. Systemic administration of 
cytokines, such as IL-2, post-ACT has also enhanced transferred T cell function and 
persistence [245, 246]. Post-conditioning with other cytokines including IL-15 or 
immunomodulatory therapies such as PD-1 and CTLA-4 blockade should also be 
considered. 
Suicide switch. In light of on- or off-target toxicities, tumor lysis syndrome, and 
cytokine storm documented with the use of engineered T cells, it would be beneficial to 
preserve the ability to eradicate the transferred T cells, if needed.  Such strategies aim 
at turning off antigen receptor expression or eliminating the engineered cells post-
transfer by incorporating certain “suicide genes” into the transgene. A long-studied 
approach utilizes the herpes simplex virus-thymidine kinase (HSV-tk) gene. Its 
incorporation into the transgene vector makes engineered T cells susceptible to 
gancyclovir treatment [247, 248]. However, because HSV-tk is potentially immunogenic, 
its expression may create unwanted immune-mediated destruction of transferred T cells 
and decreased persistence [249, 250]. Another common approach and non-
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immunogenic technique incorporates caspase 9 under an inducible promoter (iC9) to 
initiate apoptosis of transduced cells [251-254]. Additionally, studies incorporating CD20 
[255] or EGFR [256] in transgene vectors generated transduced T cells susceptible to 
rituximab and cetuximab treatment, respectively. In short, incorporation of suicide 
switch mechanisms allow for novel ways to enhance the safety of engineered T cells by 
allowing simple means to specifically eliminate them in vivo.  
Affinity maturation. As discussed earlier, TCR affinity is known to play a 
significant role in determining sensitivity of a T cell to antigen recognition. Therefore, it 
is logical to predict that higher affinity TCRs may provide better therapeutic candidates 
for reasons previously discussed. For example, the use of high affinity TCRs may better 
equip engineered T cells to combat immune suppression mechanisms that alter T cell 
function including MDSC-mediated nitration of TCR tyrosine residues, which can weaken 
TCR-pMHC binding [61]. Additionally gene transfer of high affinity TCRs can generate 
tumor-reactive MHC class I-restricted CD4+ T cells, creating a novel population of T cell 
help at the tumor site [169, 224, 225]. Moreover, a population of reactive-CD4+ T cells 
may facilitate cross-priming or epitope spreading allowing for a broad systemic anti-
tumor response. For reasons discussed, however, identifying naturally occurring, high 
affinity tumor-reactive TCRs is feasible but challenging due the principles behind thymic 
selection [30]. 
One way to identify and clone high affinity TCRs is screening for CD8-
independence against human MHC-restricted antigens in mice. It is documented that 
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mouse CD8 does not bind to the α3 domain of human MHC class I molecules [198, 257]. 
Thus, in a vaccinated HLA-A2 transgenic mouse model, isolated T cell clones reactive 
against human tumors in vitro would likely express high affinity TCRs. This approach has 
been used successfully to identify high affinity TCRs targeting CEA [258] and p53 [259].  
Additionally, a recent approach has generated allo-restricted T cells using autologous 
dendritic cells (DCs). DCs are co-transfected with in vitro transcribed RNA encoding an 
allogeneic MHC molecule and a selected antigen [260], providing allo-stimulation. This 
procedure allows for novel allo-pMHC ligands to activate high avidity, allo-restricted, 
peptide-specific T cells as a source for high affinity TCRs. Together, these approaches 
provide great flexibility for obtaining high affinity and high avidity T cells as potential 
sources of TCRs for ACT. 
While CD8-independent tumor cell recognition by a T cell clone should be a 
hallmark of a high affinity TCR, this has not always been true.  One such example 
involved a gp100 reactive T cell clone designated T4H2 that was a CD4-/CD8- T cell that 
efficiently recognized HLA-A2+ gp100+ human melanoma cells in vitro [44, 164].  
However, when the T4H2 TCR was cloned and expressed in human T cells, it surprisingly 
required CD8 expression for tumor cell recognition [44]. Therefore, each TCR must be 
evaluated individually to ensure that a CD8-independent/high affinity TCR has been 
cloned. 
More recently, TCRs have been genetically modified to improve their biophysical 
properties [210, 261-267].  Using yeast and phage display, TCRs have undergone 
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“evolution” to select for high affinity binding to pMHC [3, 4, 265, 268, 269] a technique 
also used in CAR design [89, 90].  Although it might be predicted that changes to the 
CDR3 would lead to the highest affinity TCRs, amino acid alterations in any of the three 
CDRs can contribute to enhanced TCR-pMHC affinities [262]. This was surprising because 
the CDR3 is responsible for the majority of TCR diversity and specificity.  
What is troublesome about these affinity enhancement strategies is the 
randomness of introduced mutations. Yeast and phage display rely on purely random 
generations of high volumes of different clones, followed by screening for the highest 
biophysical interactions. Thus, there is no informed decision behind the selection of the 
TCR ultimately used. Such a “blind” approach is concerning when trying to predict 
therapeutic efficacy and safety in terms of potential on- or off-target toxicities. More 
appropriate may be a rational structure-guided design of high affinity TCRs. A relatively 
new concept, this approach allows for more control and understanding of the 
mechanism of TCR affinity improvement with the potential to consciously avoid adverse 
events related to off-target toxicities [266, 270]. Taken together, in vitro and in vivo 
studies with high affinity TCRs, described earlier, indicate that TCR affinity can make a 
difference in target recognition by TCR transduced T cells. But the overall effectiveness 
and safety of high affinity TCRs in patients remains unresolved. As such, each TCR may 
need to be carefully and individually evaluated for how its properties impact a T cell. 
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Genomic Instability and Cross-Reactive TCRs 
Genomic instability plays a central role in allowing viruses and malignancies to 
escape immune surveillance [271, 272]. Mutated antigens enhance virulence by 
escaping HLA-restricted immune responses in viral infections including HBV [273-275], 
HCV [274, 276-279], HIV [280-282], EBV [283, 284], and choriomeningitis [285]. 
Similarly, a wide variety of cancers have displayed various mechanisms of immune 
escape including downregulation of MHC-I expression [187, 188], mutated or 
downregulated antigen processing proteins [286-288], and antigen loss or mutation 
[271, 289, 290]. These mechanisms pose a fundamental problem for antigen-specific 
TCR-engineered T cells that rely on proper processing and presentation of antigens by 
MHC for target recognition. 
Immune escape is not only responsible for ineffective host immune responses, 
but also cause impaired development of preventative and therapeutic vaccines, and 
inherent or acquired resistance to novel treatment strategies including 
immunotherapies. Additionally, immunotherapies designed to elicit potent anti-tumor 
or anti-viral T cell responses like ACT, checkpoint blockade, and cytokine support all 
have potential to fail in light of these immune escape mechanisms. It is imperative to 
investigate novel therapeutic approaches designed to combat genomic instability.  
One potential strategy, highlighted in this dissertation, utilizes cross-reactive TCR 
gene-modified T cells. Traditionally thought to have a lock-and-key specificity, the clonal 
selection theory proposed that individual lymphocytes are specific for a single pMHC, 
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and that alternative ligand recognition is unlikely [291, 292]. This “one-clonotype—one-
specificity” paradigm has been challenged over the years. Based on sheer numbers, the 
notion of >1015 potential foreign peptides (not including self) would require 1015 
different mono-specific TCRs [293, 294]. This does not seem feasible in terms of 
immunologic space or sheer cellular mass. Additionally, the HLA locus is one of the most 
polymorphic and fastest evolving regions of the human genome, currently encoding 
more than 7,000 allelic variants [295]. Such HLA diversity is estimated to increase the 
variety of peptides displayed. Recent studies have suggested that there are less than 108 
distinct TCRs in the human naïve T cell pool [296]. It is argued that the vast diversity of 
peptides and MHC alleles dwarfs that of TCR sequences, requiring TCRs to be able 
provide flexible immune coverage [294].   
Elegant studies have since demonstrated a varied T cell repertoire can be 
selected by a single peptide [297] and that resulting T cells can be activated by 
unrelated peptide sequences [298]. The use of combinatorial peptide libraries also 
demonstrated cross-reactivity of individual T cell clones recognizing over a million 
different individual peptides presented by a single MHC molecule [299-301]. Though 
TCR cross-reactivity is no longer a novel concept, its mechanism, the control of antigen 
sensitivity, the biophysics of TCR-pMHC engagement, and its functional consequences 
are not yet fully understood. 
A deeper understanding of what dictates the cross-reactive nature of a TCR (both 
structurally and functionally) will allow for a more informed approach to designing 
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therapeutics meant to combat mutating antigens and to limit cross-reactivity against 
self-antigens. Thus, engineering T cells with promiscuous TCRs serves not only as a 
potential therapeutic, but a tool to better understand and rationally design TCRs. In this 
way, immune effectors could be equipped with the ability to accommodate recognition 
of mutant antigens associated with immune escape. 
Concluding Remarks 
While the field of TCR gene transfer is still quite new, the use of TCR-transduced 
T cells represents a promising new approach for treating patients with cancer, viral 
infections, and their associated sequelae.  TCR gene transfer also circumvents the 
hurdles of obtaining tumor reactive T cells associated with TIL therapy and other forms 
of adoptive T cell transfer.  The use of viral vectors to engineer T cells with TCR genes 
enables us to generate populations of autologous T cells with limitless specificities. It is 
also clear that the TCR gene transfer approach is feasible and that the TCR transduced T 
cells can be delivered safely; and objective clinical responses in treated patients indicate 
that these genetically engineered T cells can be effective.  
In light of recent clinical success, however, there remain many issues in 
optimizing the efficacy and safety of this type of immunotherapy. Ultimately, extensive 
studies are needed to determine if TCR-engineered T cells can deliver improvements in 
progression-free and overall survival when compared to the other therapies. 
Dependency on co-receptors, pairing competition, and predominantly low affinities of 
physiologic TCRs call for efforts to optimize their use in ACT. But strategies that “blindly” 
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affinity-enhance TCRs are worrisome because they lack the structural understanding 
required to anticipate efficacy and unwanted cross-reactivity. Generation of more 
efficient and safer TCRs warrants a more complete understanding of the basic biology of 
a TCR gene-modified T cell and what factors are truly important in defining antigen 
recognition and T cell function. 
The goal of this dissertation is to better understand structure-function 
relationships between a high affinity, HCV-cross-reactive TCR (HCV1406 TCR) and 
naturally occurring mutant HCV pMHC ligands. We will compare changes in the kinetic, 
cellular, and structural components of TCR-pMHC interactions with the polyfunctional 
output by HCV1406 TCR gene-modified T cells. Taken together, these studies provide us 
with fundamental information to build a more suitable model to confront diseases with 
genomic instability and to better understand what factors govern antigen recognition by 
a T cell. As we learn more about how TCR behavior influences T cell function, we will be 
able to design more effective and safer TCR gene-modified T cells for ACT. 
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CHAPTER TWO 
MATERIALS AND METHODS 
Cell Lines and Media 
 All cell lines were obtained from the American Type Culture Collection (Rockford, 
MD), unless otherwise noted. All media were obtained from Corning Life Sciences 
(Corning, NY) unless otherwise noted. HEK293GP (human embryonic kidney packaging 
cell line expressing retroviral gag and polymerase proteins), COS (monkey kidney tumor, 
HLA-A2-), HepG2 (human hepatocellular carcinoma, HLA-A2+), and Huh-7 (human 
hepatocellular carcinoma, HLA-A2-) cells lines were maintained in DMEM supplemented 
with 10% fetal bovine serum (FBS; Tissue Culture Biologics, Long Beach, CA).  PG13 cells 
(stable viral producer cell line) were maintained in IMEM supplemented with 10% FBS. 
T2 (HLA-A2+, TAP-deficient antigen presenting cell), Jurkat (CD4-CD8- T cell lymphoma), 
and Jurkat76 (CD4-CD8-TCR- T cell lymphoma) cell lines were maintained in RPMI 1640 
medium supplemented with 10%. Jurkat76 cells were kindly provided by Dr. Miriam 
Heemskerk (Leiden University Medical Center, Leiden, Netherlands).  
T Cells 
All PBMC samples used for T cell transductions were obtained as apheresis 
products purchased from Key Biologics (Memphis, TN). Ficoll-Hypaque (Sigma-Aldrich, 
St. Louis, MO) density gradient centrifugation was used to isolate PBL-derived T cells 
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from PBMC of normal healthy donors. T cell clones isolated from HCV-infected 
individuals were generated from PBL samples collected from IRB-approved protocols at 
the University of Colorado Denver. 
 T cells were maintained in complete T cell medium consisting of AIM-V medium 
(Life Technologies, Grand Island, NY) supplemented with 5% heat-inactivated pooled 
human AB serum (hAB; Valley Biomedical, Inc., Winchester, VA), 300 IU/mL recombinant 
human IL-2 (rhIL-2; Novartis Pharmaceuticals Corporation, East Hanover, NJ) and 100 
ng/mL recombinant human IL-15 (rhIL-15; Biological Resources Branch, National Cancer 
Institute, Bethesda, MD) at 37oC in a humidified 5% CO2 incubator.  Prior to retroviral 
transduction, primary T cells were OKT3-activated for 3 days using 50 ng/mL anti-CD3 
mAb (Miltenyi Biotec, Bergisch Gladbach, Germany), in complete T cell medium. 
Cloning of HCV-Reactive T Cells from HCV+ Patients. 
As mentioned above, HCV-reactive T cell clones were isolated from PBMC 
samples from chronically infected patients or those with spontaneously resolved 
infection collected under University of Colorado Denver IRB-approved protocols. HCV-
reactive T cell clones were obtained from the Rosen Lab at the University of Colorado 
Denver. Briefly, T cells were Ficoll-Hypaque separated as described above and stained 
with PE-labeled HLA-A*0201 tetramer folded around HCV NS3:1406-1415 (KLVALGINAV) 
peptide (Beckman Coulter, Marseille, France). Cells were then sorted by flow cytometry 
on a FACSVantage (BD Biosciences, San Jose, CA), and cloned via limited dilution cloning 
as previously described [302].  Briefly, tetramer positive cells were plated at limiting 
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dilution (5, 10, and 100 cells/well) and cultured with 8x104 and 1.6x104 irradiated 
allogeneic PBMC and lymphoblastoid cell line (LCL), respectively in 250 µl/well of AIM-V 
medium supplemented with 5% hAB serum, 100 IU/mL rhIL-2, and 0.03 µg/mL purified 
anti-CD3 mAb (Miltenyi Biotec) in 96 well plates and incubated for 2 wk at 37oC and 5% 
CO2. After 14-21 days, wells exhibiting growth were transferred to T-25 flasks and re-
stimulated with 25x106 and 5x106 irradiated allogeneic PBMC and LCL, respectively, in 
30 mL of AIM-V medium supplemented with 5% hAB serum, 100 IU/mL rhIL-2, and 0.03 
anti-CD3 mAb. Cultures were analyzed by FACS 14 days later and used in functional 
assays. 
Vectors 
HCV NS3 Site Directed Mutagenesis 
The WT HCV NS3 gene fused to GFP by a T2A self-cleaving viral sequence was 
synthesized by Genscript (Piscataway NJ) and provided in a pcDNAIII vector. To generate 
each variant HCV NS3:1406-1415 epitope within full length NS3, site directed 
mutagenesis (GeneArt Site Directed Mutagenesis System, Invitrogen, Grand Island, NY) 
was performed in the pcDNAIII vector using a series of primers (Table 3) synthesized by 
Integrated DNA Technologies (Coralville, IA). Variants 8S/9G/12L and 8S/9S/12L/14S 
required three and four rounds of site directed mutagenesis, respectively. Methylation, 
mutagenesis, and recombination were performed according to manufacturer’s 
protocols. Methylation and PCR amplification was performed on a C1000 Thermal Cycler  
(Bio-Rad, Hercules, CA) under the following conditions: 20 min at 37oC (one cycle),  
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Table 3. Primers used for site-directed mutagenesis of HCV NS3 pCDNAIII vector 
variants. 
Epitope  Forward primer(s): 5’3’ Reverse primer(s): 5’3’ 
V1408L CTCGCCGCAAAGCTGCTCGCGTTGGGCATCA TGATGCCCAACGCGAGCAGCTTTGCGGCGAG 
A1409T GCCGCAAAGCTGGTCACGTTGGGCATCAATG CATTGATGCCCAACGTGACCAGCTTTGCGGC 
I1412L CTGGTCGCGTTGGGCCTCAATGCCGTGGCGT ACGCCACGGCATTGAGGCCCAACGCGACCAG 
I1412V CTGGTCGCGTTGGGCGTCAATGCCGTGGCGT ACGCCACGGCATTGACGCCCAACGCGACCAG 
I1412N TGGTCGCGTTGGGCAACAATGCCGTGGCGTA TACGCCACGGCATTGTTGCCCAACGCGACCA 
V1408S/ 
A1409G/ 
I1412L 
CTCGCCGCAAAGCTGAGCGCGTTGGGCATCAA TTGATGCCCAACGCGCTCAGCTTTGCGGCGAG 
CCGCAAAGCTGAGCGGGTTGGGCATCAATGC GCATTGATGCCCAACCCGCTCAGCTTTGCGG 
CTGAGCGGGTTGGGCCTCAATGCCGTGGCGT ACGCCACGGCATTGAGGCCCAACCCGCTCAG 
V1408T CTCGCCGCAAAGCTGACCGCGTTGGGCATCAA TTGATGCCCAACGCGGTCAGCTTTGCGGCGAG 
V1408S/ 
A1409S/ 
I1412L/ 
A1414S 
CTCGCCGCAAAGCTGAGCGCGTTGGGCATCAA TTGATGCCCAACGCGCTCAGCTTTGCGGCGAG 
GCCGCAAAGCTGAGCTCGTTGGGCATCAATG CATTGATGCCCAACGAGCTCAGCTTTGCGGC 
CTGAGCTCGTTGGGCCTCAATGCCGTGGCGT ACGCCACGGCATTGAGGCCCAACGAGCTCAG 
TCGTTGGGCCTCAATTCCGTGGCGTACTACC GGTAGTACGCCACGGAATTGAGGCCCAACGA 
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followed by 2 min at 94oC (one cycle), followed by 20 sec at 94oC, 30 sec at 57oC, and 5 
min at 68oC (18 cycles), followed by 5 min at 68oC (one cycle).  
Mutated vectors were transformed into Escherichia coli DH5α-T1R competent 
cells (Invitrogen) on LB ampicillin plates (25 g LB agar (Fisher, Hampton, NH) in 1 L de-
ionized water supplemented with 100 µg/mL ampicillin (Sigma-Aldrich), and colonies 
were expanded in superbroth (32 g Tryptone (Fisher), 20 g yeast extract (Fisher), and 5 
grams NaCl (Fisher) in 1 L de-ionized water) supplemented with 100 µg/mL ampicillin 
(Sigma-Aldrich). Plasmid DNA from recombinant clones was isolated using a Miniprep 
Plasmid Isolation Kit (Qiagen, Hilden, Germany) according to manufacturer’s protocol 
and sequenced (Genewiz, South Plainfield, NJ) to confirm that correct mutation had 
been made and no other errors had occurred during the mutagenesis process. Final 
products were used to transfect COS/A2 cells or subcloned into a modified SAMEN 
retroviral vector (described below). 
HCV TCR Retroviral Vectors 
The original SAMEN retroviral vector described by Treisman and colleagues [303] 
has been modified from its original components in stepwise fashion to include TCR chain 
genes [170] and later a CD34t selection marker [304] for our TCR cloning purposes. Our 
modified SAMEN retroviral vectors contains the TCR α chain, P2A self-cleaving linker, 
TCR β chain, T2A self-cleaving-linker, and truncated CD34 molecule (CD34t) as a 
transgene expression marker (Fig 6a). Each HCV1406 TCR and HCV1073 TCR containing 
SAMEN retroviral vector was used to generate high titer produced cell lines used to  
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Figure 6. Structures of retroviral vectors used for gene transfer. A modified SAMEN 
retroviral backbone was used for transferring TCR, HLA-A2, HCV NS3, and CD8 genes to 
alternate effectors and targets. pMFG retroviral vectors were used to transduce HCV 
NS3:1406-1415 and CMVpp65:495-503 minigenes into tumor cell lines. (a) TCR retroviral 
vector containing the HCV1406 TCR or HCV1073 TCR  and  chain genes fused by a P2A 
self-cleaving peptide linker. A truncated version of the CD34 molecule (CD34t), which 
serves as a marker for transduction, was fused to the 3’ end of the TCR  chain via a T2A 
self-cleaving peptide. (b) HLA-A2 encoding retroviral vector. (c) Full length HCV NS3 
fused to GFP by T2A. (d) Full length CD8αβ genes or (e) truncated CD8α’β’ lacking the 
intracellular lck-binding domain fused to an mCherry expression marker separated by 
P2A and T2A self-cleaving linkers, respectively.  Vectors containing either (f) HCV 
NS3:1406-1415 epitope or (g) CMVpp65:495-503 minigenes in pMFG both fused to GFP 
by a T2A. LTR = long terminal repeat; + = packaging signal; SD = splice donor; SA = splice 
acceptor. 
54 
 
  
harvest retroviral supernatants to transduce Jurkat cells and PBL-derived T cells 
(described in a later section). 
Subsequent Retroviral Vector Construction Scheme 
The structure of our modified SAMEN backbone offered the opportunity to swap 
in/out various other genes used for retroviral transduction-mediated delivery. NotI and 
BamHI restriction sites flank the 5’ end of the TCR α chain and the 3’ end of the CD34t 
cassette, respectively. This allowed for simple replacement of TCRα/TCRβ/CD34t with 
other genes/transduction makers with traditional cloning techniques using 5’-
NotI/BamHI-3’ compatible ends. The HLA-A2 gene was synthesized by GenScript and 
provided in the pUC57 vector engineered with 5’ NotI and 3’ BamHI restriction sites. 
HLA-A2 was subcloned out of the pUC57 vector into the modified SAMEN retroviral 
vector. Briefly, vector DNA was transformed into Escherichia coli TOP10 competent cells 
(Invitrogen) on LB ampicillin plates, and colonies were expanded in superbroth 
(supplemented with 100 µg/mL ampicillin (Sigma-Aldrich). Plasmid DNA from 
recombinant clones was isolated using a Miniprep Plasmid Isolation Kit (Qiagen) 
according to manufacturer’s protocol and screened for the presence of each gene of 
interest by restriction enzyme digest analysis. Genes were digested with NotI and BamHI 
restriction enzymes (Thermo Scientific, Grand Island, NY) and products were separated 
on a 1% agarose gel. DNA bands corresponding to the correct length of HLA-A2 were 
excised from the gel and purified (Qiagen) according to manufacturer’s protocol. 
Subsequently, gel-purified DNA was subcloned into the modified SAMEN retroviral 
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vector with compatible restriction sites. A ligation reaction containing T4 DNA ligase 
(New England Biolabs, Ipswich, MA) and T4 DNA ligase buffer (New England Biolabs) 
with vector DNA and insert DNA in a 1:5 vector:insert ratio was incubated  overnight at 
16oC. Ligation products were transformed into competent E. coli and DNA was isolated 
(Qiagen). The final product was sequenced (Genewiz, South Plainfield, NJ) to ensure no 
errors had occurred during the cloning process. 
Additionally, a pCR2.1 “shuttle vector” containing the sequence 5’-
NotI/EcoRI/T2A/transduction marker/BamHI-3’ was used to easily interchange genes 
with various transduction markers (CD34t, GFP, or mCherry) to be subcloned into 
SAMEN. CD8αβ, and CD8α’β’ genes to be inserted into retroviral backbones were 
synthesized by GenScript provided in the pUC57 vector engineered with 5’ NotI and 3’ 
EcoRI restriction sites. Truncated CD8α’β’ gene sequences have been previously 
described [305]. These genes were subcloned out of the pUC57 vector into pC2.1 shuttle 
vector containing mCherry with NotI and EcoRI restriction sites using methods described 
above. The resulting CD8-T2A-mCherry fragments were then excised from pCR2.1 and 
subcloned into the SAMEN vector using NotI and BamHI restriction sites using the same 
methodology. Final products were sequenced (Genewiz) to ensure no errors had 
occurred during the cloning process. 
HCV NS3 retroviral vector. WT HCV NS3 gene fused to GFP by a T2A linker was 
synthesized by Genscript and provided in a pcDNAIII vector. Site directed mutagenesis 
was performed to generate variant 1406-1415 epitopes (described earlier). Each of 
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these subsequent sequences was subcloned from pcDNAIII into SAMEN in the same 
manner as pUC57 vectors described above. 
Final SAMEN retroviral products included HLA-A2 fused to GFP by a T2A linker 
(Fig. 6b), HCV NS3 fused to GFP by a T2A linker (Fig. 6c), CD8α fused to CD8β fused to 
mCherry by P2A and T2A linkers, respectively (Fig. 6d), and CD8α’ fused to CD8β’ fused 
to mCherry by P2A and T2A linkers, respectively (Fig. 6e). 
HCV and CMV minigene retroviral vectors. pMFG retroviral vectors containing 
CMVpp65:495-503 as well as WT and variant HCV NS3:1406-1415 minigenes  fused to 
GFP by a T2A linker  (also containing an additional neor cassette) were kindly provided 
by Zhang Yi in the Nishimura Lab (Fig. 6f-g). All above retroviral vectors were used to 
generate high titer producer cell lines used to transduce PBL-derived T cells, Jurkat cells, 
and multiple tumor cell lines. 
Generation of High Titer Producer Cell Lines 
Generation of stable producer PG13 cell lines was accomplished as follows. For 
each retroviral vector, 3 million 293GP cells were seeded in a 10 cm poly-D-Lysine 
coated tissue culture plate (Thermo Scientific). Cells were co-transfected with 20 µg 
retroviral vector DNA and 5 µg of a plasmid containing the vesicular stomatitis virus 
envelope gene in 50 µl Lipofectamine 2000 (Life Technologies). Media was replaced 6 
hours post-transfection and viral supernatant was collected and 0.45 µm filtered after a 
48 hr incubation at 37oC in 5% CO2. 2 million PG13 cells seeded in a 10 cm tissue culture 
plate were transduced over 72 hours using this fresh viral supernatant at 37oC in 5% 
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CO2. Transduction efficiency was analyzed by measuring CD34, GFP, or mCherry 
expression depending on the retroviral vector used. CD34, GFP, or mCherry positive cells 
were sorted for high and uniform expression using a FACSAria IIIu cell sorter (BD 
BioSciences), and the resulting high-tighter producer cell lines were maintained in IMEM 
supplemented with 10% FBS. 
Preparation of retrovirus for transductions was accomplished by treating PG13 
stable producer cell lines seeded overnight at 8x106 cells/T-175 flask with sodium 
butyrate media (IMEM supplemented with 10% FBS, 1mM sodium butyrate (Sigma-
Aldrich) and 10mM HEPES (Corning Life Sciences) for 8-10 hours. Media was replaced 
with IMEM supplemented with 10% FBS and fresh viral supernatants were harvested 
and 0.45 µm filtered the next day. Virus was used fresh or stored at -80oC for later use. 
Gene Delivery 
HCV TCR Retroviral Transduction  
T cells, Jurkat cells, and Jurkat76 cell lines were transduced by spinoculation as 
previously described [15, 305]. T cells derived from healthy donors were activated for 3 
days prior to spinoculation using 50 ng/mL anti-CD3 monoclonal antibody (Miltenyi 
Biotec) in complete medium. 24-well flat-bottom non-tissue culture-treated plates 
(Thermo Fisher Scientific) were treated with 0.5 mL/well 30 µg/mL retronectin (Takara 
Bio, Otsu, Shiga, Japan) overnight at 4o-C. Plates were blocked with 0.5 mL/well 2% PBSA 
(bovine serum albumin (BSA; Fisher Scientific, Fair Lawn, NJ) in phosphate buffered 
saline (PBS; Corning Life Sciences)) for 30 min at room temperature (RT) and washed 
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with 2 mL/well PBS. 2 mL of fresh or frozen retroviral supernatant was added to each 
well and the plates were spun for 2 hr at 2,000xg at 32oC and aspirated. 2 million 
activated T cells or Jurkat cell lines were gently added to the viral-coated plates in 1 mL 
of AIM-V/5% hAb, 600 IU/mL rhIL-2, and 200 ng/mL rhIL-15 and mixed with 1 mL filtered 
retroviral supernatant. The plates were spun again for 2 hr at 2,000xg at 32oC and 
incubated overnight at 37oC in 5%CO2. After 24 hours, the transduced T cells were 
transferred to tissue-culture treated flasks.  Three days later, transduction efficiency 
was determined by flow cytometry staining for CD34 using anti-CD34-APC mAb 
(Biolegend). Cultures were enriched for TCR-transduced T cells or Jurkat cells by positive 
selection using immunomagnetic beads labeled with anti-CD34 (Miltenyi Biotec) and 
maintained in complete medium. T cells may also have been selectively sorted for CD4+ 
or CD8+ transduced T cells using anti-CD4 or anti-CD8 immunomagnetic beads, 
respectively (Miltenyi Biotec). Purity of selection was confirmed by FACS analysis. 
After immunomagnetic selection, TCR-transduced T cells were further expanded 
using a Rapid Expansion Protocol (REP). Briefly, 1x106 T cells were cultured in an upright 
T-175 cell culture flask with 200x106 irradiated (5000 rads) allogeneic PBMC in 150 mL of 
complete T cell medium supplemented with 30 ng/mL anti-CD3 mAb (Miltenyi Biotec). 
Cells were incubated at 37oC in 5%CO2 for 5 days and harvested for use in functional 
assays. 
 
 
59 
 
  
CD8αβ and CD8α’β’ Retroviral Transduction  
Jurkat and Jurkat76 cells were also transduced via spinoculation (methods 
described above) with a modified SAMEN retroviral vector containing human CD8αβ-
mCherry or CD8α’β’-mCherry (Figs. 6d-e). CD8+ cells were sorted for high and uniform 
expression by FACS using anti-CD8-PerCP/Cy5.5 mAb (Biolegend) and maintained in 
RPMI1640 supplemented with 10% FBS. 
HLA-A2 Retroviral Transduction 
A modified SAMEN retroviral vector containing HLA-A2 (Fig 6b) was used to 
transduce Huh-7 and COS cell lines. Huh-7 and COS cells were seeded in a 24-well tissue 
culture plate to yield 70-80% confluency. Two mL of 0.45 µm-filtered retroviral 
supernatants were applied to each well and incubated for 48 hr at 37oC in 5% CO2. Flow 
cytometry was used to confirm expression of HLA-A2 using an anti-HLA-A2-APC mAb 
(Biolegend, San Diego, CA). Positive cells were sorted for high and uniform expression of 
HLA-A2, and the resulting cell lines were maintained in DMEM supplemented with 10% 
FBS.  
HCV NS3:1406-1415 Ninigene Retroviral Transduction  
pFMG retroviral vectors containing WT or variant HCV NS3:1406-1415 minigenes 
(or the CMVpp65:495-503 epitope as a negative control) (Figs. 6f-g) were used to 
transduce HepG2 and Huh-7 in the same manner described above. HepG2 and Huh-7 
cells were seeded in a 24-well tissue culture plate to yield 70-80% confluency. Two mL 
of 0.45 µm-filtered retroviral supernatants were applied to each well and incubated for 
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48 hr at 37oC in 5% CO2. Flow cytometry was used to confirm expression of minigenes by 
measuring GFP expression. Positive cells were sorted for high and uniform expression of 
GFP, and the resulting cell lines were maintained in DMEM supplemented with 10% FBS 
and 500 µg/mL G418 (Geneticin; Research Products International, Mount Prospect, IL).  
Full length HCV NS3 DNA Transfection 
COS and COS/A2 cells were transiently transfected to express the full length HCV 
NS3 protein with WT or variant 1406-1415 epitopes using pcDNAIII vectors encoding 
HCV NS3 linked to GFP by the self-cleaving viral sequence P2A. Cells were plated in a 24-
well tissue culture plate to yield 70-80% confluency and were transfected with 3 µg DNA 
and 6 µl of Lipofectamine 2000 (Life Technologies) over 48 hours. Flow cytometry was 
used to confirm expression of full length HCV NS3 by measuring intracellular GFP levels. 
Full length HCV NS3 Retroviral Transduction 
Because HepG2 cells were resistant to lipid-based transfection, a modified 
SAMEN retroviral vector encoding HCV NS3-P2A-GFP was used to transduce HepG2 cells 
(Fig 6c). Cells were plated in a 24-well tissue culture plate to yield 70-80% confluency. 
Two mL of 0.45 µm-filtered retroviral supernatants were applied to each well and 
incubated for 48 hr at 37oC in 5% CO2. Flow cytometry was used to confirm expression 
of NS3 by measuring GFP expression. Positive cells were sorted for high and uniform 
expression of GFP, and the resulting cell lines were maintained in DMEM supplemented 
with 10% FBS.  
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Peptides 
All peptides used in functional assays were purchased from Synthetic 
Biomolecules (San Diego, CA) at 95% purity. Peptides were stored in 100% dimethyl 
sulfoxide (DMSO; Sigma-Aldrich) at -80oC at a concentration of 5 µg/µL. A complete list 
of all peptides used, their sequences, and their abbreviations as referred to in the text 
can be found in Table 4.  
Alanine substituted peptides were used as stimulators against T cell clones 
isolated from infected HCV+ patients (Chapter 4) as well as PBL-derived T cells and Jurkat 
cell lines transduced to express the HCV1406 TCR (Appendix). An alanine scanner set for 
the HCV NS3:1406-1415 peptide, was generated by substituting an alanine at each 
residue position (1 through 10) except where an alanine natively occurs. In these cases 
(positions 4 and 9) an isoleucine was substituted for an alanine. 
Naturally occurring mutant sequences for HCV NS3:1406-1415 and HCV 
NS3:1073-1081 epitopes were identified by searching the GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/) using the WT nucleotide sequences. Sequence 
AAGCTGGTCGCGTTGGGCATCAATGCCGTG was used for HCV NS3:1406-1415, while 
sequence TGCATCAATGGGGTGTGCTGGACTGTC was used for HCV NS3:1073-1081. Of 
the 1,000+ sequences recovered for each, silent mutations were eliminated and 8 
naturally occurring mutant epitopes were chosen for each that allowed for a spectrum 
of amino acid changes in position and class. These peptides (also listed in Table 4) were 
used for functional studies discussed in Chapters Four, Five, and Six.  
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Table 4. Peptide names, abbreviations, and sequences used for functional studies. 
Peptide Name Abbreviation Sequence 
Tyrosinase:368-376 Tyro YMDGTMSQV 
CMVpp65:495-503 CMV NLVPMVATV 
   
HCV NS3:1406-1415 HCV1406wt KLVALGINAV 
HCV NS3:V1408L V1408L KLLALGINAV 
HCV NS3:A1409T A1409T KLVTLGINAV 
HCV NS3:I1412L I1412L KLVALGLNAV 
HCV NS3:I1412V I1412V KLVALGVNAV 
HCV NS3:I1412N I1412N KLVALGNNAV 
HCV NS3:V1408S/A1409G/I1412L 8S/9G/12L KLSGLGLNAV 
NS3:V1408T V1408T KLTALGINAV 
HCV NS3:V1408S/A1409S/I1412L/A1414S 8S/9S/12L/14S KLSSLGLNSV 
   
HCV NS3:K1406A K1406A ALVALGINAV 
HCV NS3:L1407A L1407A KAVALGINAV 
HCV NS3:V1408A V1408A KLAALGINAV 
HCV NS3:A1409I A1409I KLVILGINAV 
HCV NS3:L1410A L1410A KLVAAGINAV 
HCV NS3:G1411A G1411A KLVALAINAV 
HCV NS3:I1412A I1412A KLVALGANAV 
HCV NS3:N1413A N1413A KLVALGIAAV 
HCV NS3:A1414I A1414I KLVALGINIV 
HCV NS3:V1415A V1415A KLVALGINAA 
   
HCV NS3:1073-1081 HCV1073wt CINGVCWTV 
HCV NS3:I1074V I1074V CVNGVCWTV 
HCV NS3:I1074L I1073A CLNGVCWTV 
HCV NS3:V1077A V1077A CINGACWTV 
HCV NS3:C1078F C1078F CINGVFWTV 
HCV NS3:V1081N V1081N CINGVCWTN 
HCV NS3:T1080S T1080S CINGVCWSV 
HCV NS3:V1081A V1081A CINGVCWTA 
HCV NS3:T1080S/V1081I 80S/81I CINGVCWSI 
*All peptides were acquired at 95% purity from Synthetic Biomolecules (San Diego, CA). 
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Proteins 
 MHC class I protein was kindly generated by members of the Baker Lab at the 
University of Notre Dame. Recombinant MHC-I was used for peptide-MHC thermal 
denaturation studies as well as TCR-pMHC binding affinity measurements. Briefly, 
recombinant HLA-A*0201 heavy chain and β-2 microglobulin were expressed as 
inclusion bodies in Escherichia coli [306]. Expression of HCV1406 TCR was performed 
similarly. TCR and MHC folding and assembly from inclusion bodies was performed 
according to standard procedures [307]. Protein was purified using ion exchange 
followed by size-exclusion chromatography. 
Cytokine Release Assay 
Antigen reactivity by HCV1406 TCR or HCV1073 TCR transduced T cells and Jurkat 
cell lines was measured in cytokine release assays as previously described [168]. Briefly, 
HCV+ tumor cells or peptide-loaded T2 cells were routinely used as stimulators. T2 cells 
were pulsed with 10 µg/mL peptide for 2 hrs prior to co-culture. Titration of HCV1406 
TCR reactivity used peptide concentrations ranging from 10 – 0.00001 µg/mL. 1x105 
responder and stimulator cells were co-cultured in a 1:1 ratio in 96-well U-bottom tissue 
culture plates in 200 µL complete medium. Ten ng/mL phorbol 12-myristate 13-acetate 
(PMA; Sigma-Aldrich) was added to Jurkat cell co-cultures to enhance sensitivity to 
stimulation. Co-cultures were incubated at 37oC for 20 hrs and supernatants were 
harvested. The amount of IFNγ or IL-2 released by 105 T cells or Jurkat cells, respectively, 
was measured via ELISA (R&D Systems, Minneapolis, MN). 
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Immunofluorescence Staining Reagents 
A table summarizing all immunofluorescence staining reagents can be found in 
Table 5. Sections below describe the applications for various reagents used. 
Immunofluorescence Antibodies  
Fluorochrome-conjugated antibodies were used to detect T cell surface markers 
(CD3, CD4, CD8), transduced or endogenous TCRs, and CD34 as a marker for 
transduction. Additionally, TCR-transduced T cells were analyzed for activation markers 
CD25 and CD69 and inhibitory markers PD-1 and TIM-3 to characterize a representative 
population of TCR-transduced PBL-derived T cells. In functional assays, TCR-transduced T 
cells were also stained for lytic marker CD107a and intracellular cytokines IFNγ, TNFα, IL-
2, IL-4, IL-17A, and IL-22. Pairing of fluorochromes to antibodies was determined by 
established staining profiles of each antibody to allow for detection of bright, dim, and 
negative populations. Spectral overlap between fluorescent dyes was also considered.A 
summary of antibodies, selected fluorochormes, and their manufacturers are listed in 
Table 5. 
Dextramers and Tetramers  
APC-labeled HLA-A*0201 dextamer folded around WT HCV NS3:1406-1415 
(KLVALGINAV) (Immundex, Copenhagen, Denmark) was used as a surrogate for TCR 
expression as commercially available antibodies do not bind HCV1406 TCR very well. The 
NIH Tetramer Core Facility at Emory University (Atlanta, GA) kindly provided a panel of 
monomers and tetramers used for tetramer binding experiments. The core provided  
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Table 5. Reagents and manufacturers used for immunofluorescence. 
Use Reagent Clone 
Conjugated 
Fluorochrome 
Manufacturer 
Transduced T 
Cell Culture 
Characterization 
(Chapter Three) 
anti-CD3 SK7 APC/Cy7 Biolegend§ 
anti-CD4 161A1 FITC Biolegend 
anti-CD8 SK1 AF† 700 Biolegend 
anti-CD34 581 PerCP/Cy5.5 Biolegend 
anti-CD25 BC96 BV‡ 711 Biolegend 
anti-CD69 FN50 PE/Cy7 Biolegend 
anti-PD-1 EH12.2H7 BV 421 Biolegend 
anti-TIM-3 F38-2E2 BV 605 Biolegend 
KLVALGINAV/HLA-
A*0201 Dextramer 
N/A APC Immudex¶ 
anti-TCR Vβ13.6 N/A PE Beckman Coulter|| 
     
T Cell Surface 
Markers 
(Remaining 
Chapters) 
anti-CD3 UCHT1 APC/Cy7 Biolegend 
anti-CD4 RPA-T4 PE/Cy7 Biolegend 
anti-CD34 561 PE Biolegend 
anti-CD107a H4A3 BV 510 Biolegend 
     
Polyfunctionality 
Assay-Specific 
Surface Markers 
anti-CD3 UCHT1 APC/Cy7 Biolegend 
anti-CD4 RPA-T4 PE/Cy7 Biolegend 
anti-CD8 SK1 FITC Biolegend 
anti-CD34 581 AF 700 Biolegend 
anti-CD107a H4A3 BV 510 Biolegend 
     
Intracellular 
Cytokines 
anti-IFNγ 4S.B3 BV 421 Biolegend 
anti-TNFα Mab11 BV 711 Biolegend 
anti-IL-2 
MQ1-
17H12 
PerCP/Cy5.5 Biolegend 
anti-IL-4 8D4-8 AF 647 Biolegend 
anti-IL-17A BL168 BV 570 Biolegend 
anti-IL-22 BG/IL22 PE Biolegend 
     
†AF, Alexa Fluor ‡BV, Brilliant Violet; §Biolegend, San Diego, CA; ¶Immudex, 
Copenhangen, Denmark; ||Beckman Coulter, Marseille, France 
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Table 5. Reagents and manufacturers used for immunofluorescence (cont’d). 
Use Reagent Clone 
Conjugated 
Fluorochrome 
Manufacturer 
Tetramer 
Staining and 
Dissociation 
Experiments 
KLVALGINAV/ 
HLA-A*0201 
N/A 
APC (supplied 
as a monomer) 
NIH Tetramer Core 
Facility# 
KLLALGINAV/ 
HLA-A*0201 
N/A APC NIH Tetramer Core Facility 
KLVTLGINAV/ 
HLA-A*0201 
N/A APC NIH Tetramer Core Facility 
KLVALGLNAV/ 
HLA-A*0201 
N/A APC NIH Tetramer Core Facility 
KLVALGVNAV/ 
HLA-A*0201 
N/A APC NIH Tetramer Core Facility 
KLVALGNNAV/ 
HLA-A*0201 
N/A APC NIH Tetramer Core Facility 
KLSGLGLNAV/ 
HLA-A*0201 
N/A APC NIH Tetramer Core Facility 
KLTALGINAV/ 
HLA-A*0201 
N/A APC NIH Tetramer Core Facility 
KLSSLGLNSV/ 
HLA-A*0201 
N/A APC NIH Tetramer Core Facility 
YMDGTMSQV/ 
HLA-A*0201 
N/A APC NIH Tetramer Core Facility 
Streptavidin N/A APC Prozyme** 
#NIH Tetramer Core Facility at Emory University, Atlanta, Georgia; **Prozyme, Hayward, 
CA 
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HLA-A*0201 monomers folded around WT HCV NS3:1406-1415 (KLVALGINAV) or 
tyrosinase:368-376 (TMDGTMSQV) at 2.0 mg/mL. They also provided APC-labeled HLA- 
A*0201 tetramers folded around WT and variant HCV NS3:1406-1415 peptides at 1.5 
mg/mL. A full description of tetramers and monomers provided is listed in Table 5. 
Monomer Tetramerization 
HLA-A*0201 monomers (folded around HCV NS3:1406-1415 and tyrosinase:368-
376) supplied at 2.0 mg/mL were tetramerized by adding  13.9 μL of 2.1 mg/mL 
streptavidin-APC (Prozyme, Hayward, CA) at RT 10 times in 10 minute intervals. At the 
end of 10 additions of streptavidin-APC, monomers were fully tetramerized with a slight 
excess of streptavidin-APC. 
Tetramer Binding Experiments 
Saturating concentrations of WT and variant HCV NS3:1406-1415 tetramers were 
evaluated for HCV1406 TCR transduced Jurkat or Jurkat76 cells and HCV1406 TCR-
transduced Jurkat as well as Jurkat76 cells engineered to co-express full length CD8αβ. 
Cell lines were incubated with each tetramer, concentrations ranging from 1x10-7 to 
1x10-12, and either anti-CD34/AF700 (Biolegend) (for Jurkat cells) or anti-CD3-APC/Cy 
(Biolegend) (for Jurkat76 cells) in 2% PBSA/0.2% sodium azide (Sigma-Alrich) on ice for 
at least 2 hr in the dark. Because it has been shown the presence of anti-CD8 antibodies 
can alter tetramer binding [308-310], cells were not co-stained for CD8. Rather, the 
presence of CD8 was measured by transgene marker mCherry. Cells were washed and 
resuspended in ice-cold 2% PBSA/0.2% sodium azide, and analyzed for bound 
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fluorescent tetramers using an LSRFortessa flow cytometer (BD Biosceinces). 
Fluorescence of the non-TCR-transduced cells was used for background subtraction to 
determine specific binding to TCR-transduced cells. Specific tetramer binding for each 
concentration of tetramer was calculated for each cell line as follows: 
CD8+ Jurkat:  %Tetramer+CD34+mCherry+  –  %Tetramer+CD34-mCherry + 
CD8- Jurkat: %Tetramer+CD34+mCherry -  –  %Tetramer+CD34-mCherry - 
CD8+ Jurkat76:  %Tetramer+CD3+mCherry +  –  %Tetramer+CD3-mCherry + 
CD8- Jurkat76: %Tetramer+CD3+mCherry -  –  %Tetramer+CD3-mCherry - 
Bi-Functional T cell Reactivity Assay 
Percentages of IFNγ producing and/or lytic HCV1406 TCR -transduced T cells was 
measured in an intracellular IFNγ/surface CD107a-detection assay. 3x105 responder and 
3x105 stimulator cells were co-cultured in a 1:1 ratio in 96-well U-bottom tissue culture 
plates in 200 µL complete medium. Five µL anti-CD107a mAb, 5.0 ng/mL brefeldin-A, 
and 2.0 nM monensin (all Biolegend) were added at the start of co-culture. Co-cultures 
were incubated at 37oC for 5 hours, and cells were stained for immunofluorescence 
against cell surface antigens for 20 minutes at RT. Subsequently, cells were fixed in 
Fixation Buffer (Biolegend) for 20 min, washed 3 times in Permeabilization and Wash 
Buffer (Biolegend), and counterstained for intracellular IFNγ for 20 min at RT. Data were 
acquired using an LSRFortessa flow cytometer (BD Biosciences). CD34+ events 
(transduced T cells) were gated into CD4+CD8- or CD4-CD8+ populations using FlowJo vX 
(TreeStar, Ashland, OR). Percentages of CD107a+IFNγ- (lytic only), CD107a+IFNγ+ (lytic 
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and cytokine-secreting), CD107a-IFNγ+ (cytokine-secreting only), or CD107a-IFNγ- (non-
reactive) cells were calculated for both CD34+CD4+CD8- and CD34+CD4+CD8- T cell 
populations and frequencies were converted into pie charts. 
Polyfunctional T Cell Lysis and Multi-Intracellular Cytokine Assay 
In similar methods described above, HCV+ tumor cells or peptide-loaded T2 cells 
were put into co-culture with HCV1406 TCR-transduced PBL-derived T cells. 3x105 
responder and 3x105 stimulator cells were mixed in a 1:1 ratio in 96-well U-bottom 
tissue culture plates in 200 µL complete medium. Five µL anti-CD107a mAb, 5.0 ng/mL 
brefeldin-A, and 2.0 nM monensin (all Biolegend, San Diego, CA) were added at the 
beginning of the co-culture. Co-cultures were incubated at 37oC for 5 hours, and cells 
were stained for cell surface antigens for 20 minutes at RT. Subsequently, cells were 
incubated in Fixation Buffer (Biolegend) for 20 min, washed 3 times in Permeabilization 
and Wash Buffer (Biolegend), and stained for intracellular cytokines for 20 min at RT. 
Cells were washed, resuspended in Cell Staining Buffer (Biolegend), and analyzed by 
flow cytometry. Samples were acquired using a LSRFortessa flow cytometer (BD 
Biosciences). Staining profiles were gated and analyzed using FlowJoX software 
(TreeStar, Ashland, OR). 
Multi-Dimensional Flow Cytometry Data Analysis 
Seven-parameter functional analysis by flow cytometry yields datasets far too 
complex to analyze in traditional flow cytometry analysis software such as FlowJo. We 
evaluated a series of software packages in their ability to visualize and interpret our 
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complex, high dimensional data assessing T cell polyfunctionality. Some of the 
requirements of these tools are to be able to represent rare and high frequency 
populations, visualize the data at a single cell level, preserve the relationships and 
geometry of the data, and provide an interpretable view of the data for publication or 
presentation. The programs available ranged from all manual gating to unsupervised 
gating, and analysis algorithms contained clustering, dimension reduction, hierarchy 
extraction and/or t-Distributed Stochastic Neighbor Embedding (tSNE).  
In order to uniformly evaluate the different analysis methods, the same set of 
polyfunctional T cell stimulation data was analyzed in each approach. Below we present 
detailed methods, highlighting representative graphical output for each tool evaluated. 
We also provide commentary on the general benefits and drawbacks and the feasibility 
of (or lack thereof) in generating meaningful interpretation of changes in T cell 
polyfunctionality. For consistency, we use the same experimental dataset for the 
comparison of each tool, and for simplicity, we illustrate only comparisons of negatively 
(tyrosinase:368-376) or positively (WT HCV NS3:1406-1415) peptide-stimulated HCV 
TCR-transduced CD8+ T cells. It is pointed out where additional comparisons between 
CD8+ and CD4+ T cells as well across variant peptide or tumor stimulation conditions 
would be easily interpreted in subsequent analytical approaches or would make the 
data more complicated to discern a biological message.  In summary, the goal of these 
comparative evaluations was to generate simple and meaningful graphical output 
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evaluating changes in HCV1406 TCR-transduced T cell polyfunctional phenotypes in 
response to variant HCV NS3:1406-1415 peptide and tumor stimulations. 
Gating Strategy  
Lymphocyte populations were discerned by FSC vs. SSC comparison, and events 
were gated on CD4+CD8- or CD4-CD8+ populations. CD4+ or CD8+ T cells were then gated 
on CD34+ expression to define our transduced cell populations. These CD4+CD8-CD34+ or 
CD4-CD8+CD34+ were subsequently used as starting points for subsequent analysis using 
the remaining software strategies. Functional parameters included CD107a, IFNγ, TNFα, 
IL-2, IL-4, IL-17A, and IL-22. 
GemStone 
GemStone, available through Verity Software House  (Topsham, ME), uses 
probability state modeling (PSM) to represent a set of cellular progressions or “Cell 
Types”, originally engineered to analyze and visualize multidimensional cellular 
populations [311]. The basis of PSM is creating a model consisting of different Cell 
Types, which are defined by the user. Using the information available for each of the 
Cell Types, parameter profiles are then created, and these Cell Types are used as 
progression steps in the model.   Relationships between parameters may be discovered 
and transitional cell types may also be defined. As a model is built, complexity may be 
added and then tested with the data to be analyzed.  
Major benefits of PSM analysis include accounting for population overlap, simple 
clustering routines, and identifying populations without giving biological 
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interrelationships. Additionally, gates are not drawn using GemStone so there is neither 
subjectivity nor operator variability. While gating defines positive and negative, 
GemStone allows for transitional populations and can allow for up- and down-regulation 
of markers. One disadvantage, however, is that design of templates used for analysis 
requires knowledge of some biology of the system.  
A TriCOM is a tool contained within GemStone that is used to show different 
phenotypes and activation states (Fig. 7). TriCOM analysis displays concentric pie charts 
for each level of co-expressed parameters. Multiple parameters in a single cell 
population are represented by multiple colors within a single wedge. 
For our purposes, the TriCOMs showed a distinct visualization of cytokines 
present at each order of staining, but the concentric pie charts became much harder to 
read when analyzing higher orders of staining (≥3 parameters). For example, the 
proportions of cells expressing only one cytokine each are relatively easily interpreted 
(Fig. 7, bottom pie chart). It becomes less clear, however, when trying to resolve 
populations greater than three parameters or looking at two parameter positive cells 
that occur in low frequencies. Overall, while TriCOMs are useful tools that clearly 
visualize phenotypes, they can become difficult to read at greater than three 
parameters or for low frequency populations. Additionally, making comparisons across 
multiple treatment groups would require a large number of TriCOMs with so many 
functional parameters evaluated. 
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Figure 7. GemStone TriCOM analysis. TriCOMs display percentage of CD8+ HCV1406 
TCR-transduced T cells positive for combinations of functional markers in concentric pie 
charts. The bottom pie chart represents frequency of cells positive for only 1 marker, 
and each pie chart above it represents an additional level of staining up to 7 
simultaneous markers (top pie chart). Functional phenotypes are represented by a 
single wedge with multiple colors. Frequency of cells in each category is shown to the 
right of each pie chart. Phenotypes at each level are coded by the colors that make up 
each wedge. Purple=CD107a, Blue-IFNγ, Turquoise=TNFα, Green=IL-2, Gray=IL-4, 
Pink=IL-17A, Gold=IL-22.  
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Spanning-Tree Progression Analysis of Density-Normalized Events 
Spanning-tree Progression Analysis of Density-Normalized Events (SPADE) was 
created to aid in visualization and analysis of multi-parameter data. This algorithm, 
available through Cytobank (Mountain View, CA; http://www.cytobank.org), is designed 
to extract a hierarchy from high-dimensional cytometry data in an unsupervised 
manner. This enables multiple cell types to be visualized in a branched tree structure 
[312].  SPADE contains 4 modules: i) Density-dependent down-sampling, which allows 
rare as well as abundant populations to be represented equally; ii) Agglomerative 
clustering, which separates the down-sampled data into groups containing cells with 
similar phenotypes; because the rare cells are represented equally, a node for these 
cells can be created; iii) A minimum spanning tree is created which connects all of the 
clusters with a minimal edge length; iv) Each data file is up-sampled, with the cells being 
mapped to the appropriate cluster.  The clusters are then organized and displayed as a 
two dimensional tree. SPADE has been most useful for studies looking at cell 
populations with mixed lineages or tracking distinct cellular progressions [312-315].  
Clusters form nicely when certain markers are mutually exclusive from others or if there 
is a clear progression of cellular phenotypes. After spanning-trees are generated, other 
markers can be analyzed for their intensity within these nodes, but only one a time. 
The major benefits of SPADE are that the user does not need to know a 
hierarchical order before analysis and that rare cell types are identifiable. It is also 
scalable with increasing numbers of parameters. As such, investigators can infer likely 
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cellular processes and hierarchies without needing predetermined hierarchies. The 
spanning tree is only limited by choice of markers used in an experiment and the 
subsets used for building a tree.  The major limitation of SPADE, however, is that data 
are represented as clusters rather than individual cells so single cell resolutions is lost. 
And if spanning trees fail to cluster, few useful conclusions can be made. 
For our purposes, a SPADE-derived spanning-tree was not optimal in determining 
a cellular progression of T cell polyfunctionality. Cytokine phenotypes did not cluster, 
and instead of a tree, a web-like pattern was generated. Although it is clear there are 
visual differences between spanning-trees of tyrosinase versus WT NS3:140601415 
peptide-stimulated TCR-transduced T cells (Fig. 8), SPADE-generated spanning-trees 
were not useful in easily determining phenotypes of each individual node. Addition of 
parameters that would cluster naive, memory, activating, or inhibitory T cell markers 
would create more nodal or mutually exclusive populations but would limit our ability to 
evaluate as many cytokines. 
Self-Organizing Maps of Visualizing and Interpretation of Cytometry Data 
Self-Organizing Maps of Visualizing and Interpretation of Cytometry Data 
(FlowSOM) also focuses on clustering as well as being a visualization aid [316]. An R-
based program available through BioConductor (Seattle, WA), this algorithm consists of 
four steps. First, the data is read. Data can be compensated, transformed and gated and 
then exported by FlowJo, or these functions may be performed using FlowSOM itself 
within R. Second, a self-organizing map is built which is an artificial neural network,  
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Figure 8. Graphical output provided by clustering tool SPADE. SPADE-generated 
spanning trees represent phenotypic clustering of CD8+ HCV1406 TCR-transduced T cells 
after co-culture stimulation (a) tyrosinase:368-376 or (b) WT HCV NS3:1406-1415 
peptides. Colored nodes refer to cell density. Cytokine profiles of each node are unable 
to be graphically displayed.  
a) 
b) 
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containing a grid of nodes. These nodes represent a single point in multidimensional 
space. Cells are then classified to the nearest node, and the grid places nodes that 
closely resemble each spatially proportionally. Third, a minimal spanning tree is built 
connecting the nodes that are most similar to each other in minimal branches. Lastly, 
metaclustering calculates the expected number of nodes if there is a much larger 
amount of clusters than the expected number of cell types. After this process, the data 
may be visualized either as a minimal spanning tree, similar to SPADE, or as a grid. Each 
node is coded as a pie chart with information about the phenotype of cells in that node. 
The benefits of using FlowSOM is that even though this is an R-based program, 
using the provided documentation only a minimal understanding of R will allow you to 
successfully use this program. The program also does not tax the memory usage of a 
desktop computer, and the output is very detailed. Each node of the minimal spanning 
tree contains colored wedges corresponding to the measured functional parameters.  
Similar to our analysis in SPADE, there are clear visual differences between 
NS3:1406-1415 peptide stimulation compared to negative control tryosinase (Fig. 9). 
However, the identification of nodal phenotypes was difficult to interpret. Overall,  
clustering tools can be very useful for when tracking distinct cellular progressions or 
measuring changes in mixed cell populations with distinct lineages. But when looking at 
a subset of T cells without mutually exclusive markers present, clustering tools are not 
optimal to make these multi-dimensional analyses. 
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Figure 9. Graphical output provided by clustering tool FlowSOM. FlowSOM-generated 
minimal spanning trees represent phenotypic clustering of CD8+ HCV TCR-transduced T 
cells after co-culture stimulation with (a) tyrosinase:368-376 or (b) WT HCV NS3:1406-
1415. Size of each node corresponds to cell density. Colored pie wedges refers to 
cytokine(s) produced by each nodal population.  
IL-2 
IFNγ 
CD107a 
TNFα 
IL-4 
IL-22 
IL-17A 
b) 
a) 
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viSNE 
viSNE, also available through Cytobank, is a tool for the visualization of high-
dimensional single-cell data. Analysis places a cell in a two-dimensional map but 
preserves the separation between types. This mapping takes advantage of the inherent 
structure of the data where different types are in separate regions in high-dimensional 
space. viSNE uses a nonlinear dimensionality reduction algorithm which is based on t-
Distributed Stochastic Neighbor Embedding (t-SNE) [317]. t-SNE calculates a distance 
matrix in high dimensional space, which is transformed into a similarity matrix. Low 
dimensional similarities are calculated using Student’s t-distribution. viSNE generates a 
representation of this data that is similar to a biaxial plot and retains the geometry of 
the populations. The data is represented as cells in high-dimensional data space and 
does so without relying on traditional gating strategies. viSNE can also discretely and 
automatically separate cells based on subtype, provided they exist. The cyt feature 
allows for coloring of cells based on selected expression markers. The data appears as a 
cloud biaxial plot with a specific geometry. Differences in populations can be seen as 
changes in the geometry, and events may be colored to determine which parameter or 
parameters have changed.  
A major benefit with using viSNE is that comparisons are made in high 
dimensional space. When there are populations that do not resolve when examined in 2 
or 3 dimensions, viSNE can overcome that obstacle. viSNE is also unsupervised and does 
not require in depth knowledge of the system being investigated. A limitation of viSNE is 
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that low-dimensional mapping cannot represent all of the information in high 
dimensional space as viSNE only captures the most dominant structures. Additionally, 
plots become too crowded when more than 30,000 cells are shown.   
For our purposes, viSNE was able to detect distinct changes in our populations 
when examining cytokines or CD107a singly (Fig. 10), but determination of 
polyfunctional populations required cumbersome mental overlap of the plots. For 
example, while it is evident that IFNγ+ cells reside in the top right corner of its 
corresponding cyt map, it is logical to conclude that TNFα directly overlays much of this 
area. IL-2 also seemingly occupies much of the cyt map where TNFα is positive as well, 
but that IL-4 but is limited in its overlap with IFNγ. While these observations support 
what FlowJo-generated dotplots suggest, making conclusive arguments by mentally 
overlapping multiple plots is difficult. This would be even more challenging when 
comparing multiple T cell subsets or across multiple stimulation conditions. While 
others have shown a cyt plots with color gradients coding for the number of cytokines 
present using t-SNE within R [318], viSNE is currently unable to spatially compare 
multiple cytokines in the same plot for our analysis.  
FLOw Clustering without K 
FLOw Clustering without K (FLOCK) is an unsupervised algorithm analysis 
publically available through Immunology Database and Analysis Portal (ImmPort; 
http://www.immport.org), sponsored by the NIAID, for open use by the immunology 
research community. FLOCK computationally determines the number of unique  
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Figure 10. viSNE-generated cyt maps. cyt maps displaying collected events in a 
tyrosinase peptide stimulation (top left panel) or HCV peptide stimulation (remaining 
panels) for expression of CD107a, IFNγ, TNFα, IL-2, and IL-4. Scale (blue to red) 
corresponds to strength of parameter fluorescence (low to high, respectively). 
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populations in high dimensional flow data using a rapid binning approach and maps 
across independent samples [319]. Relying on predetermined gating of populations of 
interest, it color-codes various populations within a matrix of biaxial plots. FLOCK can 
calculate many useful summary statistics through cross-sample analysis to compare 
differences across treatment groups, and is a model-independent approach to multi-
parameter analysis.  
There are 5 steps in this analysis algorithm. i) Data preprocessing: Compensated 
FCS files were converted to tab-delimited text files using a FlowJo export function. The 
data consisted of a table of rows and columns defined by cells and measured 
parameters, respectively. The columns are normalized so that the balance of each 
parameter is normalized. ii) Grid-based density clustering: Data is portioned into equally 
sized bins, and partitioning is applied to all dimensions in the dataset simultaneously. 
Each dimension is portioned into the same number of bins, resulting in partitions of n-
dimensional space called hyperregions.  Each hyperregion is assessed to determine the 
number of events in the region.  If events exceed a specific threshold, the hyperregion is 
called dense. iii) Centroid generation: Hyperregions are grouped together if they are 
adjacent to each other in n-dimensional space, each called a dense hyperregion group. 
The centroids representing all events in each dense hyperregion group are then 
determined. iv) Event assignment: After centroids are determined, each event is 
assigned to its closest centroid. The centroids are updated based on the newly assigned 
events, and the cluster membership is computed again with the new centroids. This 
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procedure, after a few iterations, is regarded as a modified K-means determination. 
FLOCK quickly converges to a stable result during the centroid recalculation, and unique 
populations are identified.  The visualization module of FLOCK contains two-dimensional 
dot plots with each population colored uniquely. Expression profiles of a population are 
presented to indicate the approximate expression level of each marker of a population 
as negative, low, or high. 
Major advantages of FLOCK are that any up-front gating can be performed using 
FlowJo, which is a familiar tool, and FLOCK’s ease of use. Data can be easily uploaded, 
and after answering a few questions an analysis is requested with a subsequent 
notification after it has been completed. 
For our purposes, FLOCK was able to identify distinct populations based on 
intensity of staining for each pair-wise comparison of functional parameters (Fig. 11). 
For example, the red population (Pop. 1) corresponds to the third most prevalent 
population consisting of IL-2 low, IFNγ negative, CD107a low, IL-17A low, TNFα negative, 
IL-4 low, and IL-22 low expressing CD8+ T cells. In this way, FLOCK adds greater 
resolution to individual polyfunctional populations but at the expense of graphical 
clarity. To be able to track changes in polyfunctional populations across variant epitope 
stimulations would require eight additional matrices per T cell subset analyzed. Overall, 
the ability to visualize each population with corresponding quantitative data is a very 
nice and useful aspect of FLOCK. But large-scale comparative analysis requires too many 
plots for clear evaluations. 
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Figure 11. Quantitative multidimensional dotplots generated in FLOCK. FLOCK analysis displays pairwise comparisons using a 
matrix of dotplots to display the relationship of expression among the 7 functional parameters. Color-coded populations for various 
combinations of markers are accompanied with frequency percentages and description of staining intensity. 1=negative 
fluorescence; 2=low fluorescence; 3=positive fluorescence; 4=high fluorescence. 
8
4 
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Simplified Presentation of Incredibly Complex Evaluations 
Simplified Presentation of Incredibly Complex Evaluations (SPICE) uses large 
FlowJo datasets to graphically normalize data. Preprocessing of the data is performed 
using both FlowJo and Pestle. After sequential gating in FlowJo, Pestle offers data 
formatting and background subtraction of multivariate datasets, which are import into 
SPICE for graphical and statistical analyses. While background subtraction can result in 
below zero values, SPICE has a threshold approach which will minimize systematic bias 
and can maximize the amount of information that can be gained from positive 
measurements [320]. SPICE also offers the ability to statistically compare the 
distributions for all parameters. A χ2 measurement uses a nonparametric partial 
permutation (Monte Carlo simulation) to determine the differences between samples. 
Visualization of data includes pie charts, bar graphs, and cool plots, a type of heat map.  
The major benefits of using Pestle/SPICE are the ease of use, readily available 
software and its range of simple visualization of data. A major drawback of SPICE 
analysis, however, is that the data is initially manipulated in FlowJo, which means a 
significant amount of subjectivity is present. Another potential drawback is the software 
is currently only offered for Apple MacTM usage.For our purposes, tandem analysis in 
Pestle/SPICE most clearly displayed polyfunctional phenotypes of TCR-transduced T 
cells. A complete interpretation of SPICE-generated data is provided in Chapter Six. 
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Hierarchical Clustering Analysis 
This approach was made popular in the era of gene expression microarray data 
analysis where both tissue samples and genes would be clustered to identify genes that 
could distinguish between tissue subtypes. The frequencies of the 128 possible 
combinations of seven parameters (generated in FlowJo) are formed into a 128xk matrix 
where k is the number of different conditions to be compared (e.g. k = 7 if there are 7 
different peptide conditions included).  The row corresponding to the frequency of cells 
with no parameters is removed, leaving a matrix of 127xk. Next, the correlation matrix 
of the 127 patterns is calculated, creating a 127x127 matrix representing the similarity 
of patterns across the cells under the different peptides. The correlation matrix is then 
used to perform agglomerative (“bottom up”) hierarchical clustering in which patterns 
that are most similar to each other (i.e. have the highest correlation) are put into one 
cluster, and clusters that are similar are merged.  There are many references that 
provide details of the algorithm and specify the different options the user is required to 
choose (i.e., similarity metric, and distance metric between clusters (called the 
“linkage”), agglomerative vs. divisive clustering) to fully generate the dendrogram (i.e., 
the tree-structure) [321].  For our purposes, we used correlation as our similarity metric, 
average linkage, and agglomerative clustering. Graphical representations are included 
with discussion of the data in Chapter Six. A comparison of all multi-dimensional flow 
cytometry data analysis strategies evaluated for T cell polyfunctionality is summarized in 
Table 6.
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Table 6. Summary of approaches used to analyze antigen-specific polyfunctional T cell responses.  
Software Analysis Strategy Advantages Disadvantages 
Graphical 
Display 
Available 
Through:* 
FlowJo 
Basic flow cytometry software 
package; Manual, sequential 
gating 
Popular, widely used 
software; output can be 
imported into other 
multidimensional software 
tools 
Limited in scope for analyzing 
>2 dimensions. Time 
consuming and subjective 
gating 
Histograms 
and dot 
plots 
TreeStar (P) 
GemStone 
Probability state modeling; 
template driven analysis 
Accounts for population 
overlap and simple clustering 
routines; lack of gating 
eliminates subjectivity and 
operator variability 
Templates require knowledge 
of some biology of the system; 
TriCOMs visually hard to 
interpret and compare  ≥3 
parameters 
TriCOMs 
Verity 
Software 
House (P) 
SPADE 
“Spanning-tree Progression 
Analysis of Density-Normalized 
Events”; unsupervised 
clustering extracts cellular 
hierarchy 
No prior knowledge of 
hierarchical order needed; 
scalable; better for mutually 
exclusive markers and mixed 
lineage populations 
Represents data as clusters 
rather than individual cells; 
does not appropriately analyze 
if data does not lend itself to 
clustering 
Spanning 
trees 
Cytobank 
(F/P) 
FlowSOM 
“Self-Organizing Maps of 
Visualizing and Interpretation 
of Cytometry Data”; R-based 
clustering tool 
Similar to SPADE; while R-
based, only requires minimal 
understanding of R to 
effectively use 
Similar to SPADE; difficultly 
detailed data to compare 
across multiple treatment 
groups 
Minimal 
spanning 
trees or 
grids 
Bioconductor 
(F) 
*(P) = software for purchase; (F) = freeware; (F/P) = freeware with additional purchasable options 
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Table 6. Summary of approaches used to analyze antigen-specific polyfunctional T cell responses (cont’d) 
Software Analysis Strategy Advantages Disadvantages 
Graphical 
Display 
Available 
Through:* 
viSNE 
Nonlinear dimensionality 
reduction algorithm based on 
t-Distributed Stochastic 
Neighbor Embedding 
(t-SNE) 
Unsupervised and does not 
require in depth knowledge of 
the system; preserves cell 
separation and retains prior 
gating information 
Low-dimensional mapping 
cannot represent all the 
information in high 
dimensional space; cyt 
maps require visual 
overlay to make multi-
dimensional comparisons 
cyt maps 
Cytobank 
(F/P) 
FLOCK 
“FLOw Clustering without K”; 
unsupervised rapid binning 
Up-front gating relies on 
familiar FlowJo; delineates 
populations based intensity of 
expression profiles; cross-
sample statistical analysis 
Difficult to demonstrate 
differences between 
populations with very 
complex matrices 
Color-coded 
dot plots 
ImmPort (F) 
Hierarchical 
Clustering 
Analysis 
Agglomerative “bottom up” 
clustering tool 
Uses FlowJo generated 
population frequencies; can 
show response relatability 
across treatment groups 
Subjective gating 
generates bias; 
Dendogram
/ heat map 
R (F) 
SPICE 
“Simplified Presentation of 
Incredibly Complex Data”; 
quantitatively compares 
discrete phenotypic profiles in 
a mixture; uses FlowJo output 
with formatting tool Pestle 
Ease of use and clear 
visualization of complex 
datasets; offers background 
subtraction and permutation 
statistical analysis 
manual gating within 
FlowJo affords significant 
amount of subjectivity 
Pie charts, 
bar graphs, 
“cool plots” 
NIAID (F) 
*(P) = software for purchase; (F) = freeware; (F/P) = freeware with additional purchasable options 
8
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In Vivo Xenograft Model 
Prior to tumor challenge, scid/beige mice (n=5 per treatment group) were given 
2Gy total body irradiation. 107 HCV NS3:1406-1415 minigene+ or HCV- HepG2 cells 
were injected subcutaneously in 0.1 cc saline. Generally, palpable tumors formed 
within 7 days after tumor challenge. Once palpable tumors formed, mice were 
adoptively transferred 106 or 107 HCV1406 TCR-transduced T cells, 107 tyrosinase-
reactive TIL 1383I TCR-transduced T cells, or no T cells. Tumor volume was measured 
every three days through day 70 post tumor challenge. A Wilcoxon rank sum test was 
used to determine significant difference in tumor burden between treatment groups. 
Circular Dichroism Spectroscopy 
Thermal denaturation of peptide/MHC complexes was performed by Yuan Wang 
in the Baker Lab at the University of Notre Dame as described previously [322, 323]. 
Briefly, proteins were dissolved in 20 mM phosphate, 75 mM NaCl, pH 7.4 at a 
concentration of 10 µM. Circular dichroism (CD) spectroscopy was performed on a Jasco 
J815 instrument (Jasco, Inc., Easton, MD). Temperature was increased from 10 °C to 100 
°C at an increment of approximately 1 °C/min, monitoring at a wavelength of 218 nm. 
Data analysis was performed in OriginPro 9.0. Because unfolding is irreversible, the 
resulting derivative curve was processed with a single peak fitting algorithm to fit the 
peak to a Gaussian function to determine the Tm and its standard error. 
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Surface Plasmon Resonance 
 TCR-pMHC binding affinity between HCV1406 TCR and WT or mutant HCV 
NS3:1406-1415/HLA*0201 was measured by the Baker Lab at the University of Notre 
Dame via surface plasmon resonance (SPR). SPR was performed using a Biacore 3000 
instrument (GE Healthcare) in 10 mM HEPES, 150 mM NaCl, 3 mM EDTA and 0.005% 
surfactant P20 (pH 7.4). The TCR was covalently coupled to a CM5 sensor chip via 
standard amine coupling. Equilibrium experiments were performed by injecting 70 µl of 
multiple concentrations of the pMHC complex at a flow of 5 µl/min. Injected 
concentrations ranged from 0.5 µM to 200 µM. The responses at equilibrium were 
determined by averaging the signal over the final 10 s of the injection and subtracting 
the responses from identical injections over a mock surface. Experiments were 
performed at 25oC. All injections were repeated three times. Fitting was performed with 
Biaevaluation 3.0.1 using a 1:1 binding model. 
Modeling of TCR-pMHC Complexes 
Computational modeling experiments were performed by Timothy Riley in the 
Baker lab at the University of Notre Dame. TCR-pMHC structural models were 
constructed using a template-based approach described recently [324].  Briefly, 
sequences for the HCV1406 and HCV1073 TCRs were aligned and compared to a panel 
of HLA-A2 restricted TCRs with known TCR-pMHC structures to serve as model 
templates.  A template TCR was selected if the TCR alignment indicated strong sequence 
similarity and/or minor loop length changes.  The DMF5-MART-1/HLA-A2 TCR-pMHC 
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complex [325] was selected as the template for the HCV1406 complex and the B7-
Tax/HLA-A2 complex [326] was chosen for HCV1073.  Using PyRosetta, a python toolkit 
for the Rosetta protein design suite [327, 328], the given TCR sequences and peptides 
were mapped onto the three-dimensional coordinates of the template TCRs and 
peptides in the TCR-pMHC complexes.  Repacking the amino acid sidechains and an 
energetic minimization of the CDR loops/peptides generated initial models of the target 
TCRs.  
Further design work performed in Rosetta followed a steepest descent design 
where many independent decoy structures were generated for each modeling stage.  
Each model underwent one stage for low resolution docking, one stage for high 
resolution docking, and multiple stages for CDR loop modeling.  Using the energy 
scoring function Talaris2013 [329], the lowest scoring decoys from each stage were 
chosen for the next step.  Following generation of an initial TCR-pMHC model, 10,000 
decoys were generated with fully randomized pMHC and TCR docking orientations 
coupled with a low resolution rigid body energy minimization move.  Since many decoys 
generated in this stage were low scoring, preference was given to structures with 
docking angles similar to the template.  After the low resolution docking stage, loop 
randomization and modeling was performed as previously described with generation of 
100 decoys for each CDR loop [330].  The first round of loop modeling was followed by 
generation of 10,000 decoys with 3 Å, 8 rigid body perturbations and docked in high 
resolution.  The final stages consisted of sequentially modeling each modified CDR loop 
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until Rosetta scores were no longer decreasing between stages.  The final model of 
HCV1406 required 19 stages and HCV1073 required only 12 stages due to a high 
template similarity (See Appendix). Structural analysis was performed with PyMol and 
Discovery Studio. 
Determination of HCV1406 TCR— NS3:1406-1415/HLA-A*0201 Crystal Structure 
Crystal structure determination was performed by Yuan Wang in the Baker Lab 
at the University of Notre Dame. Crystals of the HCV1406 TCR—WT HCV NS3:1406-
1415/HLA-A2 complex were grown in 13% (v/v) PEG 3350, 0.1M Sodium cacodylate, pH 
6.1, 0.2M ammonia sulfate and 3% (w/v) 1,5-diaminopentane dihydrochloride at a 
protein concentration of 6mg/mL at 20°C. Crystallization was performed by hanging 
drop vapor diffusion. For cryoprotection, crystals were transferred into 20% 
glycerol/80% mother liquor for 30s and immediately frozen in liquid nitrogen. 
Diffraction data were collected at 22ID (SER-CAT) beamlines at the Advanced Photon 
Source, Argonne National Laboratories, Argonne, IL.  Rigid body refinement followed by 
TLS refinement was performed with program Phenix [331] and Refmac5 [332]. 
Evaluation of models and fitting to map were performed with program COOT [333]. The 
model was checked in WHATIF and MolProbity to evaluate the structure during the 
refinement. Atomic positioning was verified with a simulated annealing composite OMIT 
map calculated in Phenix. The structure has been deposited into Protein Data Bank (PDB 
ID 4ZEZ). 
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Ethics Statement 
All recombinant DNA and retroviral transduction work was done under approved 
Medical University of South Carolina, University of Chicago, University of Colorado 
Denver, University of Notre Dame, and Loyola University of Chicago Institutional 
Biosafety Committee (IBC) protocols. All applicable international, national, and/or 
institutional guidelines for the care and use animals were followed. All animal studies 
were conducted under approved Medical University of South Carolina (MUSC) 
Institutional Animal Care and Use Committee (IACUC) protocols. The University of 
Colorado Denver institutional review board (IRB) approved the study for the collection 
of PBMC samples to generate HCV-reactive T cells clones, as described above. All adult 
subjects were provided written informed consent. All other human materials used were 
either established, de-identified tumor cell lines or PBMC purchased from commercial 
sources. 
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CHAPTER THREE 
TCR GENE-MODIFIED T CELLS CAN EFFICIENTLY TREAT ESTABLISHED HEPATITIS C-
ASSOCIATED HEPATOCELLULAR CARCINOMA: A PROOF OF CONCEPT 
 
Rationale 
As described earlier, many groups have reported that retroviral vectors 
containing TCR genes can be used to redirect the specificity of PBL-derived T cells to 
recognize tumor cells [15, 34, 165, 168, 169, 259, 334, 335]. Recent clinical success with 
TCR gene-modified T cells to treat malignancies such as melanoma encourages the 
investigation of using this approach to treat other malignancies and viral infections [210, 
211, 336]. Available technology to TCR-gene modify T cells allows for the generation of 
therapeutic autologous T cells with new anti-viral and anti-tumor immunity, provided an 
effective TCR against a viral/tumor antigen has been identified and target cells can be 
recognized. 
While the bulk of the studies in this dissertation focus on TCR cross-reactivity 
against mutagenic HCV epitopes, it is both prudent and logical to first firmly characterize 
basic T cell reactivity against its wildtype (WT) cognate ligand. Such fundamental 
information would also be imperative when evaluating the therapeutic potential of any 
TCR. In this chapter, we discuss the rationale behind the original selection of this TCR 
and how its gene transfer into PBL-derived T cell facilitates recognition of HCV+ tumor 
targets in vitro and in vivo, providing potential therapeutic benefit.
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As with any candidate for TCR gene therapy, there needs to be a rationale 
behind both the target and receptor selection. HCV is a model target for exploring the 
potential use of such adoptive transfer techniques to treat virally-infected cells and 
tumor cells. HCV infects approximately 130-150 million people globally [337] and 
chronic infection can lead to associated liver diseases including cirrhosis and 
hepatocellular carcinoma (HCC). These diseases are a leading cause of liver 
transplantation in the United States and Europe [338, 339]. Although standard 
combined therapy of pegylated-IFNα and ribavirin (RBV) have had some success, there 
has been much greater clinical responses when treating HCV+ patients with newly FDA-
approved NS3/4A protease inhibitors boceprevir, telaprevir, and simeprevir [340-342]. 
Despite this recent success, the rapidly mutating HCV genome can generate drug 
resistant variants, which might lead to virologic breakthrough or relapse [343-345]. 
Moreover, many patients who may be cured of HCV infection by these novel drugs may 
have already developed associated disease or malignancies that cannot be treated 
effectively by these anti-viral agents. These issues combined with hindered preventative 
and therapeutic vaccine development [346, 347] warrants exploration of other novel 
methods to treat HCV infection and its associated disease such as HCC. 
The TCR we have selected as a candidate to treat HCV-associated HCC recognizes 
HCV NS3:1406-1415, a highly antigenic and mutagenic epitope of the helicase/protease 
NS3, restricted by HLA-A2, and is referred to here as HCV1406 TCR. We have previously 
shown that this HCV1406 TCR was isolated from a T cell clone found in an HCV+ HLA-A2- 
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patient who received an HLA-A2+ liver allograft [302] and that we can genetically 
engineer Jurkat cells with HCV1406 TCR to recognize HCV+ targets [165]. In the sections 
described below, we demonstrate that transduced PBL-derived T cells can recognize 
naturally processed HCV NS3 protein in HCC cell lines in vitro and can inhibit the growth 
of established HCV+ tumors in vivo. These results indicate that HCV1406 TCR-engineered 
T cells may serve as a potential immunotherapy to treat HCV-associated HCC. Moreover, 
these studies provide the basis of WT ligand reactivity and provide a foundation of 
cross-reactive antigen recognition studies in subsequent chapters.  
HCV1406 TCR-Transduced T Cells Can Recognize Naturally Processed HCV NS3  
Although we have shown that TCR-transduced Jurkat cells can recognize HCV 
NS3:1406-1415 peptide-loaded T2 cells and minigene-expressing tumor cells [165], it is 
critical to establish that TCR gene-modified primary T cells can recognize both peptide-
loaded targets and HCV+ tumors to validate its potential use in ACT and provide a 
foundation for WT antigen reactivity. 
The best system to assess TCR-transduced T cell recognition of HCV antigen 
would be to use HCV-infected primary liver cells or liver tumor cells, but human liver 
containing HCC cells infected with HCV were not available for our experiments. As an 
alternative, we engineered HepG2 cells to express HCV NS3:1406-1415 as a minigene. 
Anti-CD3-activated PBL-derived T cells transduced with HCV1406 TCR for in vitro 
experiments were enriched for TCR transgene expression using anti-CD34 
immunomagnetic beads. The enriched populations are routinely ≥95% CD34+ post 
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magnetic sort. Both CD4+ and CD8+ TCR-transduced T cell populations (CD3+CD34+) post 
immunomagnetic selection are highly activated (CD25+CD69+) with low levels of 
exhaustion markers PD-1 and TIM-3. Due to poor staining with available V11 
antibodies, dextramer binding is shown to measure expression of the introduced TCR. 
Dextramer staining also allows us to identify properly paired introduced TCR. 
Representative immunofluorescence analysis for experimental HCV1406 TCR-
transduced T cells is shown in Figure 12a. T cells transduced to express HCV1406 TCR 
secreted large amounts of IFNγ when stimulated by HepG2 cells (HLA-A2+) either pulsed 
with HCV NS3:1406-1415 peptide or expressing the HCV minigene (Fig. 12b). Similarly, 
TCR-transduced T cells recognized Huh-7 cells (HLA-A2-) only when transfected to 
express the HCV minigene and HLA-A2. Thus, we have shown for the first time that 
HCV1406 TCR-transduced PBL-derived T cells can recognize HCV+ tumor targets. 
Because HCV antigen expression as a minigene is not naturally processed for 
presentation, we wanted to test HLA-A2-restricted recognition of naturally processed 
and presented HCV NS3:1406-1415 derived from a larger protein (full length NS3) to 
more accurately reflect physiologic conditions. COS/A2 cells were transiently 
transfected with a pcDNAIII vector encoding the full length HCV protein NS3 linked to 
GFP. Typical transfections yielded 40-60% GFP expression (Figure 13a). These HCV TCR-
transduced T cells were capable of recognizing the naturally processed HCV NS3 in an  
HLA-A2-dependent manner (Fig. 13b). Robust IFNγ secretion was observed when 
stimulated with COS/A2/NS3 but not any other cell lines. Additionally, HepG2 cells   
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Figure 12 HCV1406 TCR-transduced T cell recognition of HCV+ hepatocellular 
carcinoma cells.  PBL from three normal donors were transduced with the HCV1406 TCR 
retroviral vector and enriched for CD34t expressing cells using anti-CD34 
immunomagnetic beads. (a) Representative populations of CD34-enriched TCR-
transduced T cells. TCR-transduced T cells were analyzed for HCV NS3:1406-1415 
dextramer binding and markers of activation (CD25, CD69) or exhaustion (PD-1, TIM-3). 
(b) HCV1406 TCR-transduced T cells from three representative normal donors (Donor A 
(white bars), Donor B (black bars), Donor C (striped bars)) were co-cultured with various 
stimulators. (left panel) T2 cells alone or loaded with NS3:1406-1415 peptide or control 
CMVpp65 peptide; (middle panel) HepG2 cells (HLA-A2+) alone, pulsed with HCV peptide 
or expressing the HCV minigene; (right panel) Huh-7 cells (HLA-A2-) alone or expressing 
the HCV minigene±HLA-A2. IFNγ secretion was assessed as a single-point ELISA by Yi 
Zhang (University of Chicago). 
a) 
b) 
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Figure 13. HCV1406 TCR transduced T cells can recognize naturally processed HCV NS3:1406-1415 antigen. PBL from a normal 
donor was transduced with the HCV1406 TCR retroviral vector and immunomagnetically enriched for CD34t expressing cells. (a) COS 
and COS/A2 cells were transiently transfected with pcDNAIII expression vector harboring HCV NS3-GFP and analyzed for transfection 
efficiency. (b) HepG2 cells were transduced with a retroviral vector encoding HCV NS3-GFP and were analyzed for transfection 
efficiency. Transduced T cells were stimulated with T2 cells loaded with HCV NS3:1406-1415 or tyrosinase:368-376 peptides and     
(c) COS±HLA-A2 cells or (d) HepG2 cells engineered to express full length HCV NS3 protein. The amount of IFNγ released (average ± 
standard deviation of triplicate wells) was measured by ELISA. 
a) b) 
c) 
d) 
9
9 
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transduced to express NS3 (Fig. 13c) also stimulated substantial IFNγ secretion by 
HCV1406 TCR-transduced T cells (Fig. 13d). These data indicate that HCV1406 TCR gene-
modified T cells can recognize naturally processed HCV NS3 antigen, meaning they may 
have therapeutic potential against HCV-associated HCC. 
HCV NS3:1406-1415 Recognition by HCV1406 TCR-Transduced PBL Is CD8-Indpendent 
To verify CD8-independent recognition of both peptide and tumor, we purified 
TCR-transduced CD4+ and CD8+ T cells from a bulk culture and stimulated each T cell 
subset with peptide-loaded and HCV+ tumor targets. Figure 14 demonstrates that CD8-
independent recognition is conserved against peptide-loaded or HCV+ tumor targets as 
both purified CD4+ and CD8+ TCR-transduced T cells secreted robust amounts of IFNγ 
when stimulated by HCV-loaded T2 cells and HCV+ HepG2 cells. Moreover, our HCV TCR-
transduced T cells displayed lytic behavior as measured by CD107a surface expression 
against peptide-loaded targets and HCV+ HepG2 cells (Fig. 15). Counterstaining for 
intracellular IFNγ also revealed that reactive T cells can be lytic, IFNγ -producing, or 
both. CD4+ and CD8+ T cells also exhibited distinct heterogeneous functional 
phenotypes. Therefore, we are able to generate both CD8+ and CD4+ effectors, 
potentially offering MHC class I-restricted helper function against this HCV antigen in 
vivo. 
HCV TCR-Transduced T cells Mediate the Regression of Established HCV+ HCC In Vivo 
While our in vitro data firmly demonstrates that both CD4+ and CD8+ TCR-
transduced T cells can be lytic and produce IFNγ, it is necessary to validate in vivo   
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Figure 14. Recognition of HCV NS3:1406-1415 by HCV1406 TCR-transduced PBL-
derived T cells is CD8-independent.. HCV1406 TCR-transduced PBL were 
immunomagnetically purified into CD4+ (black bars) or CD8+ (white bars) populations. 
Stimulators included T2 cells pulsed with 10 µg/mL of HCV NS3:1406-1415 peptide or 
control tyrosinase:368-376 peptide as well as HepG2 engineered to express the HCV 
NS3:1406-1415 minigene. The amount of IFNγ release (average ± standard deviation of 
triplicate wells) was measured by ELISA. 
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Figure 15. Lytic and IFNγ-producing ability of HCV1406 TCR transduced T cells reactive 
against HCV NS3:1406-1415.  T2 cells pulsed with HCV NS3:1406-1415 or 
tyrosinase:368-376 and HCV+ HepG2 cells were used as targets and co-cultured with 
transduced PBL. Cells were immunofluoresnce stained for CD3, CD4, CD8, CD34, 
CD107a, and intracellular IFNγ. Gating and data analysis was performed in FlowJo. Pie 
charts reflect reactivity of TCR-transduced (CD34+) CD4+ (left) or CD8+ (right) T cells. Pie 
chart percentages are represented as CD107a+IFNγ- (lytic only=blue), CD107a+IFNγ+ (lytic 
and cytokine-secreting=red), CD107a-IFNγ+ (IFNγ -producinng only=green), or CD107a-
IFNγ- (non-reactive=gray). 
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recognition of HCV+ tumors in a xenograft mouse model to establish therapeutic 
potential. We established HCC tumors in scid/beige mice (n=5 per treatment group) by 
subcutaneous injection of HCV+ or HCV- HepG2 cells. Once the tumors were palpable 
(day 7 post injection), transduced T cells were adoptively transferred. HCV+ tumor-
bearing mice exhibited reduced tumor growth after adoptive transfer of 107 HCV TCR-
transduced T cells but not when treated with tyrosinase-reactive TIL 1383I TCR-
transduced T cells or a lower dose (106) of HCV TCR-transduced T cells (Fig. 16). It is 
important to note that in the experiment presented HCV+ HepG2 tumors in untreated 
mice grew at a slower rate after day 30 than in other HCV+ tumor-bearing mice groups. 
We attribute this to experimental variation since other experiments demonstrated more 
uniform HCV+ tumor growth in other treatment groups (Zhang, unpublished). 
Regardless, the change in tumor burden at day 70 between HCV TCR-transduced T cell-
treated HCV+ and HCV- HepG2-tumor bearing mice exhibited significance with a p-value 
of 0.02 as determined by Wilcoxin Rank Sum Test. In at least one instance, HCV+ tumors 
harvested from 107 HCV TCR-transduced T cells exhibited antigen loss, which could 
explain why tumors were not completely eliminated even though displaying a 
statistically significant reduction in tumor burden (Zhang, unpublished). Taken together, 
these data further support the HCV+ HCC recognition capability by HCV1406 TCR- 
transduced T cells and the potential for HCV1406 TCR-transduced T cells to be used in 
patients. 
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Figure 16. HCV1406 TCR-transduced T cells inhibit the growth of established HCV+ 
hepatocellular carcinoma tumors in vivo. Parental HepG2 (black) or HCV+ HepG2 
(white) tumors were established in scid/beige mice (n=5 per treatment group). Mice 
were given no T cells (diamonds), 107 TIL 1383I TCR-transduced T cells (circles), or 106 
(x’s) or 107 (squares) HCV1406 TCR-transduced T cells on day 7 post tumor challenge. 
Statistically significant differences in tumor growth over 70 days was determined using 
the Wilcoxon rank sum test, p=0.02. These data were generated by Yi Zhang (University 
of Chicago). 
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Significance 
 HCV1406 TCR-transduced T cells demonstrated their ability to recognize HCV 
NS3:1406-1415 peptide-loaded targets as well as naturally processed antigen presented 
by HCV+ HCC cells. Furthermore, in our xenograft model, HCV+ tumor-bearing mice 
exhibited tumor regression after adoptive transfer of HCV1406 TCR-engineered human T 
cells. These data suggest that HCV1406 TCR-transduced T cells may provide therapeutic 
benefit against HCV infection and/or its associated disease, such as HCC. 
Of interest is the phenotypic heterogeneity observed in TCR-transduced T cells 
reactive against peptide-loaded targets and naturally processed HCV+ tumors. While 
both CD4+ and CD8+ T cells are capable of recognizing these targets, they expressed IFNγ 
and CD107a in different proportions. While most reactive CD4+ T cells secreted IFNγ in 
response to these targets, some cells exhibited cytolytic activity as indicated by CD107a 
expression. Conversely, a greater number of CD8+ T cells exhibited a lytic phenotype; 
those that secreted IFNγ were more likely to simultaneously express CD107a as well. 
These data support other reports that CD4+ T cells can exhibit cytolytic activity [348-351] 
and provide insight into the heterogeneous behavior of T cells expressing the same TCR. 
Interestingly, not all CD34+ T cells produced IFNγ or expressed CD107a. As shown in 
Figure 12, there is a range of CD34 expressed on TCR-transduced T cells, and only a 
subset of CD34+ TCR-transduced T cells bound dextramer (indicating properly paired 
HCV1406 TCR). Perhaps, there is a minimal amount of CD34+ (TCR transgene) expression 
necessary to facilitate TCR engagement with pMHC, activating a functional response. 
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This could explain why not all CD34+ T cells were reactive against HCV targets. 
Additionally, IFNγ-CD107a-CD34+ T cells may be producing other cytokines not evaluated 
in these experiments and are not actually “non-reactive”. The influence of TCR density 
on antigen recognition as well as evaluating reactivity by other cytokines is addressed in 
subsequent chapters. 
Taken together, we have established a proof-of-principle that we can generate 
HCV1406 TCR gene-modified CD4+ and CD8+ PBL-derived T cells capable of recognizing 
and inhibiting the growth of HCV+ tumor targets. They may provide a useful tool to treat 
patients with HCV-associated diseases, such as HCC. While important observations for a 
potential immunotherapeutic candidate, these data also lay the groundwork for 
subsequent cross-reactive characterization of this TCR in light of HCV’s genomic 
instability.  
 Several groups have reported that mutations in the HCV genome can lead to 
HCV antigen escape variants [279, 352-356]. In this way, it is speculated that HCV can 
evade the immune response resulting in disease progression. Although it is not clear to 
what extent antigen loss actually leads to disease progression, especially in HCC, TCR 
gene transfer may provide an opportunity to treat patients with HCV antigen escape 
variants should a TCR exhibit cross-reactive behavior against prevalent variants. The 
next chapter describes cross-reactive behavior of TCRs against mutagenic HCV antigens, 
serving as a model to combat diseases of genetic instability.
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CHAPTER FOUR 
HEPATITIS C VIRUS-CROSS-REACTIVE TCR GENE-MODIFIED T CELLS: A MODEL FOR 
IMMUNOTHERAPY AGAINST DISEASES WITH GENOMIC INSTABILITY 
 
Rationale 
As described in Chapter One, the genomic instability of cancers and viruses can 
serve as a mechanism for immune escape, leading to HLA downregulation, alterations in 
antigen processing, antigen loss, and antigen mutation [187, 188, 271, 288, 289]. 
Contributing to poor host immune responses, such mechanisms of immune escape pose 
barriers for the development of preventative and therapeutic vaccines and impair the 
design of effective immunotherapies. Therefore, it is important to investigate novel 
treatment approaches designed to combat genomic instability.  
The HCV genome contains several regions that are genetically unstable and 
mutate readily [357, 358], making HCV an excellent model for genomic instability. 
Immune escape variants may be potential therapeutic targets for HCV infection and its 
associated disease. Despite the recent clinical success of FDA-approved protease 
inhibitors [359, 360], the very genomic instability that allows for immune escape could 
generate acquired resistant variants to these novel drugs [361, 362]. Therefore the use 
of cross-reactive TCRs targeting mutagenic epitopes may be advantageous in this 
instance. 
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We chose to use HCV as our TCR cross-reactivity model for a variety of reasons. 
First, we have the available reagents to assess T cell reactivity against mutant HCV 
epitopes. We have previously cloned multiple high-affinity HCV-reactive TCRs capable of 
transferring reactivity to both CD4+ and CD8+ PBL-derived T cells [165, 166]. Additionally, 
we have selected panels of naturally occurring and epidemiologically relevant 
immunogenic epitopes to assess cross-reactivity of a pair of HCV-reactive TCRs. More 
importantly, HCV is epidemiologically significant with a worldwide prevalence of 3% 
[337]. Strong evidence suggests that the immune system plays a key role in mediating 
viral clearance [357], but that weak or ineffective immune responses can lead to chronic 
infections [363-365]. A hallmark of HCV, and most relevant to this study, is its high rate 
of replication coupled with the lack of proofreading ability of its polymerase [366, 367]. 
This genomic instability is thought to lead to immune escape variants that evade T cell 
recognition [274, 276-278, 357, 358]. However, T cells’ ability to cross-recognize 
mutated epitopes has been previously associated with viral control [368, 369], 
suggesting TCR cross-reactivity may be advantageous for viral clearance. Additionally, 
while ineffective immune responses may be partially caused by low avidity T cells [365, 
370], it has been suggested that high avidity T cells can also quell HCV immune escape 
by selective pressure [365]. So in diseases with genomic instability, such as HCV, it 
would optimal to generate T cells with both high avidity and cross-reactivity [365].  
In this chapter, we examined whether T cells harboring cross-reactive TCRs might 
offer a therapeutic solution in instances of genomic instability, using HCV as a model. 
109 
 
 
We demonstrated cross-reactivity of two TCRs against immunogenic and mutagenic 
NS3:1406-1415 and NS3:1073-1081 epitopes in TCR-gene-modified T cells. Our 
approach includes: (1) functional studies demonstrating cross-reactive profiles; (2) 
epidemiological data supporting the relevance of mutant epitopes targeted in these 
studies; (3) TCR-pMHC structural modeling to rationalize how TCR structural properties 
accommodate recognition of certain mutated epitopes; and lastly, we (4) provide 
preliminary clinical evidence suggesting cross-reactive TCR may facilitate HCV viral 
clearance. Together, this approach serves as a model to address diseases with genomic 
instability and highlights the potential benefit of cross-reactive TCRs. A better 
understanding of such TCRs’ promiscuous behavior may allow for exploitation of these 
properties to develop novel adoptive T cell-based therapies. 
HCV1406 TCR Is Cross-Reactive Against Naturally Occurring  
HCV NS3:1406-1415 Mutant Epitopes 
We have previously reported on an HLA-A2-restricted, HCV NS3:1406-1415-
reactive TCR from an allo-specific CD8+ T cell clone isolated from an HCV+ HLA-A2+ 
patient who received an HLA-A2- liver allograft [302]. In Chapter Three, we described 
our ability to transfer CD8-independent reactivity against HCV peptide-targets and HCV+ 
HCC cells to both Jurkat cells and primary T cells [165, 371]. Because this TCR lacked any 
selective pressure against A2-restricted antigens during development or in the 
periphery, we wanted to test any potential diversity in recognition against altered but 
physiologically relevant HCV ligands. In this manner, HCV1406 TCR served as an optimal 
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candidate to assess cross-reactivity against diseases of genomic instability. We identified 
a variety of naturally occurring mutant epitopes with a GenBank search using the 
nucleotide sequence for the WT HCV NS3:1406-1415 epitope KLVALGINAV. Results were 
filtered for silent mutations and a panel of selected mutant epitopes with amino acid 
substitutions varying in both position and class is listed in Table 7. HCV1406 TCR-
transduced PBL-derived T cells from three representative normal healthy donors were 
generated as previously described [304], and enriched for transduced cells as described 
in Chapters Two and Three.  
Cross-recognition of naturally occurring mutant HCV NS3:1406-1415 epitopes 
was tested by stimulating bulk cultures of HCV1406 TCR-transduced T cells with T2 cells 
loaded with WT or mutant NS3:1406-1415 peptides in IFNγ release assays (Fig. 17). Of 
the eight naturally occurring mutants tested, seven induced robust IFNγ production by 
TCR-transduced T cells similar to or greater than that of WT peptide stimulation. We 
generally classify “reactive” peptides as those that elicit at least 200 pg/mL and twice 
above background IFNγ levels. Only T2 cells loaded with variant V1408S/A1409G/I1412L 
(subsequently referred to as 8S/9G/12L) were not recognized by a bulk culture of all 
three donors T cells. Of note, Donor B exhibited substantially less IFNγ secretion across 
all peptide stimulation conditions and did not recognize mutants A1409T, I1412N, and 
V1408S/A1409S/I1412L/A1414S (subsequently referred to as 8S/9S/12L/14S). A peptide 
titration from 1 µg/mL – 0.00001 µg/mL suggested Donor B had an overall lower 
functional avidity against the WT peptide (Fig. 18). Further analysis of Donor B’s   
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Table 7. HCV NS3:1406-1415 and NS3:1073-1081 mutant epitope sequences and 
epidemiological frequencies. 
Epitope Sequence Genotype Frequency (%)* 
HCV NS3:1406-1415 KLVALGINAV 1a 43.46 
V1408L KLLALGINAV 1b 0.31 
A1409T KLVTLGINAV 1a 1.31 
I1412L KLVALGLNAV 1a 1.63 
I1412V KLVALGVNAV 1a/1b 31.7/0.31 
I1412N KLVALGNNAV N/A† N/A 
8S/9G/12L KLSGLGLNAV 1a/1b 0.65/42.81 
V1408T KLTALGINAV 1a 1.63 
8S/9S/12L/14S KLSSLGLNSV 1b 0.31 
    
HCV NS3:1073-1081 CINGVCWTV 1a/1b 90.2/41.59 
I1074V CVNGVCWTV 1a/1b 1.31/45.57 
I1074L CLNGVCWTV 1b 0.61 
V1077A CINGACWTV 1a 0.98 
C1078F CINGVFWTV 1a 0.33 
V1081N CINGVCWTN N/A N/A 
T1080S CINGVCWSV 1a 0.33 
V1081A CINGVCWTA 1a 0.33 
80S/81I CINGVCWSI 1a 0.98 
    
Tyrosinase:368-376 YMDGTMSQV N/A N/A 
*Frequencies based on the 918 collected HCV genome sequences in the Los Alamos HCV 
Sequence Database (http://hcv.lanl.gov/content/index). †N/A: Epitope not found in 
database. 
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Figure 17. HCV1406 TCR-transduced PBL are cross-reactive against naturally occurring 
HCV NS3:1406-1415 variants. HCV1406 TCR-transduced PBL from three representative 
donors (A, black bars; B white bars; C gray bars) were co-cultured with T2 cells pulsed 
with 10 µg/mL of WT or mutant HCV NS3:1406-1415 peptides or tyrosinase:368-376 as a 
control. IFNγ secretion was measured by ELISA. Mean and standard deviation of 
triplicate measurements are shown. All variants that qualified as reactive in the text 
secreted at least 200 pg/mL IFNγ and twice above background. These data were 
generated by Gretchen Lyons in the Nishimura Lab (University of Chicago). 
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Figure 18. Relative avidity of HCV1406 donors A and B against WT HCV NS3:1406-1415. 
HCV1406 TCR-transduced PBL were co-cultured with peptide-loaded T2 cells in 
concentrations ranging from 1 - 0.00001 µg/mL. IFNγ secretion was measured by ELISA. 
Mean and standard deviation of triplicate measurements are shown. Relative avidity 
curves and estimated EC50 values of Donors A (solid, black triangles) B (dashed, white 
circles), and C (dotted, gray diamonds) are shown. These data were generated by 
Gretchen Lyons in the Nishimura Lab (University of Notre Dame). 
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transduced T cells revealed 87% CD4+ with only 10% CD8+ T cells. Comparatively, Donors 
A and C had much higher levels of CD8+ T cells compared to CD4+ T cells at 32% CD4+ / 
61% CD8+ and 14% CD4+ / 72% CD8+, respectively (data not shown). Together, these 
observations suggest that some mutant epitopes may require CD8 to be recognized, 
even though we have previously shown recognition of the WT antigen is CD8-
independent.  
Some but Not All NS3:1406-1415 Mutant Epitopes Require the CD8 Co-Receptor 
The data described above suggest that T cells may require CD8 to cross-
recognize some but not all HCV NS3:1406-1415 epitopes. To test this hypothesis, we 
evaluated the cross-reactivity of HCV1406 TCR-transduced Jurkat cells (natively CD8- 
[165, 305]) or Jurkat cells we engineered to express the α and β genes of CD8. 
Transduced cells were stimulated with peptide-loaded T2 cells, and subsequent IL-2 
release was measured by ELISA (Fig. 19). Transduced CD8- Jurkat cells recognized WT 
NS3:1406-1415 and mutants V1408L, and I1412V with similar or greater IL-2 secretion 
than CD8+ Jurkat cells. Interestingly, recognition of I1412L and V1408T was also CD8-
independent but CD8- Jurkat cells released only 25-50% as much IL-2 compared to CD8+  
Jurkat cells. In contrast, IL-2 production after stimulation with T2 cells loaded with 
mutants A1409T, I1412N, 8S/9S/12L/14S was restricted to CD8+ Jurkat cells. These 
observations suggest that certain amino acid substitutions may lower the affinity of the 
TCR-pMHC interaction enough to require stabilization by CD8 to facilitate recognition. 
These data are supportive of transduced PBL cross-reactivity shown in Figure 18 where   
115 
 
 
 
Figure 19. Recognition of some but not all mutant HCV NS3:1406-1415 peptides 
require the CD8 co-receptor. Peptide-loaded T2 cells were co-cultured with HCV1406-
transduced Jurkat cells (CD8 negative, black bars; CD8 positive, white bars). IL-2 
secretion was measured by ELISA. Mean and standard deviation of triplicate 
measurements are shown. All variants that qualified as reactive in the text secreted at 
least 200 pg/mL IL-2 and twice above background. 
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Donor B (with only 10% CD8+ T cells) was very weakly/non-reactive against these same 
three mutant peptides. Although Donor B still contains a low frequency a CD8+ T cells, it 
may require a greater number to achieve detectable levels of secreted IFNγ above 
background and comparable to that of other more strongly recognized variants. 
Additionally, peptide titration experiments down to 0.0001 µg/mL demonstrated that 
different mutations had differential impacts of functional avidity, but that avidity was 
enhanced by presence of CD8 (Fig. 20). Yet, even at low levels of antigen (1-10 nM) 
Jurkat cells were responsive to multiple antigens, which may be important for 
maintaining enough cross-reactive immune pressure to help prevent immune escape.  
It is important to consider that amino acid substitutions could disrupt peptide–
MHC binding, destabilizing the overall protein complex, which could alter antigen 
recognition [372]. We determined that a lack of or weaker peptide binding to MHC 
cannot account for an absent an attenuated response of any of the NS3:1406-1415 
variants because all epitopes bound similarly to HLA-A2 as measured by their thermal 
stability via CD spectroscopy (Table 8). Together, these data suggest that the HCV1406  
TCR is cross-reactive against a variety of naturally occurring HCV NS3:1406-1415 
variants, but some mutations require CD8 for recognition and/or maximum cytokine 
response.  
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Figure 20. Influence of the CD8 co-receptor on the functional avidity of HCV1406 TCR-
transduced Jurkat cells against naturally occurring mutant HCV NS3:1406-1415 
variants. HCV1406 TCR-transduced Jurkat cells were co-cultured with peptide-loaded T2 
cells in concentrations ranging from 1 - 0.0001 µg/mL. IL-2 secretion was measured by 
ELISA. Relative avidity curves values of CD8+ (solid, triangles) CD8- (dashed, squares) 
Jurkat cells are shown. These data were generated by Gretchen Lyons in the Nishimura 
Lab (University of Notre Dame). 
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Table 8. The apparent Tm values of HCV NS3:1406-1415/HLA-A2 variants as measured 
by circular dichroism spectroscopy. 
 
Epitope Tm (
oC)* 
WT 64. 9±0.1 
V1408L 60.7±0.3 
A1409T 64.6±0.1 
I1412L 58.1±0.3 
I1412V 58.4±0.3 
I1412N 59.3±0.1 
8S/9G/12L 62.0±0.1 
V1408T 69.2±0.2 
*Average of three independent experiments ± standard error. These measurements 
were kindly provided by Yuan Wang in the Baker Lab (University of Notre Dame). 
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Cross-Reactivity against Naturally Occurring Mutant  
HCV Epitopes Is Not Limited to HCV1406 TCR 
While we have clear evidence that the HCV1406 TCR demonstrates cross-
reactivity against mutant epitopes, it is possible that this is because this TCR is HLA-A2 
restricted but was identified in an HLA-A2- host, and by definition cross-reactive [302]. 
To better generalize the phenomenon of TCR cross-reactivity, we assessed the cross-
reactivity of a second TCR reactive against a second immunodominant HCV epitope 
NS3:1073-1081. This HLA-A2-restricted TCR was isolated from an HLA-A2+ host with 
chronic HCV infection. We previously showed T cells transduced with the HCV1073 TCR 
recognized both peptide-loaded targets and human HCC cells expressing the WT antigen 
[166]. HCV1073 TCR is not allo-restricted, and thus, a complementary TCR used to 
characterize cross-reactivity.  
A panel of naturally occurring HCV NS3:1073-1081 mutant epitopes was 
identified in the same manner described above (Table 7) and used to established cross-
reactivity of HCV1073 TCR-gene modified T cells. Remarkably, a strong cross-reactive 
profile was seen in primary T cells from three healthy donors engineered to express the 
HCV1073 TCR (Fig. 21). T2 cells loaded with utant peptides I1074V, I1074L, T1080S, and 
T1080S/V1081I (subsequently referred to as 80S/81I) stimulated robust IFNγ release by 
HCV1073 TCR-transduced T cells. Interestingly, mutant V1081A stimulated weak 
cytokine release (just over our threshold of 200 pg/mL and twice background) in all 
three donors, and V1081N was weakly reactive in two out of three donors. Mutant   
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Figure 21. HCV1073 TCR is also cross-reactive against naturally occurring HCV 
NS3:1073-1081 mutants. HCV1073 TCR-transduced PBL of three representative donors 
(Donor D, black bars; Donor E, white bars; Donor F, gray bars) were co-cultured with T2 
cells loaded with 10 µg/mL WT or mutant HCV NS3:1073-1081 peptides or 
tyrosinase:368-376 peptide as a control. IFNγ secretion was measured by ELISA. Mean 
and standard deviation of triplicate measurements are shown. Mean and standard 
deviation of triplicate measurements are shown. All variants that qualified as reactive in 
the text secreted at least 200 pg/mL IFNγ and twice above background. 
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epitope C1078F, however, only stimulated very weak IFNγ release in one donor, and 
mutant peptide V1077A was not recognized by any donors. In summary, we have 
identified an additional HCV-reactive TCR isolated from a second host exhibiting broad 
cross-reactivity against naturally occurring mutants of a second immunodominant HCV 
epitope.  
HCV NS3:1073-1081 Naturally Occurring Mutants Are Less CD8-Dependent  
To test CD8-dependent recognition of mutant HCV NS3:1073-1081 peptides, we 
engineered CD8- and CD8+ Jurkat cells with the HCV1073 TCR and stimulated them with 
peptide-loaded T2 cells (Fig. 22). Both CD8- and CD8+ HCV1073 TCR-transduced cells 
secreted similar or greater amounts of IL-2 to some but not all mutant peptides 
compared to WT. CD8- Jurkat cells secreted substantial amounts of IL-2 against mutant 
peptides I1074V, I1074L, V1070S, 80S/81I, and to a lesser extent mutant V1081A. This 
suggests that the HCV1073 TCR may exhibit flexibility to accommodate changes in some 
peptides without needing CD8 to stabilize the TCR-pMHC interaction. Interestingly, co-
expression of CD8 does not seem to greatly enhance the reactive potential against these 
five mutant epitopes. Additionally, CD8+ TCR-transduced Jurkat cells were also weakly 
reactive against V1081N, suggesting that this peptide modification requires either CD8-
driven affinity-enhancement or augmented signaling to be recognized. In summary, we 
have shown that HCV1073 TCR can facilitate CD8-independent recognition of multiple 
naturally occurring mutant HCV NS3:1073-1081 mutant epitopes.   
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Figure 22. HCV NS3:1073-1081 naturally occurring mutants are less CD8-dependent. 
CD8- (black bars) or CD8+ (white bars) HCV1073 TCR-transduced Jurkat76 cells were co-
cultured overnight with peptide-loaded T2 cells. The average and standard deviation of 
triplicate measurements of IL-2 release by ELISA is shown. All variants that qualified as 
reactive in the text secreted at least 200 pg/mL IL-2 and twice above background. 
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HCV NS3:1406-1415 and NS3:1073-1081 Mutant Epitopes  
Are Epidemiologically Relevant 
We know that the mutant HCV NS3:1406-1416 and NS3:1073-1081 epitopes 
studied here are naturally occurring because they were identified in the GenBank. 
However, our cross-reactive TCRs would only be clinically advantageous if the mutant 
epitopes recognized were highly prevalent in infected individuals. To evaluate the 
prevalence of these mutations, we searched the Los Alamos HCV Sequence Database, 
which contains 918 HCV genome sequences recorded worldwide in a variety of known 
viral genotypes. Using the QuickAlign search tool, we examined the database for 
epitope frequency of both NS3:1406-1415 and NS3:1073-1081 using KLVALGINAV or 
CINGVCWTV, respectively, as the reference peptide sequence. Frequencies of recorded 
altered sequences were generated and sorted by known HCV genotype. Table 7 
illustrates the predominant frequency and genotype(s) of these naturally occurring 
mutant immunodominant epitopes.  
In the United States, HCV genotypes 1a and 1b make up greater than 75% of 
prevalent infections and the most common genotypes worldwide [373]. Interestingly, 
for the NS3:1406-1415 epitope, the WT sequence KLVALGINAV makes up only 43.46% or 
genotype 1a frequencies in this database, and mutant I1412V makes up an additional 
31.7% of recorded genome sequences ranking as the second most common recorded 
epitope sequence. Of note, both of these epitopes are recognized independently of CD8 
expression, allowing for both CD4+ and CD8+ transduced T cells to recognize these 
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HCV+ targets. While the nine total epitope sequences studied here account for 42.38% 
of all recorded sequences in the Los Alamos HCV Sequence Database, they comprise 
80.38% of the recorded genotype 1a sequences. Inclusion of these mutant epitopes 
recognized by this TCR nearly doubles the amount of recorded sequences recognized by 
CD8+ effectors from only 43.46%, representative of only the WT epitope. This suggests 
HCV1406 TCR could provide enhanced coverage against observed HCV NS3:1406-1415 
variants most applicable to the United States. However, this TCR does not recognize 
variant 8S/9G/12L, which is the dominant epitope of genotype 1b at 42.81%, suggesting 
the HCV1406 TCR may not be as effective in genotype 1b-infected individuals.  
Comparing HCV1073 TCR cross-reactivity with epidemiological frequencies also 
suggests that a second cross-reactive TCR may have clinical benefit. While genotype 1a 
HCV NS3:1073-1081 epitope is well conserved with 90.2% of the recorded genomes 
have the WT CINGVCWTV sequence, genotype 1b is dominated by the I1074V mutant 
(45.57%); WT comprises only 41.59% of recorded sequences. In total, the various 
epitope sequences studied here account for 64.28% of total sequences in the database, 
but they provide coverage of 94.46% and 89.3% of genotypes 1a and 1b, respectively 
(most relevant to the United States’ and Europe’s viral prevalence [373]). The ability for 
HCV1073 TCR to mediate CD8-independent recognition includes upwards of 90% of the 
recorded epitope sequences in both genotypes 1a and 1b instead of being limited to 
41.59% of recorded cases in genotype 1b. Thus, our HCV model suggests there could be 
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clinical benefit in using cross-reactive TCRs if mutant epitopes in the TCR recognition 
patterns are highly prevalent. 
Computational Modeling of TCR-pMHC Structures  
Rationalizes Biological Outcomes 
To generate structural hypotheses for the cross-reactivity of the HCV1073 and 
HCV1406 TCRs, we generated models of the two TCR-pMHC complexes using a 
template-based approach that combines loop and peptide modeling with low and high 
resolution docking procedures. We previously demonstrated this modeling procedure 
can reliably reproduce key structural features such as interface contacts and TCR 
docking modes [324]. After identifying appropriate template structures, the TCRs and 
peptides were computationally morphed and several rounds of structural and energetic 
refinement were applied. The TCR-pMHC complexes were subsequently subjected to 
multiple rounds of fully randomized low resolution docking, high resolution interface 
refinement, and restrained high resolution docking (See Appendix). Both TCRs are 
predicted to engage with binding modes typical for class I-restricted TCRs [374] (Fig. 
23a). In the model of the HCV1406 TCR-pMHC complex, the NS3:1406-1415 peptide is 
predicted to adopt a conformation similar to that in the known pMHC crystal structure 
(Protein Databank (PDB) identification 3MRM) (Fig. 23b). Detailed interpretation of 
structure-based assessment of each TCR’s cross-reactivity is described below.  
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Figure 23. Computational models of the HCV1406 and HCV1073 TCR-pMHC complexes 
rationalize receptor cross-reactivity. (a) Overview of the modeled complexes, showing 
the traditional TCR binding mode. (b) The conformation of the peptide in the model of 
the HCV1406 complex (grey) is predicted to be very similar to the conformation seen in 
the unligated peptide/HLA-A2 complex (green). (c) V1408 of the NS3:1406-1415 peptide 
occupies a large space near the HLA-A2 α1 helix, with no contacts predicted from the 
TCR. (d) A1409 of NS3:1406-1415 is predicted to interact with Y31 of CDR1α. (e) I1412 
of NS3:1406-1415 is predicted to interact with Y50 of CDR2α, as well as H70 of the HLA-
A2 α1 helix. (f) I1074 and V1081 of the NS3:1073-1081 peptide occupy the P2 and P9 
pockets of HLA-A2 as expected. C1078 is predicted to face downward towards the base 
of the peptide binding groove. T1080 is predicted to be fully exposed, with no contacts 
to the TCR. (g) V1077 of NS3:1073-1081 is predicted to interact with L94 of CDR3α as 
well as W1079 of the peptide. These data were kindly provided by Timothy Riley in the 
Baker Lab (University of Notre Dame).  
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Structure-Based Assessment of HCV1406 Cross-Reactivity 
In the model of the HCV1406 TCR-pMHC complex, the NS3:1406-1415 peptide is 
predicted to adopt a conformation very similar to that in the known pMHC crystal 
structure (PDB 3MRM) (Fig. 23b). The side chain of V1408 is directed down towards the 
base of the HLA-A2 1 helix, in a loosely-packed region with sufficient space to 
accommodate other side chains (Fig. 23c). There are no TCR atoms in proximity to 
contact the WT valine or a mutant leucine, serine, or threonine. The region is solvent 
exposed, ensuring a serine or threonine would be able to satisfy hydrogen bonding 
requirements. The model is thus consistent with the observation that the V1408L and 
V1408T mutant peptides are recognized as equally well as the wild type epitope. In 
contrast to V1408, A1409 is directed towards the TCR, contacting Y31 of CDR1 (Fig. 
23d). Substitution with a threonine would require TCR and/or peptide rearrangements 
to resolve atomic clashes and satisfy the threonine hydrogen bonding needs. This would 
likely weaken TCR binding and could account for the weaker potency and loss of CD8 
independence seen with the A1409T mutant peptide. 
The side chain of I1412 of NS3:1406-1415 is directed towards the HLA-A2 1 
helix, but interacts with Y50 of CDR2 as well as H70 of HLA-A2 (Fig. 23e). Substitution 
with leucine would be predicted to retain these interactions, accounting for the high 
level of reactivity with the I1412L peptide. The I1412V peptide, however, would lose 
interactions with HLA-A2, likely resulting in weaker peptide binding and/or peptide 
conformational changes. Some combination of either of these could account for the 
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weaker potency of the I1421V peptide. Substitution with asparagine would require 
more drastic structural alterations, accounting for the even weaker potency of the 
I1412N mutant peptide. 
For the NS3:1406-1415 V1408S/A1409G/I1412L triple mutant, as V1408S and 
I1412L should be well-tolerated, the loss of activity may be attributable to the loss of 
interactions Y31 stemming from the A1409G mutation (Fig. 23d). Additionally, 
substitution of A1409 with glycine may render the peptide more dynamic, further 
reducing TCR binding by raising the entropic penalty for binding [375]. The latter 
explanation may explain the weakened but not eliminated potency of variant 
8S/9S/12L/14S. Mutants V1048S, I1412L, and A1414S should all be tolerated as 
described above. On the other hand, substitution of A1409 to serine rather than glycine 
would be expected to impact interactions with Y31, but still retain peptide rigidity. A 
summary of these structural interpretations of functional responses is listed in Table 9. 
Structure-Based Assessment of HCV1073 Cross-Reactivity 
The model of the HCV1073 complex provides for similar structural 
interpretations as with the HCV1406 complex. The side chain of the P2 I1074 of the 
NS3:1073-1081 peptide is predicted to occupy the HLA-A2 P2 pocket as is typical for a 
peptide bound to HLA-A2 [376, 377], with sufficient room for a valine and leucine (Fig. 
23f). Although some effect on peptide binding affinity is anticipated, the lack of any TCR 
contacts to this position coupled with the relatively conserved mutations can explain the 
strong activity of the I1074V and I1074L mutant peptides. A similar interpretation is 
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Table 9. Summary of predicted structural consequences of the HCV NS3:1406-1415 and NS3:1073-1081 mutations. 
Epitope Structural Interpretation Figure 
Potency 
–CD8 
Potency  
+CD8 
HCV NS3:1406-1415 
    
V1408L No changes in TCR/MHC/peptide contacts 23C ++ ++ 
V1408T No changes in TCR/MHC/peptide contacts 23C ++ ++ 
A1409T 
Altered TCR contacts, rearrangements needed for  
hydrogen bonding 
23D - + 
I1412L No changes in TCR/MHC/peptide contacts 23E ++ ++ 
I1412V Loss of MHC contacts, altered peptide conformation 23E + + 
I1412N 
Loss of MHC contacts and introduction of polar group requiring 
changes in peptide conformation 
23E - + 
8S/9G/12L 
Loss in TCR contacts, greater peptide dynamics from  
introduction of glycine 
23C-E - - 
8S/9S/12L/14S Loss in TCR contacts 23C-E - + 
     
HCV NS3:1073-1081 
    
I1074V Conservative P2 anchor substitution 23F ++ ++ 
I1074L Conservative P2 anchor substitution 23F ++ ++ 
V1077A Loss of and alteration in TCR contacts 23G - - 
C1078F Altered MHC contacts and peptide conformation 23F - - 
V1081N Substantially weaker peptide binding from inappropriate P9 anchor 23F - + 
T1080S No changes in TCR/MHC/peptide contacts 23F ++ ++ 
V1081A Weaker peptide binding from P9 anchor substitution 23F + + 
80S/81I No change in TCR/MHC/peptide contacts 23F ++ ++ 
1
2
9 
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possible for mutant V1081A, as the valine at P9 occupies the HLA-A2 PΩ pocket (Fig. 
23f). Substitution of an alanine here is likely to have a greater effect on peptide binding, 
explaining the reduced activity of the V1081A mutant. 
The model shows the P6 cysteine of the NS3:1073-1081 peptide vectored down 
towards the base of the HLA-A2 binding groove (Fig. 23f), as commonly seen with 
peptides bound to class I MHC proteins [377]. Substitution to a bulky amino acid such as 
phenylalanine is likely to substantially alter peptide conformation and likely weaken 
peptide binding to HLA-A2, explaining the loss of activity of the C1078F peptide. The P8 
threonine is predicted to be fully exposed (Fig. 23f), with no interactions with the TCR, 
and hence a serine substitution here is expected to be well tolerated, explaining the full 
potency of the conservative T1080S mutant. Similar explanations hold for the fully 
active T1080S/V1081I double mutant. 
The model shows the P5 valine of NS3:1073-1081 pointing directly up into the 
TCR-pMHC interface, packing against L94 of CDR3 (Fig. 23g). This valine also packs 
against the P7 tryptophan of the peptide, which interacts with multiple residues of the 
TCR  chain. In addition to removing interactions with CDR3, replacement of the valine 
with alanine could have knock-on effects on the position of the tryptophan, further 
impacting TCR interactions with the peptide. A combination of these  
effects may explain the loss of activity seen with mutant V1077A. A summary of these 
structural interpretations is also reported in Table 9. Together, we can begin to 
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rationalize how various amino acid substitutions can alter functional responses by 
HCV1406 TCR- and HCV1073 TCR-transduced T cells. 
HCV Cross-Reactive TCRs May Be Clinically Advantageous  
to Help Prevent Chronic Infection 
It has been suggested that a major cause of chronic HCV infection is the ability of 
the virus to escape immune surveillance with a rapidly mutating genome [279, 352-356]. 
Therefore, it would be logical to predict that infected individuals with more cross-
reactive TCRs might facilitate clearance of HCV infection or prevent chronic infection 
better than those with a more restricted repertoire of HCV-reactive TCRs. Such an 
observation would also support the claim that cross-reactive TCRs may be 
therapeutically beneficial in diseases exhibiting genomic instability. A very preliminary 
set of experiments to detect any such clinical evidence of this theory examined 
recognition capability of T cells isolated from chronically infected patients and from 
those who spontaneously resolved infection. After raising HCV NS3:1406-1415 tetramer 
positive T cell clones from both types of patients, reactivity of multiple clones was 
tested against an alanine scanner set of the HCV NS3:1406-1415 peptide and a variety of 
naturally occurring mutants. Based on a limited number clones evaluated, T cells 
isolated from chronically infected patients tended to have a similar and limited cross-
reactive profile. Conversely, representative clones isolated from patients who 
spontaneously resolved infection tended to have a much more varied and diverse 
response against both alanine-substituted peptides and naturally occurring mutant 
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epitopes. Reactivity profiles from two representative clones of each patient cohort are 
shown in Figure 24. While not an exhaustive characterization or a conclusive study, 
these observations support the hypothesis that cross-reactive TCRs may have play a 
beneficial role in combating HCV and other diseases with genomic instability. 
Significance 
Immune evasion by viruses and cancer cells has been a critical barrier to 
mounting effective host immune responses and has been problematic for the 
development of successful immunotherapies including ACT. A combination of 
viral/cancer genomic instability and immense selective pressure by successful immune 
effectors can lead to these escape variants. Finding a way to harness the immune 
system’s ability to selectively eliminate its targets while maintaining flexibility to combat 
genomic instability, a driving force behind immune escape, is the ultimate therapeutic 
goal for these diseases. 
Overall, in our HCV model for genomic instability, we have characterized CD8-
independent recognition of multiple naturally occurring mutant epitopes for two HCV-
cross-reactive TCRs. The reported prevalence of mutant epitopes adds clinical relevance 
to potential therapeutic use of either or both of these receptors in ACT. Furthermore, 
preliminary experiments testing cross-reactivity of T cell clones raised from chronically 
infected versus spontaneously resolved patients support the hypothesis that HCV-cross-
reactive TCRs could have an impact on clearance of HCV infection or its associated 
disease. Our structural modeling also provides a context for altered T cell responses. An 
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Figure 24. T cell clones raised from patients with spontaneously resolved HCV infection have a more diverse cross-reactivity than 
those isolated from chronically infected HCV patients. HLA-A2*01/HCV NS3:1406-1415 tetramer positive T cell clones raised from 
(a) chronically HCV-infected patients or (b) patients who spontaneously resolved HCV infection were co-cultured with T2 cells pulsed 
with 10 µg/mL of WT HCV NS3:1406-1415 peptide (white bars), HCV NS3:1406-1415 peptides with alanine substitutions at positions 
1 through 10 (black bars; left panels), a variety of naturally occurring mutant epitopes (black bars; right panels) or tyrosinase:368-
376 peptide as a control. Two representative clones from each cohort are shown. IFNγ secretion was measured by ELISA. Peptides: 
1-V1408L, 2-V1408T, 3-A1409T, 4-A1409V, 5-I1412L, 6-I1412V, 7-8S/9G/12L, 8-8S/9S/12L, 9-8S/9S/12L/14S. These data were kindly 
provided by the Rosen Lab (University of Colorado Denver). 
 
1
3
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improved structural understanding of how amino acid substitutions impact the pMHC 
topography and subsequently T cell function will be helpful. Nonetheless, our approach 
serves as an important model for identifying and designing cross-reactive TCR-based 
immunotherapies for diseases with genomic instability, including HCV. Studies aimed to 
address what kinetic, biological, and structural factors influence antigen recognition, 
TCR cross-reactivity, and T cell function are addressed in the following chapters.  
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CHAPTER FIVE 
ASSESSING THE IMPORTANCE OF TCR-pMHC AFFINITY ON  
ANTIGEN RECOGNITION BY HCV1406 TCR GENE-MODIFIED T CELLS 
 
Rationale 
In Chapter Four, we discussed how two TCRs exhibited cross-reactivity against 
naturally occurring mutant HCV epitopes and how TCR cross-reactivity may be 
advantageous for treating diseases with genomic instability. Additionally, structural 
modeling of the TCR-pMHC interface helped rationalize altered antigen recognition (or 
lack thereof). But modeling does not identify the mechanism(s) responsible for the 
changes in the pMHC ligand that might alter T cell function. Although speculation 
revolves around which parameters best explain a productive or non-productive TCR-
pMHC interaction, TCR-pMHC affinity is generally thought to play the most central role 
[1]. 
A better understanding of how a TCR engages with the pMHC complex and how 
that interaction activates a T cell could help manipulate TCR gene-modified T cells to 
enhance therapeutic efficacy and limit off-target toxicities. Our HCV model allows us to 
evaluate antigen recognition of a single TCR against a series of naturally occurring 
mutant epitopes with varied TCR-pMHC affinities. In this chapter, we begin our 
investigation into which parameters influence antigen recognition by comparing altered 
TCR-pMHC binding affinities with functional responses. We also address how other 
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factors, including the CD8 co-receptor, pMHC ligand density, and TCR density affect 
recognition of altered pMHC ligands and TCR cross-reactivity. 
We have chosen to focus the remainder of these structure-function studies on 
the HCV1406 TCR. Structure-function studies using the HCV1073 TCR would not be 
feasible because the HCV NS3:1073-1081 epitope contains two cysteine residues 
(CINGVCWTV). This peptide and its mutants have the propensity for oxidization and 
forming disulfide bridges. These properties make NS3:1073-1081 peptides extremely 
challenging to generate reliable peptide-MHC and TCR-pMHC binding measurements 
and would be troublesome for additional kinetic or structural evaluations. For these 
reasons, the remaining kinetic, functional, and structural studies will focus on HCV1406 
TCR.  
TCR-pMHC Affinity Trends with but  
Does Not Completely Dictate Antigen Recognition 
 Most investigators in the field believe that the critical feature of a TCR-pMHC 
interaction is its affinity [1]. Our model using WT and naturally occurring mutant HCV 
NS3:1406-1415 peptides enables us to examine how TCR-pMHC interactions with 
varying affinities impact T cell function. By surface plasmon resonance (SPR), we 
measured the equilibrium KD of HCV1406 TCR with all NS3:1406-1415 pMHC except 
8S/9S/12L/14S—HLA-A2 (Table 10). We determined that HCV1406 TCR bound WT HCV 
NS3:1406-1415/HLA-A2 at the highest affinity of all pMHC with an average of 16.8 μM. 
Although functionally a high affinity TCR exhibiting CD8-independent target recognition,   
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Table 10. TCR-pMHC binding affinities for HCV1406 TCR—HCV NS3:1406-1415/HLA-A2 
variants as measured by surface plasmon resonance. 
 
Epitope KD (µM)* 
WT 16.8±0.3 
I1412L† 32.4±0.7 
V1408T† 45.9±0.6 
V1408L† 60.1±5.2 
I1412V† 63.4±3.0 
A1409T‡ 119.7±9.2 
I1412N‡ 168.0±17.6 
8S/9G/12L‡ 169.3±23.4 
*average KD of three independent experiments ± standard error. These measurements 
were kindly provided by Yuan Wang in the Baker Lab (University of Notre Dame). 
†“moderate affinity”  
‡“lower affinity” 
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the affinity measurement of HCV1406 TCR-WT pMHC interaction falls short of a 
traditional high affinity KD. Traditional high affinity interactions are classified in the nM 
or <10 µM range and low affinity TCRs are generally >300 µM; but we are arbitrarily 
categorizing the remaining TCR-pMHC interactions as “moderate” and “lower” as a 
point of comparison to WT. TCR-pMHC interactions containing variants I1412L (32.4 
μM), V1408T (45.9 μM), V1408L (60.1 μM), and I1412V (63.4 μM) exhibited relatively 
similar measurable affinities (within a two-fold range). We categorized these variants in 
a “moderate affinity” range compared to WT. TCR-pMHC interactions containing 
variants A1409T, I1412N, and 8S/9G/12L were approximately one log fold higher KD than 
the WT peptide, measuring in a similar range we called “lower affinities”: 120 μM, 168 
μM, and 169 μM, respectively. Although the TCR- 8S/9S/12L/14S–MHC interaction could 
not be measured by SPR, its amino acid substitutions would predict it to fall into the 
“lower affinity” range.  Taken together, we have established multiple ranges of 
measurable affinities (comprised of various amino acid substitutions) to compare the 
influence of TCR-pMHC affinity on T cell function. 
 We discussed in Chapter Four that recognition of some but not all mutant HCV 
NS3:1406-1415 peptides required the CD8 co-receptor. Thus, we wanted to evaluate  
whether changes in TCR-pMHC affinity correlate with CD8-dependence. Figure 25 
demonstrates WT and variant HCV NS3:1406-1415 peptide recognition of PBL-derived 
HCV1406 TCR-transduced CD4+ and CD8+ T cells ranked by affinity (decreasing left to 
right). Recall, we normally define “reactive” T cells as producing >200 pg/mL IFNγ and at   
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Figure 25. Reorganization of cross-reactivity by decreasing affinity reveals an inverse 
trend. PBL from a normal donor were transduced with the HCV1406 TCR retroviral 
vector. TCR-transduced cells were enriched using anti-CD34 immunomagnetic beads 
and subsequently isolated into CD4+ and CD8+ populations. T cells were co-cultured with 
T2 cells pulsed with 10 µg/mL of WT or mutant HCV NS3:1406-1415 peptides or 
tyrosinase:368-376 as a control. IFNγ secretion was measured by ELISA. Mean and 
standard deviation of triplicate measurements are shown. All variants that qualified as 
reactive in the text secreted at least 200 pg/mL IFNγ and twice above background and at 
least >5% of WT cytokine release. Affinities of TCR-pMHC interactions are shown in red. 
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least twice above background (tyrosinase stimulation). However, in the case of HCV1406 
where TCR-transduced T cells and Jurkat cells can secrete cytokine > 40,000 ng/mL, 
reactive ligands must also exceed 5% of WT cytokine response. Interestingly, the IFNγ 
secretion patterns are distinctly different between CD4+ and CD8+ TCR-transduced T 
cells. Both CD4+ and CD8+ TCR-transduced T cells were reactive against T2 cells loaded 
with WT (17 μM) and the four variant ligands that fall into our “moderate affinity” range 
(32-63 μM). CD8+ T cells routinely exhibited comparable averages of IFNγ secretion 
against all five of these peptides. This suggests there may be an upper limit at which a 
higher affinity no longer augments cytokine secretion. While CD4+ T cells responded 
with similar magnitudes of IFNγ secretion against WT, I1412L, and V1408L, they 
reproducibly secreted up to 50% less IFNγ against V1408T, and I1412L. This is surprising 
because decreased function is not consistent with decreased affinity.  
However, none of the “lower affinity” pMHC variants (A1409T, I1412N, 
8S/9G/12L, and 8S/9S/12L/14S) were recognized by CD4+ T cells, suggesting that a 
threshold for CD8-independece exists somewhere between 63 and 120 μM. However, 
variant 8S/9G/12L was not recognized by either CD4+ or CD8+ T cells, despite having 
virtually identical TCR-pMHC affinity as CD8-dependent mutant I1412N (169 μM 
compared to 168 μM). While we observed antigen recognition trends with affinity, 
these data do not support TCR-pMHC affinity as the defining characteristic dictating 
antigen recognition. With that in mind, it is prudent to explore other potential factors   
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including co-receptors, antigen density, or TCR density that may contribute to T cell 
recognition of altered peptide ligands. 
CD8-Dependent TCR Cross-Reactivity Relies on the Recruitment of Lck 
Although we observed a relationship between CD8-dependence and TCR-pMHC 
affinity, it was uncertain how CD8 was actually permitting or enhancing functional 
recognition of some mutant peptides. One way the CD8 co-receptor facilitates antigen 
recognition is through stabilization of the TCR-pMHC complex, thus enhancing the 
affinity of the TCR-pMHC interaction [378]. TCR-pMHC stabilization by CD8 helps justify 
differences in the recognition of mutant peptides between HCV1406 TCR-transduced 
CD4+ and CD8+ T cells (segregated by “moderate” and “lower” affinities). However, CD8 
can also bind the src kinase, lck [379]. Recruitment of lck to the TCR/CD3 complex helps 
facilitate the initiation of the TCR signaling cascade [26]. It has previously been 
suggested that a T cell’s sensitivity to antigen stimulation can be more dependent on 
the signaling capacity of CD8 rather than its affinity-enhancement, especially among 
high affinity TCRs [305]. To determine the influence of affinity-enhancement versus 
signaling augmentation by CD8 on TCR cross-reactivity, we engineered Jurkat cells 
(natively CD8-) to express full length CD8αβ, or a truncated form (CD8α’β’), lacking the 
intracellular lck-binding domain. CD8-transduced cells were sorted to have roughly 
equivalent expression of CD8 (Figure 26a). Examining the reactivity of these CD8-
engineered Jurkat cells against each of the mutant peptides allowed us to separate the 
importance of affinity enhancement and signaling augmentation by CD8.  
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Figure 26. CD8 co-receptor signaling components are required for reactivity against 
CD8-dependent ligands. (a) Jurkat cells were transduced to express either full length 
CD8αβ or truncated CD8α’β’ lacking the intracellular lck-binding domain. (b) Each group 
was transduced with a retrovirus encoding the HCV1406 TCR. After anti-CD34 
immunomagnetic enrichment, these cells were co-cultured with T2 cells loaded with 
HCV NS3:1406-1415 (WT and variants) peptide or tyrosinase:368-376 peptide as a 
negative control. IL-2 secretion by Jurkat cells was measured by ELISA. Mean and 
standard deviation of triplicate measurements are shown. All variants that qualified as 
reactive in the text secreted at least 200 pg/mL IL-2 and twice above background and 
>5% of WT reactivity. Affinities of TCR-pMHC interactions are shown in red. These data 
are representative of three independent experiments. 
 
a) 
b) 
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HCV1406 TCR-transduced Jurkat cells stimulated with WT HCV NS3:1406-1415 
peptide-loaded T2 cells reproducibly resulted in minimal differences in IL-2 secretion 
among CD8 negative, CD8αβ, or CD8α’β’ cells (Fig. 26b). The previously characterized 
CD8-independent ligands, I1412L, V1408T, V1408L, and I1412V stimulated robust IL-2 
release from all three Jurkat cell lines. Of note, the presence of CD8 (full length or 
truncated) did not seem to always augment cytokine release against all of these 
“moderate affinity” variants. This observation contradicts what we and others have 
found whereby the presence of CD8αβ can augment cytokine release in TCR-transduced 
T cells [305]. Perhaps there is an upper limit to CD8 help if the TCR-pMHC interaction is 
maximally efficient at inducing T cell activation. Jurkat cells lacking CD8 are again not 
reactive (by our established criteria) against “lower affinity” ligands A1409T, I1412N, 
8S/9G/12L, or 8S/9S/12L/14S. The introduction of full length CD8αβ, however, rescues 
reactivity against all mutant peptides except 8S/9G/12L. Interestingly, Jurkat cells 
expressing truncated CD8α’β’ were minimally or non-reactive reactive against these 
“lower affinity” variants, suggesting that TCR-pMHC stabilization is not sufficient and  
that the intracellular lck-binding domain is also required for T cell activation. These 
results also support the claim that TCR-pMHC affinity is not necessarily the determining 
factor in antigen recognition. We have also highlighted the important role of CD8 
signaling on facilitating or enhancing antigen recognition of multiple mutant peptides.   
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Antigen Density Influences Cross-Reactive Responses 
 Clinical reports of on-target/off-tumor or off-target effects by TCR-transduced T 
cells used in ACT have been attributed to recognition of low levels of antigen by high 
affinity TCRs [122, 184, 186]. We also acknowledge that evaluating reactivity against 
peptide-loaded T2 cells is not necessarily a physiological representation of the antigen 
density a T cell might encounter on a virally-infected cell or tumor. For these reasons, 
the effect of antigen density on recognition of WT and naturally occurring mutant 
peptides by a TCR is an important point to consider for anti-tumor responses and 
potential cross-reactivity.  
Therefore, we established multiple levels of antigen density arbitrarily defined as 
highest, lowest, and intermediate (Fig. 27). T2 cells are TAP-deficient and incapable of 
presenting endogenously processed antigen, which allows for saturating levels of 
exogenously loaded peptide. Peptide-pulsed T2 cells serve as our highest ligand density 
and have been used in reactivity assays thus far. To achieve an arbitrarily lower level of 
antigen density, we engineered a panel of HepG2 cells expressing WT and variant HCV 
NS3:1406-1415 epitopes each as a minigene fused to GFP by a 2A linker. Transduced  
cells were sorted for high and uniform GFP expression (Fig. 28a). We define minigene+ 
HepG2 cells as lower antigen density because they require the internal expression of 
epitopes with minimal antigen processing, but compete with endogenously processed 
peptides for available MHC-I. To establish an intermediate density of antigen between 
peptide-loaded T2 cells and antigen-expressing HepG2 cells, we exogenously loaded   
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Figure 27. A model for pMHC ligand density.  (a) T2 cells are TAP-deficient and 
incapable of presenting endogenously processed antigens (green triangles, red stars, 
purple rectangles). Exogenously loading with HCV NS3:1406-1415 peptide (white ovals) 
saturates available surface MHC-I with antigen. (b) HepG2 cells are TAP+ and present 
internally processed antigens on MHC-I. Exogenously loading with high concentrations 
of HCV NS3:1406-1415 peptide can compete out endogenous antigen presented on 
MHC-I, but are presented at a lower density than peptide-loaded T2 cells. (c) HepG2 
cells engineered to express HCV NS3:1406-1415 epitopes as minigenes require internal 
expression and minimal antigen processing and compete with endogenously processed 
peptides for MHC-I. HCV minigene-expressing HepG2 cells present HCV NS3:1406-1415 
peptide at the “lowest” density of our three systems. HCV1406 TCR-transduced T cells 
were stimulated with each of these arbitrarily defined densities of pMHC ligand to 
assess the impact of ligand density on antigen recognition and TCR cross-reactivity.   
a) b) c) 
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HCV NS3:1406-1415 peptides on HepG2 cells. While peptides are not internally 
expressed, the loaded antigen still has to compete out occupied surface MHC-I  on TAP+ 
HepG2 cells for effective presentation to T cells. These three antigen expression-
presentation systems allow for an arbitrary evaluation of the influence of antigen 
density on the cross-reactivity of a single TCR.  
We previously showed that CD4+ TCR-transduced T cells recognized WT and all 
“moderate affinity” mutants, while CD8+ TCR-transduced T cells recognized all but 
mutant 8S/9G/12L. (Fig. 25) Changes in the amount of cytokine released by “reactive” T 
cells reproducibly differed by no greater than two-fold when stimulated with variant 
pMHC ligands. Interestingly, the antigen recognition pattern varied much more at a 
lower density of antigen, consistent with the results of a peptide titration presented 
earlier (Fig. 20). Not unexpected, peptide-loaded HepG2s were better recognized than 
minigene-expressing HepG2 cells (Fig. 28b). WT peptide recognition did not differ 
dramatically, but a decrease in antigen density had the greatest impact on “moderate” 
and “lower affinity” interactions. HepG2 cells expressing I1412L, V1408T, and V1408L  
minigenes stimulated nearly 20-fold less IFNγ secretion compared to peptide-loaded 
HepG2 cells. Interestingly, despite nearly identical affinity to V1408L, expression of 
I1412V as a minigene abrogated recognition by our defining criteria. Additionally, “lower 
affinity” ligands A1409T, I1412N, and 8S/9S/12L/14S exogenously loaded onto HepG2 
cells were non-reactive defined by our criteria (<5% WT reactivity response), but still 
elicited hundreds more pg/mL IFNγ secretion compared to minigene-expressing cells.   
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Figure 28. HCV1406 TCR cross-reactivity is substantially diminished in the context of 
HCV+ tumor cells. (a) HepG2 cells were transduced with retroviral vectors encoding HCV 
NS3:1406-1415 variants as minigenes fused to GFP by a T2A linker. Cells were sorted for 
high and uniform expression of GFP. MFI are shown in parenthesis. (b) PBL from a 
normal donor were transduced with the HCV1406 TCR retroviral vector and enriched for 
CD34t expressing using anti-CD34 immunomagnetic beads. CD34+ T cells co-cultured for 
18 hr with WT or mutant HCV NS3:1406-1415 peptide-loaded or minigene-expressing 
HepG2 cells . IFNγ secretion was measured by ELISA. Mean and standard deviation of 
triplicate measurements are shown. All variants that qualified as reactive in the text 
secreted at least 200 pg/mL IFNγ and twice above background and at least >5% of WT 
reactivity. SPR-measured affinities of TCR-pMHC interactions are shown below in red. 
These data are representative of three independent experiments. 
a) 
b) 
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These results suggest the density of antigen plays an important role in facilitating 
antigen recognition and T cell activation. 
To evaluate if the CD8 co-receptor impacts antigen recognition in light of 
decreased antigen density, we stimulated HCV1406 TCR-transduced CD4+ or CD8+ T cells 
with “intermediate density" peptide-loaded HepG2 cells (Fig. 29a) or “lower density” 
minigene-expressing HepG2 cells (Fig. 29b). We found that CD4+ T cells were most 
susceptible to changes in antigen density. For example, we previously demonstrated 
that TCR-transduced CD4+ T cells were highly reactive against WT and all “moderate 
affinity” antigen-loaded T2 cells. Differences in magnitude of IFNγ secretion were 
reproducibly no more than 2-3 fold (Fig. 25). Interestingly, mutant peptides (V1408T and 
I1412V) loaded on HepG2 cells (a lower density of antigen compared to T2) stimulated 
less than 750 pg/mL of IFNγ, while WT and V1408L stimulated over 60,000 and 20,000 
pg/mL of IFNγ, respectively.  Additionally, the presence of the CD8 co-receptor 
compensated for intermediate densities of “moderate affinity” ligands, but “lower  
affinity” mutant ligands stimulated nearly 60-fold less IFNγ secretion. Only two-fold 
differences were observed between “moderate” and “lower” affinity ligands in T2 cell 
stimulations (Fig. 25). These observations suggest that even antigen densities between 
peptide-loaded targets (tumor cells vs T2 cells) can have a profound effect on antigen 
recognition. Also, differences in cytokine secretion are not always reconciled by 
differences in TCR-pMHC affinity.  
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Figure 29. HCV1406 TCR CD4+ T Cells are more susceptible to changes in ligand density. 
(a) HepG2 cells exogenously loaded with 10 μg/mL WT or variant HCV NS3:1406-1415 
peptides or HepG2 cells engineered to express WT and variant HCV NS3:1406-1415 
minigenes were co-cultured with PBL-derived T cells transduced with the HCV1406 TCR 
retroviral vector. (b) HCV1406 TCR-transduced PBL were immunomagnetically isolated 
into CD4+ or CD8+ populations and co-cultured with HepG2 cells loaded with WT or 
variant HCV NS3:1406-1415 peptides.  IFNγ secretion after 18 hr co-culture was 
measured by ELISA. Mean and standard deviation of triplicate measurements are 
shown.  All variants that qualified as reactive in the text secreted at least 200 pg/mL 
IFNγ and twice above background and at least >5% of WT reactivity. SPR-measured 
affinities of TCR-pMHC interactions are shown below in red. These data are 
representative of three independent experiments. 
a) 
b) 
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In our lowest antigen density system, minigene-expressing HepG2 cells elicited 
reproducibly similar amounts of IFNγ release from both CD4+ and CD8+ TCR-transduced 
T cells. However, only “moderate affinity” mutant pMHC could be recognized at lowest 
densities and now required the presence of CD8. In summary, recognition of lower 
affinity ligands seems to be affected more dramatically by changes in antigen density. 
However, CD8 can facilitate recognition of higher affinity antigens at lower densities.  
These data suggest that antigen density plays a critical role in antigen recognition of 
altered ligands. 
TCR Transgene Levels Influence IFNγ Production Independent of Affinity 
 Given that antigen density influences antigen recognition and TCR cross-
reactivity, it would be logical to predict that TCR density may also impact T cell 
recognition of altered ligands. The composition of our retroviral vector used to gene-
modify T cells provides a useful tool to answer this question. As discussed previously, 
our TCR retroviral vector contains a CD34t cassette as a marker of transduction 
efficiency. While useful for enriching transduced T cell populations for in vitro studies 
and clinical treatment, our CD34t marker also allows us to assess relative TCR expression 
without staining for the TCR with an antibody or tetramer, which can influence the 
outcome of functional assays [380-382]. 
 We evaluated the impact of TCR density on antigen recognition and TCR cross-
reactivity by HCV1406 TCR-transduced PBL by relating intracellular IFNγ production with 
TCR transgene levels. HCV1406 TCR-transduced T cells were stimulated with WT and 
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mutant HCV NS3:1406-1415 peptide-loaded T2 cells and analyzed for intracellular IFNγ 
production by flow cytometry. We also stained T cells for surface markers CD4 and CD8 
and our transduction marker CD34t. We have previously shown that increased levels of 
CD34 relate to increased tetramer binding (Foley unpublished, [304]), suggesting that 
CD34 serves as a good correlate for TCR expression. This approach enabled us able to 
relate the various levels of TCR transgene with intensity of cytokine production. Figure 
30 displays representative CD34 vs IFNγ dotplots and our gating strategy used to assess 
IFNγ production in High, Medium, and Low CD34-expressing CD4+ or CD8+ TCR-
transduced T cells. Mean fluorescence intensity (MFI) of intracellular IFNγ was 
calculated in each CD34 expression gate for both CD8+ (Fig. 31a) and CD4+ T cells (Fig. 
31b). 
 In TCR-transduced CD8+ T cells, IFNγ production was positively associated with 
TCR transgene expression. CD34 Hi-expressing CD8+ T cells exhibited the greatest 
intensity of IFNγ, and all peptide but 8S/9G/12L stimulated similar levels of IFNγ staining 
in the CD34 Med and CD34 Low populations. However, only CD34 Hi-expressing CD4+ T 
cells produced high IFNγ levels above background against all CD8-independent peptides. 
The WT epitope, as well as mutant peptides I1412L and V1408L, stimulated modest IFNγ 
production in CD34 Med- and CD34 Low-expressing cells. Despite having similar 
affinities to I1412L and V1408L, however, mutants V1408T and I1412V only stimulated 
substantial amounts of IFNg production in CD34 Hi-expressing T cells. Together, these 
data suggest that TCR transgene expression influences antigen recognition, but that the   
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Figure 30. Gating strategy used to establish the relationship between TCR transgene 
expression and IFNγ production. PBL from a normal donor were transduced to express 
HCV1406 TCR and enriched for TCR-transduced cells using anti-CD34 immunomagnetic 
beads. T cells were co-cultured with peptide-loaded T2 cells for 5 hr and IFNγ 
production was assessed by intracellular cytokine staining. Representative 
immunofluorescence and gating of surface CD34 vs intracellular IFNγ for (a) CD8+ and 
(b) CD4+ TCR-transduced T cells. CD34+ populations were subgated to delineate CD34 
high, medium, and low expressing populations. Mean fluorescence intensity (MFI) of 
intracellular IFNγ was calculated for each CD34-expressing population.  
a) 
b) 
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Figure 31. IFNγ production is positively associated with TCR transgene expression but 
high expression is required for CD4+ T cells to produce IFNγ. PBL from a normal donor 
were transduced to express HCV1406 TCR and enriched for transduced cells using anti-
CD34 immunomagnetic beads. T cells were co-cultured with peptide-loaded T2 cells for 
5 hr and evaluated for IFNγ production by intracellular cytokine staining. Mean 
fluorescence intensity (MFI) of IFNγ production in CD34 high (black), medium (gray), and 
low (white) expression populations are shown in (a) CD8+ and (b) CD4+ TCR-transduced T 
cells. These data are representative of three independent experiments with three 
different donors each.  
a) 
b) 
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relationships between TCR-pMHC affinity, TCR density, CD8, and the intensity of 
cytokine production remain ill-defined.  
Elimination of TCR Pairing Competition Enhances Cross-Reactivity 
In an effort to better understand the interplay between TCR density, CD8 co-
receptor function, and TCR cross-reactivity, we designed a panel of Jurkat cells equipped 
to delineate these contributions. Jurkat cells, like PBL-derived T cells, express an 
endogenous TCR. Consequently, TCR chains introduced into Jurkat cells have the 
potential to mispair with the endogenous TCR chains and also compete for association 
with CD3, limiting the density of functional introduced TCRs. Conversely, a variant Jurkat 
cell line, Jurkat76, lacks an endogenous TCR [383] (Fig. 32a). Introduction of a TCR into 
Jurkat76 cells eliminates the opportunity for both TCR chain mispairing and competition 
for CD3. Therefore, Jurkat76 cells serve as a system with optimal density of the  
introduced TCR. We also engineered Jurkat76 cells (natively CD8-) to express full length 
CD8αβ, or truncated CD8α’β’  lacking the intracellular lck-binding domain (Figs. 32b-c). 
Comparing functional responses between Jurkat and Jurkat76 cell lines may provide 
better insight into the impact of both TCR density and CD8 on antigen recognition and 
TCR cross-reactivity. A schematic of this model is provided in Figs 32d-e. 
As described earlier, we observed CD8-dependence in Jurkat cells in light of TCR 
pairing competition between endogenous and introduced TCRs (Fig. 33a). We evaluated 
the effect of TCR chain pairing competition on cross-reactivity by peptide-stimulating 
our engineered Jurkat76 cell lines (Fig. 33b). Jurkat76 cells with and without CD8   
155 
 
 
 
                      
Figure 32. A Jurkat model for TCR chain pairing and CD8 signaling. (a) Jurkat cells 
express an endogenous TCR (measured by Vβ8 expression) while Jurkat76 cells lack an 
endogenous TCR. Both (b) Jurkat and (c) Jurkat76 cells were engineered to express full 
length CD8αβ or a truncated version (CD8α’β’) lacking the intracellular lck-binding 
domain. (d) Introduced TCRs (red) can mispair with endogenous TCRs (green) and 
compete to associate with CD3 (blue) in Jurkat cells. (e) TCR pairing competition is 
absent in Jurkat76 cells. Introduction of full length CD8αβ stabilizes the TCR-pMHC 
interaction and facilitates TCR/CD3 signaling by recruiting lck. Introduction of CD8α’β’ 
uncouples signaling from TCR-pMHC stabilization.   
(a) 
(b) 
a) b) 
d) 
c) 
e) 
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Figure 33. Absence of TCR pairing competition alleviates CD8-dependence. (a) Jurkat 
and (b) Jurkat76 cells (lacking an endogenous TCR) were transduced to express either 
full length CD8αβ or truncated CD8α’β’. Each group was transduced with a retrovirus 
encoding the HCV1406 TCR. After anti-CD3 immunomagnetic enrichment, Jurkat cells 
were co-cultured with peptide-loaded T2 cells. IL-2 release by Jurkat cells was measured 
by ELISA. Mean and standard deviation of triplicate measurements are shown. All 
variants that qualified as reactive in the text secreted at least 200 pg/mL IFNγ and twice 
above background and at least >5% of WT reactivity. SPR-measured affinities of TCR-
pMHC interactions are shown in red. These data are representative of three 
independent experiments. 
a) 
b) 
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variants demonstrated similar levels of IL-2 release against WT or “moderate affinity” 
ligands. In contrast, mutants V1408T and I1412V, which exhibited a reproducibly lower 
reactivity in TCR-transduced CD8- Jurkat cells, had comparable cytokine release to WT in 
in all Jurkat76 cells. Overall, the lack of an endogenous TCR had minimal impact on 
recognition of ligands with moderate affinities (17 µm – 64 µM). Surprisingly, 
eliminating TCR pairing competition (enhancing TCR density) facilitated the recognition 
of “lower affinity” ligands A1409T, I1412N, and 8S/9S/12L/14S by CD8- Jurkat76 cells. 
CD8α’β’ Jurkat76 cells also recognized “lower affinity” mutant pMHC, with IL-2 secretion 
levels falling between CD8- and CD8αβ Jurkat76 cells’. Together, these data suggest that 
in the presence of TCR chain pairing competition, both the stabilization and signaling 
functions of CD8 are required. However, increased TCR expression in the absence of TCR 
chain pairing competition reduces the importance of the CD8 signaling component. 
Most unexpectedly, we observed IL-2 secretion by CD8αβ Jurkat76 when 
stimulated with variant 8S/9G/12L. Countless experiments in WT Jurkat cells, numerous 
PBL donors, and even the parent T cell clone from which this TCR originated consistently 
showed no reactivity (Figs. 17,19,25-26,28-31).  While the lack of recognition of 
8S/9G/12L by the parent T cell clone seems puzzling, the most plausible explanation is 
that the parent clone underwent aberrant allelic exclusion during development and 
expressed two productively rearranged TCR α chains [165]. Thus, the parent clone 
exhibited endogenous TCR pairing competition and sub-optimal TCR density. Overall, it 
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is clear that limiting or enhancing TCR expression can have dramatic effects on antigen 
recognition and TCR cross-reactivity.  
We also performed a peptide titration to determine if the elimination of TCR 
pairing competition alters the requirement of CD8 for enhanced functional avidity. We 
evaluated IL-2 release by Jurkat76 cells in response to peptide-stimulation, 
concentrations ranging from 10 – 0.0001 μM (Fig. 34). Based on similarly estimated EC50 
values, functional avidity seemed to be independent of CD8 TCR-pMHC stabilization and 
lck recruitment upon stimulation with WT and “moderate affinity” mutants I1412L, 
V1408T, V1408L, and I1412V. “Lower affinity” ligands A1409T, 8S/9G/12L, and 
8S/9S/12L/14S depended more on CD8 signaling in order to achieve maximum  
magnitude of cytokine release, but maintained relatively similar functional avidities 
compared to CD8α’β’ Jurkat76 cells. We previously showed that in TCR-transduced 
Jurkat cells (Fig. 20), functional avidity of CD8- Jurkat cells was modestly reduced in WT 
and V1408L stimulation, but all other “moderate affinity” ligands had very low 
functional avidity with estimated EC50 values ranging between 10-1 µM.  In the absence 
of TCR chain pairing, the estimated EC50 values were only a log-fold lower for CD8
- 
Jurkat76 cells (Fig. 34) suggesting that CD8 not as important for high functional avidity 
with enhanced TCR density.  
We also evaluated the impact of TCR density (as a function of TCR chain pairing) 
on antigen recognition by comparing the ability of HCV1406 TCR-transduced Jurkat and 
Jurkat76 cells to bind tetramers. A panel of tetramers containing WT or mutant HCV   
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Figure 34. CD8 signaling is not necessarily required for enhanced functional avidity in 
the absence of TCR chain pairing competition. Jurkat76 cells (black diamonds) were 
transduced to express either full length CD8αβ (white squares) or truncated CD8α’β’ 
(gray triangles). Each group was transduced with a retrovirus encoding the HCV1406 TCR 
and co-cultured with T2 cells loaded with peptides at various concentrations. IL-2 
release by Jurkat cells was measured by ELISA. Means of triplicate measurements are 
shown. Compare to Figure 20 for functional avidity of Jurkat±CD8 cells. These data are 
representative of three independent experiments. 
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NS3:1406-1415 epitopes folded around HLA-A2 was kindly provided by the NIH 
Tetramer Core Facility at Emory University (Atlanta, Georgia). Tetramers containing 
mutant epitope 8S/9G/12L were not provided by the Core. We performed a steady-state 
binding assay with each tetramer, concentrations ranging from 10-7 – 10-12 M, and 
calculated the specific staining by HCV1406 TCR-transduced Jurkat or Jurkat76 cells by 
subtracting %Tetramer+ non-transduced cells from %Tetramer+ transduced cells. Often, 
non-TCR-transduced Tetramer+ populations were due to non-specific tetramer binding 
by CD8 [384]. TCR-transduced Jurkat cells were identified using the CD34 marker in our 
retroviral vector. Jurkat76 cells endogenously express CD34, so TCR-transduced cells 
were instead identified by the expression of CD3; Jurkat76 cells will only express surface 
CD3 when a TCR is expressed on the surface.  
Steady-state tetramer binding curves are shown in Figures 35-36 representing 
Jurkat76 or Jurkat cells, respectively. HCV1406 TCR-transduced Jurkat76 cells bound WT 
tetramer very efficiently, with nearly 90% of TCR-transduced CD8+ Jurkat76 cells bound 
to tetramer (Fig. 35). A lower percentage of TCR-transduced cells, however, bound 
tetramers containing mutant epitopes at saturating concentrations, and decreases in 
tetramer binding generally trended with decreases in TCR-pMHC affinity. The presence 
of CD8 enhanced the EC50 of tetramers only one log-fold or less throughout. 
Interestingly, the presence of TCR chain pairing in HCV1406 TCR-transduced Jurkat cells 
affected the ability to bind tetramer (Fig. 36). Vertical axes are scaled to 100% tetramer 
bound TCR-transduced Jurkat cells for easy comparison to Jurkat76 cells (Fig. 35). Nearly   
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Figure 35. Steady-state binding of WT or mutant HCV NS3:1406-1415 tetramers by 
HCV1406 TCR-transduced Jurkat76 cells. Jurkat76 cells (black diamonds) were 
transduced to express full length CD8αβ (white squares). Both groups were transduced 
with a retrovirus encoding the HCV1406 TCR and stained with tetramers containing WT 
or mutant HCV NS3:1406-1415 epitopes at concentrations ranging from 10-7 – 10-12 M. 
Cells were counterstained for CD3 and analyzed for mCherry expression (CD8). Specific 
tetramer binding by HCV1406 TCR-transduced Jurkat76 cells was calculated as 
%CD3+Tetramer+ - %CD3-Tetramer+. These data are representative of two independent 
experiments. 
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Figure 36. Steady-state binding of WT or mutant HCV NS3:1406-1415 tetramers by 
HCV1406 TCR-transduced Jurkat cells. Jurkat cells (black diamonds) were transduced to 
express full length CD8αβ (white squares). Both groups were transduced with a 
retrovirus encoding the HCV1406 TCR and stained with tetramers containing WT or 
mutant HCV NS3:1406-1415 epitopes at concentrations ranging from 10-7 – 10-12 M. 
Cells were counterstained for CD3 and analyzed for mCherry expression (CD8). Specific 
tetramer binding by HCV1406 TCR-transduced Jurkat cells was calculated as 
%CD34+Tetramer+ - %CD34-Tetramer+. These data are representative of two 
independent experiments. 
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50% fewer TCR-transduced Jurkat cells bound tetramer than Jurkat76 cells for each 
tetramer evaluated. Additionally, while tetramers containing mutant peptides A1409T, 
I1412N, and 8S/9S/12L/14S bound both CD8- and CD8+ Jurkat76 cells (ranging from 40-
60% at saturating concentrations), they bound only 20% or less of HCV1406 TCR-
transduced CD8+ Jurkat cells, and did not bind CD8- Jurkat cells. These differences in 
tetramer binding are consistent with functional assays shown in Figure 33, further 
suggesting that TCR chain pairing competition can have a substantial impact on antigen 
recognition and TCR cross-reactivity. 
The relationship between TCR expression levels and tetramer binding was also 
evaluated for HCV1406 TCR-transduced Jurkat76 (Fig. 37a) and Jurkat (Fig. 37b) cells. 
For simplicity, staining of WT, V1408L, I1412V, and I1412N tetramers are shown at 
limited concentrations. Please see The Appendix for all tetramers and concentrations 
evaluated for both Jurkat cell lines. In HCV1406 TCR-transduced Jurkat76 cells, a linear 
relationship existed between CD3 (TCR) expression and WT tetramer binding at 
saturating concentrations (10-7 M). As the concentration of tetramer decreased, the 
relationship became less linear, and the ability to bind tetramer was more dependent 
on higher levels of TCR expression. Dependence on higher TCR density was exaggerated 
when evaluating TCR vs tetramer staining of lower affinity ligand I1412N (168 µM, 
compared to WT 17 µM). At saturating concentrations (10-7 M) the distribution of CD3 
and tetramer positive cells suggests a higher threshold of TCR is necessary for tetramer 
binding. Furthermore, it is clear that a higher density of TCR is required to bind I1412N   
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Figure 37. Influence of TCR-pMHC affiity and TCR chain pairing competition on 
tetramer binding. (a) Jurkat76 or (b) Jurkat cell lines were transduced to express full 
length CD8αβ. Both groups were transduced with a retrovirus encoding the HCV1406 
TCR and stained with tetramers containing WT or mutant HCV NS3:1406-1415 epitopes 
at concentrations ranging from 10-7 – 10-12 M. Cells were also stained for CD3 or CD34. 
The relationship between TCR density and tetramer binding was evaluated using CD3 
(Jurkat76 cells) or CD34 (Jurkat cells) as a surrogate marker for TCR transgene 
expression.  
a) b) 
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tetramer at lower concentrations compared to WT tetramer. Interestingly, TCR 
expression and tetramer binding between mutant ligands V1408L and I1412V were not 
consistent despite nearly identical affinity measurements (60 and 63 μM, respectively). 
For comparison, fewer HCV1406 TCR-transduced Jurkat cells bound tetramers compared 
to Jurkat76 cells and the distributions of TCR-transduced cells binding tetramers are 
remarkably different in the presence of TCR chain pairing competition (Fig. 37b). This is 
also reflected in the lower overall percentages of TCR-transduced Jurkat cell bound to 
tetramer shown in Figure 36.  
In summary, both tetramer binding and functional studies suggest that TCR 
density plays a critical role in antigen recognition. When TCR density is high enough, it 
can allow for CD8-independent antigen recognition, despite a log-fold change in TCR-
pMHC affinity. This evidence further supports that the ability of a T cell to recognize 
antigen does not solely depend on TCR-pMHC affinity. 
Significance 
 The ability to fully understand what factors govern antigen recognition by T cells 
and TCR cross-reactivity may help improve TCR-based therapeutics. While affinity is 
generally accepted as the most important factor dictating antigen recognition, the field 
is relying on affinity-enhancement of TCRs to presumably augment their efficacy in TCR 
gene-modified T cells. Therefore, it is critical to evaluate the true importance of affinity. 
Appreciating how TCR antigen recognition is affected by TCR-pMHC affinity will help 
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modulate the field’s approach in optimizing affinities to enhance or limit cross-reactivity 
of TCRs.  
The data described in this chapter surprisingly suggest that TCR-pMHC affinity 
may not be the most important influence on antigen recognition. While decreases in T 
cell reactivity (especially in CD8- T cells) trended with decreases in TCR-pMHC affinity, 
cytokine release were not always proportional to changes in affinity. Additionally, 
mutant peptides with similar or equal affinities sometimes elicited substantially 
different IFNγ or IL-2 release. Other cellular parameters, including ligand density, TCR 
density, and CD8 co-receptor signaling, greatly impacted antigen recognition and 
functional avidity. Additionally, modification of any of these parameters altered 
functional response, sometimes independent of TCR-pMHC affinities. Collectively, these 
data suggest that TCR-pMHC affinity is not necessarily the driving force behind T cell 
function.  
Through this point, we have admittedly evaluated T cell function based on the 
release of a single cytokine. We also acknowledge the potential for T cells to act as 
multi-functional effector cells. Thus, the evaluation of one cytokine may not accurately 
reflect changes in overall T cell function. In the next chapter, we aim to evaluate the 
polyfunctionality of T cells and to relate changes in polyfunctional phenotypes to 
alterations in TCR-pMHC interactions. 
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CHAPTER SIX 
ANALYSIS OF POLYLFUNCTIONAL PHENOTYPES BY  
CROSS-REACTIVE HCV1406 TCR GENE-MODIFIED T CELLS 
 
Rationale 
We have suggested that affinity may not necessarily play the most central role in 
determining antigen recognition. In fact, it is clear that T cell function relies on a 
complex relationship between TCR-pMHC affinity, CD8 signaling, antigen density, and 
TCR density. We have defined the importance of these interactions by evaluating IFNγ 
or IL-2 release by HCV1406 TCR-transduced PBL and Jurkat cells, respectively. While 
standard assays in the field measure the production of a single cytokine to define T cell 
reactivity [385-393], it is important to acknowledge that T cells are multi-functional 
effectors.  
Historically, effector T cells have been classified into type 1 (Th1, Tc1) or type 2 
(Th2, Tc2) T cells based on the production of signature cytokines (i.e. IFNγ, IL-2, and 
TNFα for type 1; IL-4 and IL-13 for type 2) [394]. These functional profiles have also been 
related to therapeutic efficacy of individual T cell populations [395-399]. In general, a T 
cell population that has a type 1 phenotype is considered to have better anti-tumor 
efficacy than T cells with a type 2 phenotype [395, 396]. However, both type 1 and type 
2 responses have been shown to play important roles in viral infections [400-402]. More 
recently, other T cell subsets have been implicated in facilitating anti-tumor or anti-viral 
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responses. For example, IL-9-producing CD4+ T cells (Th9 cells) facilitated CD8+ CTL-
mediated anti-tumor immunity in a melanoma mouse model [403]. Furthermore, the 
presence of T cell subsets producing IL-17 (Th17, Tc17) or IL-22 has been recently 
associated with spontaneous HCV viral clearance [404]. The presence of multiple T cell 
subsets secreting varying combinations of cytokines suggest the evaluation of a single 
type 1 cytokine may not accurately characterize the reactivity of a T cell culture. 
In fact, investigators have shown that in patients with advanced stage IV 
malignant melanoma who received a therapeutic vaccine, analysis of intracellular IFNγ 
induction in PBL-derived T cells showed no correlation in survival advantage [405].  
However, evaluation of an additional cytokine (IL-2) by flow cytometry found an 
association in clinical outcome. Namely, there was enhanced survival in patients with 
induction of IL-2+IFNγ- T cells. These studies support the hypothesis that evaluation of a 
single pro-inflammatory cytokine may hinder the proper biologic evaluation of T cells in 
a given experimental system. Flow cytometry-based approaches staining for multiple 
intracellular cytokines offer alternatives to more appropriately evaluate the true biology 
of a T cell culture and differential T cell responses.  In this chapter, we describe how the 
inclusion of more than one functional parameter when evaluating antigen recognition 
can change or enhance the biologic message. We also evaluate how alterations in TCR-
pMHC interactions can influence polyfunctional T cell responses.  
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Evaluating Bi-Functional HCV1406 TCR-Transduced T Cells 
While single cytokine release assays are standard in the field, we wanted to 
begin our assessment of multi-functional T cell populations by simultaneously evaluating 
IFNγ production and cytolytic activity by HCV1406 TCR-transduced T cells. Target cell 
lysis is important in facilitating anti-tumor and anti-viral immunity [406] and thus a 
reasonable second functional parameter in evaluating antigen reactivity. Although 
CD107a is a surrogate marker for degranulation [406], traditional chromium release 
assays would prevent us from simultaneously measuring cytokine production and 
correlating with lytic behavior on a per-cell basis. In this way, we simultaneously 
measured intracellular IFNγ production and surface CD107a expression to assess the 
impact of variant HCV NS3:1506-1415 pMHC on T cell function.  
Heterogeneity of Bi-Functional CD4+ and CD8+ T Cell Responses Is Not Evident In Bulk 
Culture Analysis  
We first characterized bi-functional responses of HCV1406 TCR-transduced T 
cells against WT HCV NS3:1406-1415 peptide-loaded T2 cells. Figure 38 displays 
percentages of lytic-only (CD107a+IFNγ-), IFNγ producing-only (CD107a-IFNγ+) or bi-
functional (CD107a+IFNγ+) phenotypes. T cells were analyzed as a bulk culture or gated 
on CD4+CD8- or CD4-CD8+ TCR-transduced T cells. Assessing bulk culture reactivity 
suggests of the 49% of TCR-transduced T cells that are reactive, with nearly equal 
proportions only producing IFNγ (15%), only being lytic (15%), or are bi-functional (20%). 
Subsequent gating on CD4+ or CD8+ T cells revealed how proportionally different these   
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Figure 38. Bi-functional T cell reactivity assay demonstrates T cell subset 
heterogeneity. PBL from a normal donor were transduced with a retroviral vector 
encoding the HCV 1406 TCR. HCV TCR-transduced T cells were co-cultured for 5 hours 
with T2 cells loaded with tyrosinase:368-376, HCV NS3:1406-1415, or no peptide in the 
presence of monensin, brefeldin-A, and anti-CD107a. Co-cultures were then stained for 
T cell surface markers and IFNγ. (a) TCR-transduced T cells were identified by CD34+ 
phenotype (Bulk culture, left panel) and subsequently gated as CD4+CD8- (CD4, middle 
panel) or CD4-CD8+ (CD8, right panel). Each population was evaluated with a biaxial 
comparison of CD107a and intracellular IFNγ. (b) Percentages of each CD107a vs IFNγ 
quadrant were converted into pie charts. CD107a+ IFNγ- (lytic-only, blue); CD107a+IFNγ+ 
(bi-functional lytic and IFNγ producing, red); CD107a-IFNγ+ (IFNγ producing-only, green); 
CD107a-IFNγ- (nonreactive, gray). Pie charts reflect a minimum of 2,000 cells (average 
4,000 cells). These data are representative of a single donor from three independent 
experiments using three different donors each. 
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subsets behave. This representative example shows that of CD4+ T cells, 32% only 
produce IFNγ, 7% are only lytic, but 18% exhibit dual functions. Conversely, CD8+ T cells 
are predominantly bi-functionally lytic and IFNγ-producing (38%), but with smaller 
populations being only lytic or only producing IFNγ (24% and 8%, respectively).  
Additionally, the fact that there were a higher percentage of non-reactive CD4+ T cells 
supports our previous claim that the presence of CD8 can impact overall function. 
Together, this analysis provides a unique perspective on T cell function than evaluation 
of either IFNγ or lysis alone.  
Bi-Functional T Cell Populations Are Disproportionately Affected by Alterations in 
pMHC 
We have previously shown that the magnitude of IFNγ release differs between 
mutant peptide stimulations. We subsequently evaluated whether changes in TCR-
pMHC interactions could affect T cell function as measured by both IFNγ and CD107a. 
Figure 39 displays percentages of lytic-only (CD107a+IFNγ-), IFNγ producing-only 
(CD107a-IFNγ+) or bi-functional (CD107a+IFNγ+) TCR-transduced CD4+ or CD8+ T cells 
after stimulation with naturally occurring mutant HCV NS3:1406-1415 peptides. Mutant 
peptides are grouped into “moderate affinity” (middle column) and “lower affinity” 
(right column) in decreasing affinity (top to bottom). Representative flow cytometry 
data are provided in The Appendix.  
We observed again that CD4+ T cell functional responses are restricted to variant 
ligands I1412L, V1408T, V1408L, and I1412V. We defined reactivity in these assays when   
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Figure 39. HCV1406 TCR-transduced CD4+ and CD8+ T cells have varying bi-functional 
responses against naturally occurring mutant HCV NS3:1406-1415 peptides. HCV1406 
TCR-transduced PBL were co-cultured for 5 hr with T2 cells loaded with WT and mutant 
HCV NS3:1406-1415 peptides or tyrosinase:368-376 peptide as a control, T cells were 
analyzed by flow cytometry for T cell surface markers, CD107a expression, and 
intracellular IFNγ. Percentages lytic and/or IFNγ producing TCR-transduced CD4+ (left 
pie) or CD8+ T (right pie) cells are displayed as pie charts for corresponding stimulation 
conditions. Variant peptides are grouped into “moderate affinity” (middle column of 
each panel) and “lower affinity” (right column of each panel) in decreasing order of 
affinity (top to bottom). Pie charts reflect a minimum of 2,000 cells (average 4,000 cells). 
Reactivity is defined by greater than twice the percentage of total reactive cells against 
background (tyrosinase) stimulation. These data are representative of a single donor 
from three independent experiments using three different donors each. 
  
173 
 
 
the total percentage of functional cells was greater than twice background (tyrosinase) 
stimulation. It was clearly evident that alterations in TCR-pMHC interactions affected 
the overall percentage of reactive cells. While 57% of TCR-transduced CD4+ T cells 
stimulated with WT peptide were reactive, this amount decreased when T cells were 
stimulated by any of the mutant peptides. Interestingly, however, the decrease in 
reactive T cells was not necessarily proportional to the decrease in TCR-pMHC affinity as 
V1408L (46 µM)-stimulated T cells exhibited nearly twice as many reactive T cells when 
stimulated by V1408T (60 µM) peptide-loaded T2 cells. Additionally, mutant I1412V 
stimulated nearly 50% less reactive T cells than V1408L, despite having nearly identical 
affinities (63 and 60 µM, respectively). 
Remarkably, when the overall percentage of reactive T cells was reduced, the bi-
functional population disproportionately decreased compared to either mono-
functional population. For example, when CD4+ T cells were stimulated with I1412L 
compared to WT peptide-loaded targets, the mono-functional lytic-only population was 
modestly reduced by 15% (7% compared to 6%) and the IFNγ-only population was 
reduced by 16% (32% compared to 27%). However, bi-functional cells decreased by 51% 
(18% compared to 9%) (Table 11). Interestingly, a reduction in bi-functional populations 
sometimes occurred despite comparable affinities. V1408L and I1412V have measurable 
TCR-pMHC affinities of 60 and 63 µM, respectively. Yet, their bi-functional responses 
compared to WT were drastically different. Compared to WT stimulation, V1408L 
peptide-loaded T2 cells elicited 95% as many lytic-only cells, 89% as many IFNγ-only   
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Table 11. Percent of WT reactivity in mono- and bi-functional populations upon 
stimulation with HCV NS3:1406-1415 mutant peptides.  
Epitope 
CD4+ TCR-Transduced T Cells CD8+ TCR-Transduced T Cells 
Lytic only IFNγ only Lytic/IFNγ Lytic only IFNγ only Lytic/IFNγ 
WT 100 100 100 100 100 100 
I1412L 84.7 84.3 48.7 112.3 73.3 75.5 
V1408T 58.4 54.4 29.8 98.3 90.1 76.9 
V1408L 94.6 89.3 79.7 116.9 75.7 86.6 
I1412V 50.1 56.2 34.5 96.9 104.7 72.5 
A1409T* 47.0 21.7 10.5 63.8 81.7 37.5 
I1412N* 45.0 13.6 8.7 87.4 92.9 51.6 
8S/9G/12L*† 52.5 15.9 11.5 20.6 42.4 5.0 
8S/9S/12L/14S* 71.8 13.3 4.5 83.3 62.2 40.8 
*Non-reactive against CD4+ T cells; †Non-reactive against CD4+ or CD8+ T cells 
Percentages reflect the ratio of mutant:WT antigen stimulations for each functional 
phenotype. WT is normalized at 100%. These data are representative of a single donor 
from three independent experiments using three different donors each. 
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producing cells, and an 80% decrease in bi-functional populations. However, I1412V 
with essentially the same affinity as V1408L stimulated roughly 50% fewer mono-
functional cells, and curbed the presence of bi-functional cells by nearly two thirds 
compared to WT stimulation (Table 11). Together, these data suggest that alterations in 
TCR-pMHC interactions can disproportionately alter bi-functional T cell responses. 
Similar trends in altered responses held true for CD8+ T cells as well. Stimulation 
with I1412L peptide-loaded targets elicited a modest change in overall reactivity from 
70% to 62% total reactive T cells. Interestingly, the entire 8% decrease in overall 
reactivity is lost in the bi-functional population. This trend is even more dramatic when 
comparing TCR-transduced CD8+ T cells against “lower affinity” ligands (A1409T, I1412N, 
and 8S/9S/12L/14S). When CD8+ T cells were stimulated by the WT antigen, bi-
functional populations were roughly 50% greater than lytic only cells. But when the TCR-
pMHC interaction is at a lower affinity, the proportion of bi-functional CD8+ T cell was 
less than or equal to lytic-only cells. As mentioned, a summary of each phenotype’s 
percent change compared to WT stimulation, emphasizing a larger percent change in bi-
functional populations, can be found in Table 11. Overall, these findings support the 
hypothesis that alterations in TCR-pMHC interactions (sometimes independent of 
affinity) elicit varied functional responses. These data also suggest that when measuring 
two functional parameters simultaneously, blunted T cell reactivity disproportionately 
affects bi-functional T cells and is not necessary influenced by changes in TCR-pMHC 
affinity. 
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Recognition of Naturally Processed NS3 Is Restricted to HCV1406 TCR-Transduced CD8+ 
T Cells  
The data described above compare changes in bi-functional phenotypes in light 
of high antigen density (peptide-loaded T2 cells). In the last chapter, we provided 
evidence that antigen density played a role dictating antigen recognition. Here, we 
establish a new “lowest antigen density” model using COS/A2 cells engineered to 
expressing the full length NS3 protein with WT or mutant 1406-1415 epitopes (Fig. 40). 
In NS3+ COS/A2 cells, the 1406-1415 epitope must be naturally processed before 
competing with endogenous peptides for available MHC-I. This system allows us to 
measure the effects of even lower antigen density on T cell bi-functionality. 
Figure 41 illustrates that reactivity against WT naturally processed antigen is 
limited to CD8+ T cells.  Recall, we previously defined that for an antigen to be arbitrarily 
reactive, the total percentage of functional cells must be greater than twice background 
(here, COS/NS3) stimulation.  Compared to HCV minigene+ HepG2 cells, which 
stimulated both CD4+ and CD8+ TCR-transduced T cells (Figs. 14,29), COS/A2 cells 
express a lower density of antigen. These data suggest that CD8 is most necessary at 
lowest levels of antigen density, which would be predicted based on the function of 
CD8. 
Interestingly, naturally processed mutant epitope recognition was also restricted 
to HCV1406 TCR-transduced CD8+ T cells. Only V1408T, V1408L, and I1412V qualified as 
reactive, despite I1412L exhibiting the lowest TCR-pMHC affinity out of this group of   
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Figure 40. Generation of COS/A2 expressing naturally processed HCV NS3 with WT and 
naturally occurring mutant NS3:1406-1415 epitopes. COS cells and COS/A2 cells were 
transfected with a pcDNAIII vector encoding full length HCV NS3 protein containing WT 
or variant NS3:1406-1415 epitopes fused to GFP by a T2A linker. Representative 
transfection efficiency as measured by GFP expression is shown. Mean fluorescence 
intensity of each total population (MFI-1) and the GFP+ population (MFI-2) are listed as: 
(MFI-1|/MFI-2). 
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Figure 41. HCV1406 TCR-transduced CD4+ and CD8+ T cells have limited bi-functional 
reactivity against HCV NS3:1406-1415 naturally processed antigen. HCV1406 TCR-
transduced PBL were co-cultured for 5 hr with COS/A2 cells transiently transfected to 
express full length WT HCV NS3 or HCV NS3 with various mutant 1406-1415 epitopes. T 
cells were analyzed by flow cytometry for T cell surface markers, surface CD107a 
expression, and intracellular IFNγ. Percentages lytic and/or cytokine producing TCR-
transduced CD4+ (left pie) or CD8+ (right pie) T cells are displayed as pie charts for 
corresponding stimulation conditions. Variant peptides are grouped into “moderate 
affinity” (middle column of each panel) and “lower affinity” (right column of each panel) 
in decreasing order of affinity (top to bottom). Pie charts reflect a minimum of 2,000 
cells (average 4,000 cells). Reactivity is defined by greater than twice the percentage of 
total reactive cells against background (tyrosinase) stimulation. These data are 
representative of a single donor from three independent experiments using three 
different donors each. 
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mutant ligands. Additionally, mutant V1408T elicited a greater percentage of reactive 
cells compared to WT antigen (37% compared to 28%). These data provide further 
evidence that TCR-pMHC affinity may not be the most critical influence on T cell 
function. 
A Decrease in Ligand Density Preferentially Diminishes Bi-Functional Responses 
 A dramatic decrease in bi-functional T cells was also evident when comparing 
peptide versus naturally processed antigen stimulations (Fig. 42). Over half (38% out of  
70%) of total reactive TCR-transduced CD8+ T cells were bi-functional when stimulated 
with WT peptide-loaded T2 cells. But when stimulated with naturally processed antigen, 
bi-functional populations were reduced to 29% of the peptide-elicited response. Lytic-
only and IFNγ-only populations were only reduced by 54% and 50%, respectively. This 
trend is consistent for the remainder of reactive naturally processed antigens 
(summarized in Table 12). These data not only support the claim made in the previous 
chapter that decreased ligand density impacts antigen recognition, but that a decrease 
in antigen density also contributes to a preferential loss of bi-functional T cell responses. 
A Two-Parameter Analysis Enhances Our Understanding of Antigen Recognition over a 
One-Parameter Evaluation 
As mentioned earlier, traditional techniques used to assess T cell reactivity 
usually rely on the evaluation of a single pro-inflammatory cytokine secreted by a mixed 
culture of lymphocytes. Interestingly, we found that evaluation of a single cytokine 
measured by ELISA is limited in its interpretation. Decreases in the magnitude of a   
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Figure 42. A decrease in HCV NS3 ligand density preferentially decreases bi-functional 
HCV1406 TCR-transduced CD8+ T cells. HCV1406 TCR-transduced PBL were co-cultured 
for 5 hr with T2 cells loaded with WT and mutant HCV NS3:1406-1415 peptides  
(“Peptide”, left pie) or COS/A2 cells transiently transfected to express full length WT 
HCV NS3 or HCV NS3 with mutant 1406-1415 epitopes (“NS3”, right pie). Cells were 
analyzed by flow cytometry for T cell surface markers, CD107a expression, and 
intracellular IFNγ. Percentages of lytic and/or cytokine producing TCR-transduced CD8+ T 
cells are displayed as pie charts for each stimulation conditions. Variant peptides are 
grouped into “moderate affinity” (middle column of each panel) and “lower affinity” 
(right column of each panel) in decreasing order of affinity (top to bottom). Pie charts 
reflect a minimum of 2,000 cells (average 4,000 cells). Reactivity is defined by greater 
than twice the percentage of total reactive cells against background (tyrosinase) 
stimulation. These data are representative of a single donor from three independent 
experiments using three different donors each. 
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Table 12. Percent of peptide-stimulated reactivity in mono- and bi-functional 
populations upon stimulation with HCV NS3 naturally processed antigen.  
Epitope 
CD8+ TCR-Transduced T Cells 
Lytic only IFNγ only Lytic/IFNγ 
WT 54.9 56.8 27.6 
I1412L 16.5 70.5 9.4 
V1408T 69.1 94.6 49.5 
V1408L 18.3 106.2 10.7 
I1412V 46.5 67.1 32.2 
A1409T 17.5 57.6 9.5 
I1412N 13.5 52.4 6.8 
8S/9G/12L* 53.4 182.7 67.0 
8S/9S/12L/14S 24.6 69.6 15.3 
*Non-reactive; Percentages reflect the ratio of naturally processed antigen:peptide 
stimulation for each functional phenotype. These data are representative of a single 
donor from three independent experiments using three different donors each.  
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response suggest that either there are less overall reactive T cells, or that an equal 
number of reactive T cells are producing less cytokine. This confusion can be resolved by 
two-parameter analysis using flow cytometry (Fig. 43a). Additionally, IFNγ ELISAs fail to 
identify that in dampened cytokine release, CD8+ T cells contribute to almost all of the 
cytokine production (Fig. 43b).  By simultaneously measuring intracellular IFNγ and 
surface CD107a, we also demonstrated that HCV1406 TCR-transduced CD4+ and CD8+ T 
cells display different proportions of mono- and bi-functional populations in light of 
changes in the TCR-pMHC interaction as well as antigen density. Taken together, 
comparing magnitudes of a single cytokine release within a bulk T cell culture may 
oversimplify changes in reactivity. However, even a two-parameter assessment using 
CD107a and IFNγ may not most accurately depict the impact of altered TCR-pMHC 
interactions on T cell function. Therefore, the addition of more markers will likely better 
reflect the functional phenotypes in a T cell population.  
Seven-Dimensional Comparisons Provide Complicated Analysis 
We expanded our assessment of altered TCR-pMHC interactions’ impact on T cell 
function by using multi-dimensional flow cytometry to measure six intracellular 
cytokines (IFNγ, TNFα, IL-2, IL-4, IL-17A, IL-22) and lytic marker CD107a. A multi-
functional evaluation such as this may better reflect the changes in functional 
phenotypes of a T cell population than one or two parameters. We wanted to be able to 
compare differences in polyfunctional profiles between transduced CD4+ and CD8+ T 
cells across various HCV NS3:1406-1415 peptide and HCV+ tumor stimulation conditions.   
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Figure 43. Comparing bulk-culture single cytokine release assay versus two-parameter 
FACS-based analysis provides a much different functional interpretation. IFNγ cytokine 
release analyzed by ELISA by a bulk (mixed CD4+ and CD8+ HCV1406 TCR-transduced T 
cell) culture is compared with bi-functional reactivity assessed by flow cytometry. 
Affinity measurements for TCR-pMHC interactions are displayed below pie charts in red  
(a) Reactivity against peptide-loaded T2 cells. (b) Reactivity against naturally processed 
antigen. 
a) 
b) 
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The analysis of seven functional parameters after gating on our lymphocyte 
population markers generated 128 possible combinations of positivity/negativity for 
these functional markers. Compounding the analysis were multiple peptide or tumor 
stimulation conditions between two T cell subsets (CD4+ and CD8+). This yielded a 
grossly complex dataset that was difficult to analyze with basic flow cytometry software.  
For example, practical limitations in FlowJo, a standard software for flow 
cyotmetry analysis, generally restrict the visualization of data to one or two parameters 
at a time. Analysis of seven functional parameters required a matrix of 21 pairwise 
dotplots for a single stimulation condition (Fig. 44). Although this matrix is limited in its 
scope, we can deduce simple observations. Figure 44 displays a representative example 
of pairwise comparisons in CD8+ TCR-transduced T cells stimulated with WT HCV 
NS3:1406-1415 peptide-loaded T2 cells. All seven functional markers are present, but in 
varying proportions. While a limited number of TCR-transduced cells produced IL-17A 
and IL-22 (7.2% and 2.4%, respectively), larger proportions were positive for TNFα, 
CD107a, IL-4, IFNγ, and IL-2 (ranging from 42% to 20% in decreasing order). Evaluating 
two parameters simultaneously revealed interesting expression patterns. For example, 
pairwise comparisons between IL-2 and TNFα demonstrated that 90% of IL-2+ cells were 
also positive for TNFα, but that less than half of the TNF+ cells were also positive for IL-2. 
This may suggest that IL-2 production is strictly associated with TNFα production, but 
that some T cells’ TNFα production is independent of IL-2. Additionally, pairwise 
comparisons in FlowJo demonstrated that while 24% of the CD8+ T cells were IFNγ+,   
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Figure 44. Seven-parameter comparative analysis in FlowJo. PBL-derived T cells from a 
normal donor were transduced with the HCV1406 TCR retroviral vector. TCR-transduced 
T cells were enriched using anti-CD34 immunomagnetic beads. T cells were co-cultured 
for 5 hr with T2 cells loaded with 10 µg/mL of HCV NS3:1406-1415 peptide or 
tyrosinase:368-376 peptide. Cells were stained for CD3, CD4, CD8, CD34 and surface 
CD107a and intracellular IFN-γ, TNFα, IL-2, IL-4, IL-17A, and IL-22 using 
immunofluorescence.  Gating and analysis was performed in FlowJovX. Uni-dimensional 
histograms and biaxial dotplots depict single or pairwise functional comparisons in 
CD34+CD8+ HCV1406 TCR-transduced T cells. Gates set against background (tyrosinase) 
stimulation can be found in The Appendix, Figure 73. 
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nearly equally as many IFNγ - cells were positive for either CD107a or TNFα. This 
highlights the important point that evaluation for only IFNγ would incorrectly label a 
large proportion of the T cells as “non-reactive”. However, analysis in FlowJo does not 
easily display how many other cytokines might be expressed by IFNγ- cells.  
Most surprising were T cell populations that expressed unexpected combinations 
of cytokines. IL-4, a type 2 cytokine, is generally thought to be restricted to type 2 T 
cells, whereas type 1 cytokines (IFNγ, TNFα, and IL-2) are restricted to type 1 T cells [64]. 
However, our analysis indicated that a substantial number of CD8+ T cells are doubly 
positive for IL-4 and a type 1 cytokine. For example, of the 29% of IL-4+ T cells, nearly 
one third were also positive for IFNγ, over one third also expressed IL-2, and nearly two 
thirds also stained for intracellular TNFα. These data contradict what is normally 
accepted and reported in the literature concerning type 1 and type 2 T cell populations. 
Perhaps evaluation of T cell function on similarly large scales could clarify the biology of 
T cell reactivity. 
Portrayal of this data in FlowJo allows for simple comparisons, but would require 
an inordinate number of pairwise dotplots to compare variant peptide or tumor 
stimulations. In fact, it would require 756 dotplots to compare WT and mutant peptide 
and naturally processed antigen stimulation between CD4+ and CD8+ T cells. This makes 
meaningful interpretations of the data quite challenging. Limited to pairwise 
comparisons also does not resolve how many other non-type 2 cytokines IL-4+ T cells 
may also express. Similarly, pairwise comparison does not easily reveal how many 
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cytokines are expressed by IFNγ- cells that would be “lost” in traditional assays.  We 
attempted higher resolution of multi-dimensional analysis within FlowJo, by Boolean 
gating all 7 parameters to generate frequencies in each of the 128 phenotypes (2n, n = 
number of parameters). FlowJo cannot easily accommodate these multi-parameter 
comparisons, so we summed the frequencies of populations into categories of 0 to 7 
functional parameters positive. By categorizing phenotypes into pie charts according to 
the number of functional parameters expressed, we can make clearer comparisons 
between CD4+ and CD8+ T cell responses across mutant epitope stimulations (Fig 45).   
We found that HCV TCR-transduced CD4+ and CD8+ T cells contained a similar 
percentage of antigen reactive T cells when stimulated with the WT HCV NS3:1406-1415 
peptide (50.3% versus 56.5%, respectively). Both populations also exhibited a similar 
number of functional markers (1 marker-13.1% vs 14.4%; 2 markers-14.5% vs 13.3%; 3 
markers-11.5% vs 14.6%; 4 markers-7.0% vs 9.4%; 5 markers-3.1% vs 3.8%, 
respectively). At this point, however, we still lack the resolution to detect what 
combinations of cytokines are present in each category. Despite similarities in between 
CD4+ and CD8+ TCR-transduced T cells upon WT peptide stimulation, there were 
observable differences between polyfunctional populations across altered TCR-pMHC 
interactions. For example, “moderate affinity” ligand I1412L exhibited only a slight 
decrease in antigen reactive CD8+ T cells compared to WT stimulation (56.5% compared 
to 51.1%). But this mutation led to a dramatic decrease in antigen reactive CD4+ T cells 
(50.3% to 33.2%) (Table 13). I1412L stimulation also induced relatively modest changes   
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Figure 45. Number of functional markers produced by HCV 1406 TCR-transduced T 
cells when stimulated with naturally occurring mutant HCV NS3:1406-1415 peptides. 
Human PBL-derived T cells were transduced to express the HCV 1406 TCR. TCR-
transduced T cells were enriched using anti-CD34 immunomagnetic beads. T cells were 
co-cultured for 5 hours with T2 cells loaded with 10 µg/mL of each peptide and stained 
for CD107a expression and intracellular IFN-γ, TNFα, IL-2, IL-4, IL-17A, and IL-22. Cells 
were also stained for CD3, CD4, CD8, and CD34 to measure the individual transduced T 
cell subsets. Each pie wedge represents the percent of cells producing no (gray), 1 (red), 
2 (green), 3 (yellow), 4 (blue), 5 (orange), 6 (purple), or 7 (pink) functional markers. 
These data are representative of a single donor from three independent experiments 
using three different donors each.
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Table 13. Frequencies of polyfunctional populations upon stimulation with HCV NS3:1406-1415 mutant peptides.  
Epitope 
CD4+ T cell Functional Markers (%+)* 
0 1 2 3 4 5 6 7 
WT 49.7 13.1 14.5 11.5 7.0 3.3 0.9 0.2 
I1412L 66.8 11.6 10.1 5.9 3.6 1.5 0.5 0.0 
V1408T 85.9 6.3 4.6 2.0 0.8 0.2 0.0 0.0 
V1408L 63.1 11.9 11.7 7.0 3.9 1.8 0.5 0.1 
I1412V 83.7 7.6 4.4 2.4 1.2 0.5 0.1 0.0 
A1409T† 91.5 5.0 2.0 0.9 0.4 0.1 0.1 0.0 
I1412N† 92.7 4.9 1.5 0.6 0.3 0.1 0.0 0.0 
8S/9G/12L† 93.5 4.1 1.7 0.5 0.2 0.0 0.0 0.0 
8S/9S/12L/14S† 93.4 4.3 1.5 0.6 0.2 0.1 0.0 0.0 
Epitope 
CD8+ T cell Functional Markers (%+)* 
0 1 2 3 4 5 6 7 
WT 43.5 14.4 13.3 14.6 9.4 3.8 0.9 0.1 
I1412L 48.7 13.0 12.9 13.0 7.9 3.7 0.8 0.1 
V1408T 56.4 12.5 11.1 11.5 6.1 2.3 0.2 0.0 
V1408L 48.3 13.7 13.3 12.8 8.2 3.1 0.7 0.1 
I1412V 53.7 12.2 12.3 11.6 6.7 2.8 0.5 0.1 
A1409T 72.9 9.5 7.1 5.8 3.2 1.2 0.2 0.0 
I1412N 65.7 10.8 9.0 7.6 4.9 1.6 0.5 0.1 
8S/9G/12L† 94.4 2.7 1.7 0.8 0.3 0.1 0.0 0.0 
8S/9S/12L/14S 74.9 8.6 6.6 5.9 2.8 1.1 0.1 0.0 
*Percentages reflect frequency of cells positive for only the number of parameters indicated in each column; †Non-reactive. 
These data are representative of a single donor from three independent experiments using three different donors each. 
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in polyfunctional frequencies compared to WT stimulation in CD8+ T cells. Percentages 
differed anywhere from 1.6-0.1% in each category (1 marker-14.4% vs 13.0%; 2 markers-
13.3% vs 12.9%; 3 markers-14.6% vs 13.0%; 4 markers-9.4% vs 7.9%); 5 markers-3.8% vs 
3.7%). There was more of a dramatic decrease, however, in the number of 
polyfunctional markers among CD4+ T cells. Percentages differed as much at nearly 50% 
compared to WT (1 marker-13.1% vs 11.6%; 2 markers-14.5% vs 10.1%; 3 markers-
11.5% vs 5.9%; 4 markers-7.0% vs 3.6%; 5 markers-3.3% vs 1.5%) (Table 13). 
Interestingly, differences in polyfunctional percentages were more pronounced in 
higher order polyfunctional categories (3, 4, and 5 functional parameters). Additionally, 
differences in polyfunctional population frequencies were even more pronounced in 
CD4+ T cells stimulated with V1408L and I1412L peptides. Although similar in affinity to 
that of V1408T and I1412V, their polyfunctional profiles were substantially reduced, to 
fewer than 2.5% of the cells producing 3, 4, or 5 functional makers. This is consistent 
with previous observations that variant TCR-pMHC interactions with similar affinities do 
not necessarily correlate with similar biologic outcomes. 
A similar decrease in higher order polyfunctional categories (≥3 parameters) is 
seen in CD8+ T cells stimulated with “lower affinity” mutants (A1409T, I1412N, 
8S/9S/'12L/14S) compared to WT. These data support observations discussed earlier 
where “lower affinity” ligands had pronounced effects on bi-functional CD107a+IFNγ+ 
greater than either mono-functional population. This provides further evidence that 
perturbations in TCR-pMHC interactions have a biased effect on polyfunctional 
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populations. Taken together, these results indicate that multi-parameter per-cell 
analysis of T cell reactivity is able to resolve differences that standard assays fail to 
detect.  
Despite these meaningful interpretations, analysis in FlowJo still lacked the 
ability to graphically portray individual polyfunctional phenotypes or display how altered 
TCR-pMHC interactions impact their relative abundance. We addressed this issue by 
evaluating a series of software packages in their ability to visualize and interpret our 
complex, high dimensional datasets. Software evaluated included GemStone [311], 
SPADE [312], FlowSOM [316], viSNE [317], and FLOCK [319]. Detailed analysis methods, 
advantages and disadvantages, and representative graphical output for each tool using 
our datasets are described in Chapter Two for your reference. Based on our extensive 
evaluation of these software packages, tandem analysis is Pestle/SPICE was the user-
friendliest and provided the most interpretable graphical output. Thus, the rest of the 
discussion will focus on polyfunctional phenotypes analyzed with SPICE. 
T Cell Polyfunctional Responses Are Extremely Diverse  
Boolean gating within FlowJo followed by tandem analysis in Pestle/SPICE data 
processing software packages adequately visualized individual polyfunctional 
populations. One of the first observations was the heterogeneity in polyfunctional 
populations and their frequencies between CD4+ and CD8+ TCR-transduced T cells. 
Figure 46 quantitatively compares the frequencies of polyfunctional phenotypes of CD4+ 
and CD8+ TCR-transduced T cells stimulated with WT NS3:1406-1415 peptide-loaded T2   
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Figure 46. Polyfunctional heterogeneity between WT HCV NS3:1406-1415 peptide-
stimulated CD4+ and CD8+ HCV1406 TCR-transduced T cells.  Boolean-gated frequencies 
within FlowJo were formatted within Pestle and exported into SPICE. Bar heights 
compare frequencies of CD4+ (red) and CD8+ (blue) TCR-transduced T cell polyfunctional 
populations after stimulation with NS3:1406-1415 WT peptide-loaded T2 cells. The bar 
graph has been limited to include only populations above 0.25%. Please refer to The 
Appendix, Figure 74, for frequencies of all 128 possible phenotypes. These data are 
representative of three independent experiments using three different donors each. 
  
%
 T
C
R
-t
ra
n
sd
u
ce
d
 T
 c
e
lls
 
%
 T
C
R
-t
ra
n
sd
u
ce
d
 T
 c
e
lls
 
193 
   
 
cells.  For simplicity, a cut off has been set to only display frequencies of at least 0.25% 
for either CD4+ or CD8+ T cells. Please refer to The Appendix for original output showing 
frequencies of all 128 combinatorial phenotypes. It is clearly evident how 
heterogeneous CD4+ and CD8+ T cells behave. For example, the two most dominant 
phenotypes for both CD4+ and CD8+ are IFNγ+TNFα+ and TNFα+-only (remaining 
parameters negative). But a number of phenotypes exist in CD4+ T cells that are not 
evident in CD8+ T cells (TNFα+IL-4+, TNFα+IL-17A+, IL-2+IFNγ+TNFα+IL-4+). Additionally, 
certain phenotypes were present in the CD8+ T cell subsets but not in CD4+ T Cells 
(CD107a+TNFα+IL-4+, IL-2+CD107a+IL-17A+, IL-2+CD107a+IL-4+IL-22+). It is interesting how 
many phenotypes are actually present and how variable the frequencies are between 
CD4+ and CD8+ T cells. Analysis in SPICE finally provides us to resolution to make these 
highly complex observations. 
Another useful comparison tool in SPICE is a heat-map-like feature, known as a 
cool plot. Cool plots allow us to compare changes in the frequencies of polyfunctional 
phenotypes in light of altered TCR-pMHC interactions. Figure 47 displays a complete 
cool plot showing frequencies (denoted by shade of blue) of polyfunctional phenotypes 
(read by +/- combinations of each of the 7 functional parameters in columns). Figure 47 
specifically compares the changes in polyfunctional phenotype frequencies of HCV1406 
TCR-transduced CD8+ T cells after stimulation by WT and variant HCV NS3:1406-1415 
peptide-loaded T2 cells. The respective cool plot for this PBL donor’s TCR-transduced 
CD4+ T cells can be found in The Appendix. This representation evaluates frequencies of 
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Figure 47. SPICE-generated cool plot comparing changing frequencies of T cell polyfunctional phenotypes in light of altered TCR-
pMHC interactions. HCV 1406 TCR-transduced T cells were co-cultured for 5 hours with T2 cells loaded with 10 µg/mL of each WT 
and mutant HCV NS3:1406-1415 peptide. Cells were stained for CD3, CD4, CD8, CD34, and CD107a surface expression as well as 
intracellular IFN-γ, TNFα, IL-2, IL-4, IL-17A, and IL-22. Boolean gating for each functional marker was performed in FlowJo.  19
4 
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Resulting multivariate datasets were formatted and background subtracted (tryosinase stimulation) in Pestle, and cool plot overlay 
was generated in SPICE. Evaluation along the x-axis (red box) determines frequency (shade of blue) of TCR-transduced cells for each 
of the 128 phenotypes. Each column is a separate phenotype denoted by +/- for each functional parameter. Evaluation along the y-
axis (purple box) determines changes in frequency upon variant peptide stimulation for a given phenotype. Unique populations of 
simultaneously type 1 and type 2 cytokine producing cells are denoted in green boxes. Populations negative for IFNγ are surround by 
an orange box. TCR-pMHC interactions are ranked from bottom to top by decreasing affinity. These data are representative of three 
independent experiments using three different donors each.
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all 128 possible phenotypes for a given stimulation condition read across the x-axis (red 
box). It can also compare changing frequencies of an individual functional phenotype 
across mutant epitope stimulations in the y-direction (purple box). Alterations in TCR-
pMHC interactions are ranked from bottom to top by decreasing TCR-pMHC affinities. 
We can finally gain a clearer picture of the polyfunctional potential of these gene-
modified T cells and how polyfunctionality fluctuates with altered TCR-pMHC 
interactions. First, it is clear that while 128 phenotypes are possible given seven-
parameter analysis, not all phenotypes are observed. Second, we again detect surprising 
cytokine combinations produced by individual cells. Highlighted in green boxes are IL-4+ 
cells (a type 2 cytokine) that also express at least one additional type 1 cytokine (IL-2, 
TNFα, or IFNγ) and/or are lytic. Third, we can start to delineate differences in 
polyfunctional responses in light of altered TCR-pMHC interactions by comparing 
changing frequencies in the y-direction. Fourth, is it clearly evident how many reactive T 
cells would be unaccounted for if only IFNγ were measured. IFNγ- populations 
(surrounded by an orange box in Figure 47) accounted for surprisingly the majority of 
the CD8+ T cells in the population.  Once again, examining more cytokines than just IFNγ 
reveals a much more complete picture of a T cell culture. Polyfunctional analysis also 
suggests that the field’s conception of T cell function and the classification of T cells into 
restricted cytokine-producing populations (type 1 vs type 2, etc.) may be drastically 
oversimplified. 
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A clearer interpretation is achieved when cool plots are condensed to display 
only detectable populations in each culture. Figure 48 shows condensed cool plots for 
both CD4+ (Fig. 48a) and CD8+ (Fig. 48b) HCV1406 TCR-transduced T cells stimulated 
with HCV NS3:1406-1415 mutant peptides. TCR-pMHC interactions are ordered from 
bottom to top by decreasing affinity. Condensed cool plots also highlight the 
heterogeneity between CD4+ and CD8+ T cell responses.  Additionally, while lower 
affinity TCR-pMHC interactions yield overall lower frequencies, not each polyfunctional 
population is affected equally, nor are changes in polyfunctional responses directly 
correlated with affinity. For example, TNFα +-only population fluctuated much more in 
CD4+ TCR-transduced T cells despite the strength of the mutant TCR-pMHC interactions 
(I1412L, V1408T, V1408L, I1412V) being relatively similar (32-63 µM) (Fig. 48a). Higher 
order phenotypes (3 or 4 functional markers) were also restricted to WT, I1412L, and 
V1408L peptide stimulations. These results suggest that certain pMHC ligands may be 
recognized differently by the TCR (despite similar affinities) leading to a less diverse 
polyfunctional response. 
A similar trend is seen when comparing functional frequencies of CD8+ TCR-
transduced T cells (Fig. 48b). For example, the frequencies of the CD107a+-only 
population were very consistent with roughly 5% of CD8+ T cells present in nearly all  
mutant peptide stimulations. However, IFNγ+TNFα+ (all other parameters negative) CD8+ 
TCR-transduced T cells exhibit a higher degree of change. There was less variability in 
response to the “moderate affinity” group of TCR-pMHC interactions, but V1408L   
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Figure 48. Polyfunctional phenotypes are heterogeneous and fluctuate with altered 
TCR-pMHC interactions. Human PBL-derived T cells were transduced to express the 
HCV1406 TCR. T cells were co-cultured for 5 hours with T2 cells loaded with 10 µg/mL of 
each WT and mutant HCV NS3:1406-1415 peptide. Cells were stained for CD3, CD4, CD8, 
CD34, and CD107a surface expression as well as intracellular IFN-γ, TNFα, IL-2, IL-4, IL-
17A, and IL-22. Multivariate analysis was performed using FlowJo, Pestle, and SPICE 
software packages. Condensed cool plots display frequencies of polyfunctional 
populations of (a) CD4+ or (b) CD8+ TCR-transduced T cells shown in increasing order of 
polyfunctionality (right to left). Each column is a separate phenotype denoted by +/- for 
each functional parameter. TCR-pMHC interactions are ranked from bottom to top by 
decreasing affinity. Complete cool plots are shown in Figures 47 and 75. These data are 
representative of three independent experiments using three different donors each.  
a) 
b) 
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induced lower frequencies of reactive T cells in almost all phenotypes compared to 
I1412L, V1408L, or I1412V. Interestingly, “lower affinity” pMHC (A1409T,  
I1412N, and 8S/9S/12L/14S) induced a fewer number of detected phenotypes overall. 
Generally, the absence of higher order polyfunctional populations (4 or 5 functional 
markers) correlated with lower TCR-pMHC affinity. Furthermore, the frequency of all 
functional phenotypes was decreased when T cells were stimulated with lower affinity 
compared to moderate affinity ligands. Overall, portraying data in SPICE-generated cool 
plots provided a remarkable tool to characterize the polyfunctionality of T cells. We can 
very easily observe the polyfunctional heterogeneity between CD4+ and CD8+ T cells and 
the varying impact that alterations in TCR-pMHC interactions have on the spectrum and 
frequency of polyfunctional populations.  
Heterogeneity in Polyfunctional Responses Exists Among PBL Donors 
 We examined whether polyfunctional phenotypes against our panel of mutant 
pMHC were donor-dependent by evaluating polyfunctionality in HCV TCR-transduced T 
cells derived from PBL of additional donors. Representative condensed cool plot of CD4+ 
or CD8+ HCV TCR-transduced T cells from two different donors are displayed in Figures 
49-50, respectively. Full cool plots for these and other donors can be found in The 
Appendix. Interestingly, functional T cell phenotypes were not the same between 
different donors despite being transduced with the same TCR and stimulated with the 
same ligands. For example, Figure 48 displays cool plots highlighting differences 
between T cell functional phenotypes of two donors’ CD4+ TCR-transduced T cells 
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against HCV NS3:1406-1415 peptide-loaded T2 cells. Compared to Donor 2, Donor 1’s 
TCR-transduced CD4+ T cells (Fig. 49a) were less reactive overall (56.5% vs 78.2% total 
reactive T cells) and less heterogeneous (fewer functional phenotypes present; 12 vs 18) 
(Fig. 49b). Additionally, Donor 1 exhibited functional phenotypes lacking in Donor 2 (i.e. 
TNFα+IL-4+ (approximately 8% of WT peptide-stimulated)). Similarly, certain phenotypes 
were absent in Donor 1 that were present in Donor 2 (i.e. IL-22+TNFα+IL-17A+ 
(approximately 4% of WT peptide-stimulated)). Donor 2 was also more polyfunctional 
upon stimulation with WT peptide. For example, donor 2 exhibited 8 quad-functional 
populations compared to Donor 1 having only 1 quad-functional population. 
Polyfunctional profiles of additional donors have been evaluated and representative 
cool plots can be found in The Appendix. These observations suggest that the number 
and type of functional phenotypes between PBL donors are not necessarily consistent. 
Similar trends were observed between TCR-transduced CD8+ T cells of Donor 1 
(Fig. 50a) and Donor 2 (Fig. 50b). Donor 1 also had polyfunctional CD8+ TCR-transduced 
T cell populations missing in Donor 2 (bi-functional TNFa+IL-2+ (approximately 2% of WT 
and “moderate affinity”-stimulated T cells)). Conversely, Donor 2 quad-functional 
TNFα+IL-17A+CD107a+IFNγ+ population (ranging from 2-6% of total cells) was absent in 
Donor 1. These donors exhibited similar numbers of individual polyfunctional 
populations present (equal at 19), but varied in the number of simultaneous parameters 
detected. For example, Donor 1 had fewer higher order polyfunctional (3 parameters or 
less) populations (5 mono-functional, 5 bi-functional, 5 tri-functional, 3 quad-functional,   
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Figure 49. Heterogeneity of HCV1406 TCR-transduced CD4+ T cells in two PBL donors. T 
cells from two PBL donors were transduced to express the HCV 1406 TCR. T cells were 
co-cultured for 5 hours with T2 cells loaded with 10 µg/mL of each WT and mutant HCV 
NS3:1406-1415 peptide. Cells were stained for CD3, CD4, CD8, CD34, and CD107a 
surface expression as well as intracellular IFN-γ, TNFα, IL-2, IL-4, IL-17A, and IL-22. 
Multivariate analysis was performed using FlowJo, Pestle, and SPICE software packages. 
Condensed cool plots display frequencies of polyfunctional populations CD4+ TCR-
transduced T cells of (a) Donor 1 and (b) Donor 2 shown in increasing order of 
polyfunctionality (right to left). Each column is a separate phenotype denoted by +/- for 
each functional parameter. TCR-pMHC interactions are ranked from bottom to top by 
decreasing affinity. Complete cool plots are shown in The Appendix, Figures 75-76.  
a) 
b) 
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Figure 50. Heterogeneity of HCV1406 TCR-transduced CD8+ T cells in two PBL donors. T 
cells from a second PBL donor were transduced to express the HCV 1406 TCR. T cells 
were co-cultured for 5 hours with T2 cells loaded with 10 µg/mL of each WT and mutant 
HCV NS3:1406-1415 peptide. Cells were stained for CD3, CD4, CD8, CD34, and CD107a 
surface expression as well as intracellular IFN-γ, TNFα, IL-2, IL-4, IL-17A, and IL-22. 
Multivariate analysis was performed using FlowJo, Pestle, and SPICE software packages. 
Condensed cool plots display frequencies of polyfunctional populations CD8+ TCR-
transduced T cells of (a) Donor 1 and (b) Donor 2 shown in increasing order of 
polyfunctionality (right to left). Each column is a separate phenotype denoted by +/- for 
each functional parameter. TCR-pMHC interactions are ranked from bottom to top by 
decreasing affinity. Complete cool plots are shown in Figure 47 and in The Appendix, 
Figure 77.   
a) 
b) 
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and 1 penta-functional phenotypes), whereas Donor 2 demonstrated much more higher 
order (4 or greater parameters) populations (3 mono-functional, 4 bi-functional, 4 tri-
functional, 3 quad-functional, 4 penta-functional, and 1 hexa-functional phenotypes). 
These observations suggest that PBL can be comprised of very heterogeneous T cell 
populations within a single culture and between donors. Despite being engineered with 
the same TCR and stimulated with the same pMHC, both number and frequency of 
polyfunctional populations can dramatically differ but general trends between altered 
ligand reactivity remained the same. 
Such heterogeneity is difficult to explain, but may begin to offer explanations for 
different patients responses to therapies. For instance, if a more polyfunctional 
response is more advantageous, than Donor 2’s T cells may perform better 
therapeutically. However, if a certain individual phenotype is a “better” anti-tumor 
phenotype (i.e. IL-2+TNFα+IL-4+) Donor 1 may have the advantage because this 
population is present in approximately 5% of reactive CD8+ T cells against WT and 
multiple mutant antigens, but is absent all together in Donor 2. This inherent 
heterogeneity between donors is an interesting observation and concept, but further 
investigation into identifying which functional populations are “better” for anti-tumor or 
anti-viral responses is needed. 
Reduced Ligand Density Dampens Polyfunctional Responses 
 Earlier, we described that reduced ligand density had a dramatic effect on T cell 
function. As a follow up to this concept, we evaluated if there were altered 
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polyfunctional responses against HepG2 cells engineered to express naturally processed 
NS3 variants (Fig. 51). Similar to previous experiments, CD4+ T cells were non-reactive 
against this “lowest density” naturally processed antigen, but CD8+ T cells demonstrated 
polyfunctional responses against WT and “moderate affinity” ligands I1412L, V1408T, 
V1408L, and I1412V (Fig. 52a). Remarkably, there was a dramatic reduction in 
polyfunctional phenotypes compared to peptide-stimulated CD8+ T cells (Fig. 52b). 
Peptide-stimulated cells exhibited a robust response comprised of 19 different 
functional phenotypes ranging from mono-functional to hexa-functional (6 
simultaneous parameters). Conversely, tumor-stimulated CD8+ T cells were restricted to 
only 9 different functional phenotypes, the majority (6/9) being limited to mono- or bi-
functional. There were only 2 tri- and 1 quad-functional populations present. Penta-and 
hexa-functional populations that made up roughly 25% of peptide-stimulated 
phenotypes were now completely absent. Tumor stimulation also seemed to 
preferentially reduce higher order polyfunctional populations and restricted the 
heterogeneity of responses. This suggests that a lower level of antigen density may 
result in incomplete T cell activation. 
To further evaluate the effects of decreasing antigen density on polyfunctional T 
cell responses, we stimulated HCV TCR-transduced T cells with T2 cells loaded with the 
WT NS3:1406-1415 peptide at concentrations ranging from 10 µg/mL  to 10-11 µg/mL. 
We also stimulated HepG2 cells expressing naturally processed WT NS3 (“lowest 
density” of ligand) or HepG2 cells exogenously loaded with 10 µg/mL WT peptide to   
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Figure 51. Generation of HepG2 cells expressing naturally processed HCV NS3 with WT 
and naturally occurring mutant NS3:1406-1415 epitopes. HepG2 cells were transduced 
retroviral vectors encoding full length HCV NS3 protein containing WT or variant 
NS3:1406-1415 epitopes fused to GFP by a T2A linker. Cells were sorted for high and 
uniform GFP expression. WT antigen was slightly downregulated after multiple 
passages. Mean fluorescence intensity of each population is listed in parentheses. 
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Figure 52. NS3+ HepG2 stimulation reveals a markedly reduced polyfunctional 
response. T cells from two PBL donors were transduced to express the HCV 1406 TCR. T 
cells were co-cultured for 5 hours with HepG2 cells engineered to express full length 
HCV NS3 with WT of variant 1406-1415 epitopes. Cells were stained for CD3, CD4, CD8, 
CD34, and CD107a surface expression as well as intracellular IFN-γ, TNFα, IL-2, IL-4, IL-
17A, and IL-22. Multivariate analysis was performed using FlowJo, Pestle, and SPICE 
software packages. Condensed cool plots display frequencies of polyfunctional 
populations CD8+ TCR-transduced T cells stimulated by (a) HCV NS3+ HepG2 cells or (b) 
Peptide-loaded T2 cells. Functional phenotypes are shown in increasing order of 
polyfunctionality (right to left). Complete cool plots are in The Appendix, Figures 77,79. 
Data are representative of three independent experiments using three different donors. 
a) 
b) 
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augment ligand density (Fig. 53). We found that a reduction in ligand concentration 
from 10 to 10-3 µg/mL eliminated nearly all functional responses in CD4+ TCR-transduced 
T cells. Interestingly, the IL-4+-only population maintained prevalence throughout, which 
might suggest that production of IL-4 has lowest the threshold of TCR-pMHC contacts 
for initiation. CD8+ TCR-transduced T cells on the other hand exhibited a greater 
tolerance for reduced antigen density, with gradual reductions in frequency across 
multiple functional phenotypes. Interestingly, higher order polyfunctional populations (4 
or 5 parameters positive) were more susceptible to changes in ligand density as they 
were eliminated when stimulated with lower concentrations (10-5-10-7 µg/mL) 
compared to mono- or bi-functional populations that were still present when stimulated 
with 10-11 µg/mL of antigen.  
NS3+ HepG2 cells expressing naturally processed antigen, on the other hand, 
stimulated minimal polyfunctional responses, suggesting the density of ligand may be 
less than that of 10-11 µg/mL peptide-loaded T2 cells. Remarkably, exogenously loading 
HepG2 cells with 10 µg/mL peptide, increasing relative ligand density, rescued the 
frequency and range of polyfunctional phenotypes. Polyfunctional responses were now 
comparable to stimulation by “highest density” T2 cells. Increasing antigen density on 
HepG2 cells even restored polyfunctional responses in CD4+ T cells that had minimal 
reactivity against naturally processed antigen. Overall, these data support the notion 
that ligand density not only plays a role in binary T cell reactivity, but highly influences 
polyfunctional responses, especially higher order polyfunctional T cells.  
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Figure 53. Influence of ligand density on polyfunctional phenotypes. PBL-derived T 
cells transduced with the HCV1406 TCR retroviral vector were co-cultured with T2 cells 
loaded with WT HCV NS3:1406-1415 peptide ranging from 10 – 10-11 µg/mL. T cells were 
also co-cultured with HepG2 cells expressing naturally processed full length NS3 protein 
or HepG2 cells exogenously loaded with 10 µg/mL NS3:1406-1415 peptide. Cells were 
stained for extracellular markers and intracellular cytokines; multivariate analysis was 
performed in FlowJo, Pestle, and SPICE software packages. Condensed SPICE-generated 
cool plots display frequencies of polyfunctional populations for (a) CD4+ and (b) CD8+ 
TCR-transduced T cells. Complete cool plots are shown in The Appendix, Figures 84-85. 
These data are representative of independent experiments using two different donors.  
a) 
b) 
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Hierarchical Clustering Relates Polyfunctional Phenotypes  
to Alterations in TCR-pMHC Interactions 
While it is clear that there are differences in polyfunctional phenotypes against 
our panel of naturally occurring HCV NS3:1406-1415 variants, it would be helpful to 
relate these changes to alterations in TCR-pMHC affinity. To do this, we utilized a 
classical bioinformatic approach known as hierarchical clustering analysis, which clusters 
phenotypic patterns which are most similar to each other. It was made popular in the 
era of gene expression microarray data analysis where both tissue samples and genes 
would be clustered to identify genes that could distinguish between tissue subtypes  
[321].  In our experimental data, hierarchical clustering ranked the frequencies of T cell 
functional phenotypes as well as their relatability using dendograms. Phenotype 
patterns that do not occur are in a sense relegated to the bottom of the clustering 
analysis output, providing an easy way to focus on pertinent data.  
The hierarchical clustering analysis shown here is a tailored version, visualizing 
only the phenotypes present in a CD8+ TCR-transduced T cell culture stimulated with T2 
cells, loaded with each HCV NS3:1406-1415 peptide (Fig. 54), corresponding to Donor 1 
cool plots shown in Figures 47-48.  Complete hierarchical clustering for multiple donors’ 
CD4+ and CD8+ TCR-transduced T cell stimulations can be found in The Appendix. 
Hierarchical clustering also relates pMHC ligands by their induced functional 
phenotypes. So, ligands that stimulated a similar intensity or number of functional 
phenotypes are represented closer together in the dendogram than pMHC ligands that 
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Figure 54. Bioinformatic hierarchical clustering relates polyfunctional responses to TCR-pMHC affinity. A hierarchical clustering 
analysis using FlowJo Boolean gated frequencies organizes polyfunctional phenotype by frequency and relatedness (left 
dendograms) by peptide-stimulated TCR-transduced CD8+ T cells. This analysis can also demonstrate response relatedness between 
HCV NS3:1406-1415 peptide stimulations (top dendograms). An affinity value for each variant TCR-pMHC interaction is denoted in 
red. Output has been modified to portray only positively identified phenotypes. Please refer to The Appendix, Figure 88 for complete 
output.  
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stimulated less intense or more dissimilar functional phenotypes. Comparing 
hierarchical clustering of pMHC ligands with TCR-pMHC affinity measurements (red 
font) demonstrated that the strength or diversity of a T cell response is not necessary 
dependent on affinity. While “moderate” and “lower” affinity variants tended to be 
related in larger groups, dendograms did not order individual mutant pMHC ligands 
strictly by their KD values. This relatedness (grouping) of pMHC ligands was conserved in 
multiple peptide-stimulated donors (Figs. 54-55). Interestingly, the relatedness 
(grouping) of pMHC ligands changed upon tumor stimulation (Fig. 56), suggesting that 
the alterations in TCR-pMHC interactions can have a different impact on functional 
outcomes at lower densities. While TCR-pMHC affinity is routinely thought to be the 
most influential factor governing antigen recognition, we demonstrate yet again, that 
this is not entirely true. 
Significance 
It is clear that the evaluation of T cell reactivity based on a single cytokine 
readout is not a completely accurate representation of the biology of the T cell culture. 
We first established this by evaluating two distinct functions, lytic activity and cytokine 
production, by measuring surface CD107a and intracellular IFNγ by flow cytometry. We 
were able to observe functional heterogeneity between CD4+ and CD8+ HCV TCR-
transduced T cells. We also established that alterations in TCR-pMHC interactions and 
changes in ligand density preferentially decreased bi-functional CD107a+IFNγ+ 
212 
   
 
 
 
 
 
 
Figure 55. A second PBL donor relates mutant peptide responses similarly but with different clustering of polyfunctional 
phenotypes. A hierarchical clustering analysis using FlowJo Boolean gated frequencies organizes polyfunctional phenotype by 
frequency and relatedness (left dendograms) by peptide-stimulated TCR-transduced CD8+ T cells in a second PBL donor. This analysis 
portrays the same relatedness between HCV NS3:1406-1415 peptide stimulations evaluated in a previous donor (top dendograms). 
Affinity values for each variant TCR-pMHC interaction are denoted in red. Output has been modified to portray only positively 
identified phenotypes. Please refer to Appendix, Figure 90 for complete output.  
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Figure 56. Hierarchical clustering also relates tumor-stimulated responses. A hierarchical clustering analysis using FlowJo Boolean 
gated frequencies organizes polyfunctional phenotype by frequency and relatedness (left dendograms) by HepG2 or NS3+ HepG2 
cell-stimulated TCR-transduced CD8+ T cells in a second PBL donor (peptide response displayed in Figure 55).  This analysis portrays 
the relatedness between naturally processed antigen stimulations (top dendograms). An affinity value for each variant TCR-pMHC 
interaction is denoted in red. Output has been modified to portray only positively identified phenotypes. Please refer to The 
Appendix, Figure 92 for complete output. 
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populations over either mono-functional phenotype. Large changes in total reactivity 
and individual phenotype frequencies occurred, in some cases, despite similar TCR-
pMHC affinities. These data provided further evidence that affinity does not entirely 
dictate antigen recognition. 
We then expanded our assessment of T cell polyfunctionality to include 
additional cytokines TNFα, IL-2, IL-4, IL-17A, and IL-22, which yielded highly complex 
multi-dimensional data sets. Analysis in software packages FlowJo, Pestle, and SPICE 
allowed us to graphically compare functional responses of HCV TCR-transduced T cells 
against our panel of naturally occurring mutant peptides. We found that CD4+ and CD8+ 
TCR-transduced T cells exhibited a much greater degree of phenotypic and functional 
complexity than previously appreciated. It was also clear that altered TCR-pMHC 
interactions influenced these diverse responses. This observed large degree of 
functional diversity may give T cells a remarkable degree of flexibility in responding to 
pathogens or tumor. Furthermore, at a single cell level, most of the traditional 
functional classifications (type 1, type 2, etc.) do not always hold true. These results 
suggest that polyfunctional analysis of T cells was able to perceive differences that 
standard assays fail to detect. Observations using human TCR-transduced T cells are 
intriguing because they represent the kinds of T cell populations we transfer to patients. 
Heterogeneity between PBL donors demonstrated differences in phenotypes identified 
as well as overall polyfunctionality. Expansive evaluation of T cell polyfunctionality in the 
context of anti-viral or anti-tumor responses may allow for better treatment 
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correlations, biomarkers for predictive outcomes, or the ability to select for or design an 
“optimal” phenotype of T cells to be used in ACT.  
However, it is still unclear how alterations in TCR-pMHC interactions dictate 
changes in polyfunctional phenotypes. While hierarchical clustering analysis supports 
our hypothesis that TCR-pMHC affinity is not necessarily correlated with antigen 
recognition, we still lack a firm explanation for this phenomenon. The next chapter 
attempts to give weight to all these data in light of what is accepted in the field. We will 
speculate on structural observations that may help rationalize discrepancies in 
polyfunctional outcomes. We will also discuss how our novel observations may 
influence what should be considered when optimizing TCRs for gene-modification of T 
cells used in ACT.  
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CHAPTER SEVEN 
CONCLUSIONS 
Introduction 
Adoptive cell transfer using TCR gene-modified T cells is an exciting and rapidly 
evolving field. Numerous in vitro and in vivo studies discussed in Chapter One have 
demonstrated various levels of feasibility, safety, and efficacy using TCR-engineered T 
cells to treat cancer and viral infections. Although evidence suggests their use can be 
effective, how effective and how to improve these therapeutics are still remaining 
questions.  
Various means of improving the efficacy of TCR-engineered T cells, previously 
discussed, include cytokine and chemokine support, modifying retroviral vectors to 
promote pairing of introduced TCR α and β chains, and affinity-enhancement of the TCR. 
Because the affinity of TCR-pMHC interaction is thought to play the central role in 
defining T cell specificity and sensitivity , most of the field has adopted the theory that 
creating affinity-enhanced TCRs results in better functioning T cells. Although 
physiologic TCR-pMHC affinities traditionally range anywhere from 1-100 µM [11], the 
use of yeast and phage display can generate TCRs with affinities in the nM to pM range 
[3, 4]. However, enhanced affinity creates the opportunity for cross-reactivity. In fact, it 
has been shown in vitro that high affinity TCRs are much more tolerant of TCR contact 
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residue substitutions and dramatically increase the number of stimulatory peptides 
[407]. Additionally, a clinical trial using a MART-1-specific TCR with a KD of only 30 µM 
demonstrated serious adverse events due to on-target/off-tumor activity [184]. 
Moreover, a murine-derived, affinity-enhanced MAGE-3-specific TCR caused lethality in 
another clinical trial due to off-target cross-reactivity with structurally similar epitopes 
[211, 213]. 
While TCR cross-reactivity was unwanted and detrimental in these cases, cross-
reactive TCRs may offer therapeutic benefits if the antigens targeted are susceptible to 
mutation from genomic instability. Thus, the proper choice and design of therapeutic 
TCRs mandates a broader understanding of the basic principles governing antigen 
recognition by a T cell. In light of what is known about TCRs and T cell function, 
numerous factors still need to be addressed. These include: (1) what kinetic or cellular 
factors are most important in facilitating antigen recognition; (2) how is T cell function 
affected by alterations in TCR-pMHC interactions; (3) how can we structurally rationalize 
the cross-reactivity of a TCR; and (4) how might such cross-reactivity augment or inhibit 
therapeutic benefit.  
The studies discussed in this dissertation aimed to address the above questions. 
Below we revisit key findings identified in each chapter and discuss how they contribute 
to an enhanced understanding of antigen recognition and T cell function. We also point 
out what questions are still unanswered and what needs to be addressed to advance 
the development of safe and efficacious TCR-engineered T cells for ACT.  
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HCV1406 TCR Displays Anti-Tumor Activity In Vivo 
For any adoptive immunotherapy to be a viable treatment option, it must be 
clearly evident that antigen-reactive T cells are capable of being generated. Additionally, 
physiologically relevant targets need to be recognized by functional T cells. We believe 
that we have fulfilled these criteria.  We demonstrated that we can engineer T cells with 
an HLA-A2-restricted, HCV NS3:1406-1415-reactive, CD8-independent TCR (HCV1406 
TCR). We also showed that PBL-derived T cells engineered to express HCV1406 TCR are 
capable of recognizing naturally processed HCV NS3 antigen presented by HCC cell lines 
in vitro and can mediate the regression of established HCV+ tumors in vivo.  
To date, only a limited number of naturally occurring CD8-independent TCRs 
have been cloned and characterized. The ability of the HCV1406 TCR to transfer 
reactivity to both effector and helper T cells is advantageous for an effective 
immunotherapy candidate. HCV1406 TCR-transduced CD4+ and CD8+ PBL-derived T cells 
recognized both peptide-loaded targets and a variety of HCV+ tumor cells lines. Our in 
vivo tumor regression model further supports our in vitro data that this TCR is capable of 
recognizing HCV+ tumors. Further analysis of differential adoptive transfer of CD8+ T cells 
with and without CD4+ T cells may better distinguish the importance of generating CD4+-
reactive T cells for eliminating tumor, which may influence treatment modality in 
patients. Since one of the fundamental problems typical of chronic or recurrent HCV 
infections is a weak or absent HCV-specific CD4+ T cell response [363, 364, 408, 409], the 
ability to engineer CD4+ T cells capable of secreting cytokines and exhibiting cytolytic 
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activity may be extremely beneficial for an effective treatment. Taken together, we have 
established a proof-of-principle that we can generate TCR gene-modified CD4+ and CD8+ 
PBL-derived T cells capable of impacting on the growth of HCV+ tumor targets and may 
be a useful tool to treat patients with HCV-associated diseases, such as HCC. 
While other studies have examined AFP [410-412], ferritin [413], NY-ESO-1 [414-
418] or Glypican 3 [417, 419-424] as biomarkers or therapeutic targets for HCC, we have 
chosen to investigate HCV for its nonself nature, its immunogenicity, and the fact that 
HCV is a major risk factor for the development of HCC. While the role of HCV proteins in 
hepatocarcinogenesis is not well described, HCV is mainly thought to cause HCC via 
indirect pathways including chronic inflammation, cell death, proliferation, and cirrhosis 
[425-428]. Consequently, it is possible that HCV TCR-transduced T cells would target 
both normal and malignant hepatocytes, potentially leading to severe adverse events, 
as noted by another group investigating HCV TCR-redirected T cells [222]. This 
accompanied with cirrhosis and liver dysfunction in many HCC patients may limit a 
systemic infusion of HCV TCR-transduced T cells. Thus, clinical trials for this 
immunotherapy are designed to involve CT or ultrasound guided intratumoral injection 
in a manner similar to transarterial chemoembolization or radioembolization. A similar 
intratumoral technique was used successfully in one of our previous clinical trials [207]. 
Such carefully thought approaches would help preclude significant exposure of normal 
hepatocytes to the HCV TC- transduced T cells and minimize adverse events.  
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In summary, our results are encouraging that HCV1406 TCR gene-modified T cells 
could serve as an immunotherapeutic candidate for HCV-associated HCC. However, the 
propensity for HCV to generate immune escape variants due to its genomic instability 
[279, 352-356] may require an effective TCR to recognize mutated epitopes. Therefore, 
it is important to assess the cross-reactivity of HCV-reactive TCRs against naturally 
occurring and epidemiologically relevant mutant epitopes to better evaluate their 
therapeutic benefit. Characterizing TCRs cross-reactive against mutagenic HCV antigens 
not only serves as a model for designing therapeutics against diseases with genomic 
instability, but also serves as a model to study the kinetic and biologic principles 
governing antigen recognition. 
Cross-Reactive TCRs May Be Therapeutic Against  
Diseases with Genomic Instability 
Immune evasion by viruses and cancer cells has been a critical barrier to 
mounting effective host immune responses and has been problematic for the 
development of successful immunotherapies including ACT. A combination of 
viral/cancer genomic instability and immense selective pressure by successful immune 
effectors can lead to such escape variants. Manipulating the immune system to 
selectively eliminate its target while maintaining flexibility to combat genomic 
instability, a driving force behind immune escape, is the ultimate therapeutic goal. As 
discussed, we hypothesize that TCRs flexible enough to facilitate T cell recognition of 
mutated epitopes may serve as a vehicle to achieve this goal. 
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We addressed this hypothesis by establishing a model to evaluate the 
therapeutic benefit of cross-reactive TCRs to combat diseases with genomic instability. 
As discussed, the HCV genome contains several regions that are genetically unstable and 
mutate readily [357, 358], making HCV an excellent model for genomic instability. To 
create our model, we selected panels of naturally occurring and epidemiologically 
relevant mutants of two immunogenic epitopes to assess the cross-reactivity of a pair of 
HCV-reactive TCRs. The cross-reactivity observed by two independently isolated TCRs 
against two different, but highly antigenic HCV epitopes argues strongly that the ability 
of a TCR to be cross-reactive against a spectrum of mutant antigens is a generalizable 
phenomenon. 
We were originally interested in the cross-reactive potential of HCV1406 TCR 
because it was an allo-reactive TCR [302]. Interestingly, we found that HCV1406 TCR-
transduced T cells recognized numerous naturally occurring HCV NS31406-1415 
epitopes identified in the GenBank. Aside from being naturally occurring, it is important 
to evaluate the epidemiologic prevalence of these mutations in infected individuals. 
Such validation would enhance the clinical relevance of the HCV1406 TCR, and would be 
an important point to consider for establishing the therapeutic merit of any cross-
reactive TCR. A QuickAlign search of the Los Alamos HCV Sequence Database, which 
houses 918 recorded worldwide HCV genome sequences from infected individuals, 
provided a tool to perform this analysis. 
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While the WT and eight variant epitope sequences studied for NS3:1406-1415 
account for 42.38% of all recorded sequences in the Los Alamos HCV Sequence 
Database, they comprise 80.38% of the recorded genotype 1a sequences, most 
applicable to the United States [373].  As discussed, cross-reactivity against seven out of 
the eight mutant epitopes by TCR-transduced CD8+ effectors nearly doubled the amount 
of recorded sequences recognized compared to the prevalence of the WT epitope 
(43.46%). Additionally, CD8-independent recognition of WT and four mutant epitopes 
suggests HCV1406 TCR is a high affinity receptor and may facilitate CD4+ T cell cytokine 
support against 78.42% of recorded sequences. Thus, HCV1406 TCR’s cross-reactivity 
profile greatly enhances coverage against observed mutant epitopes. Furthermore, the 
generation of both helper and effector T cells allows for a novel population of MHC-class 
I restricted T helper cells to contribute to a broadened immune response.  
We also characterized the cross-reactivity of a second, non-allo-restricted, TCR 
against a second immunodominant HCV epitope NS3:1073-1081. Gene transfer of 
HCV1073 TCR into T cells also facilitated CD8-independent recognition of multiple 
naturally occurring and epidemiologically relevant mutant epitopes. As discussed, the 
NS3:1073-1081 epitope for genotype 1a is well conserved with 90.2% of the recorded 
genomes in the Los Alamos Database exhibiting the WT CINGVCWTV epitope. However, 
genotype 1b is dominated by the I1074V mutant at 45.57% , WT comprising only 41.59% 
of recorded sequences. Cross-reactivity of the HCV1073 TCR against WT and I1074V  
epitopes alone could provide enhanced coverage for 94.46% and 89.3% of genotypes 1a 
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and 1b, respectively, most relevant to the United States’ and Europe’s viral prevalence 
[373]. Based on the prevalence of mutations studied, our HCV model suggests T cells 
engineered with such cross-reactive TCRs may provide therapeutic benefit while limiting 
selection for escape variants [365]. 
In light of observations that cross-reactive TCRs might enhance recognition 
against epidemiologically prevalent mutant targets, it is important to understand the 
biology behind TCR cross-reactivity. How peptide amino acid changes are tolerated or 
weaken the ability of the T cell to recognize pMHC are important points to consider 
when identifying or designing an immunotherapeutic candidate.  
In our model for genomic instability, we have combined our functional studies 
with TCR-pMHC structural modeling. Our structural models allowed us to generate 
rational hypotheses for cross-reactivity by the HCV1406 and HCV1073 TCRs. Generally, 
we found amino acid substitutions that do not impact function occur in regions with few 
or no TCR or MHC contacts, or alternatively, are conservative substitutions that are not 
predicted to alter contacts.  
Presumably, other TCRs in patients from which the viruses harboring the various 
NS3 mutant sequences propagated made more crucial TCR contacts at these positions, 
permitting viral escape. It is logical to predict that HCV1406 and HCV1073 TCRs exhibit a 
greater flexibility than TCRs in patients that would have allowed these immune escape 
variants to exist and persist. However, because HCV14073 TCR was isolated in a patient 
with a chronic HCV infection [166] this may not always be the case. Such TCRs may also 
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not be able to accommodate every possible mutation (i.e. HCV1406 TCR non-reactivity 
against variant 8S/9G/12L). However, if immune pressure is cross-reactive enough or 
there are multiple clonal cross-reactive T cell responses in an infected individual, it may 
limit the ability for a virus to avoid such a diverse immune pressure. 
 One might predict viral mutations affecting proteosomal processing or peptide 
binding to MHC (namely anchor residues) would be most beneficial for immune evasion 
should it reduce or eliminate the ability of the peptide to be properly presented by 
MHC-l. However, in the case of NS3:1406-1415, there were only 6 out of 918 recorded 
substitutions involving anchor positions 2 or 10. What would seemingly be an 
advantageous mutation for the virus may have been restricted if these residues are 
important for NS3 function or necessary for overall viral fitness. Verification of our 
structure-based hypotheses as well as a more detailed examination of potential 
structural alterations not predicted by our modeling would be helpful to understand 
implications of altered pMHC on T cell function. 
Overall, in our HCV model for genomic instability, we have characterized CD8-
independent recognition of multiple naturally occurring mutant epitopes for two HCV-
cross-reactive TCRs. The reported HCV genome sequence data greatly adds clinical 
relevance to the potential therapeutic use of either or both of these receptors in ACT. 
Furthermore, preliminary experiments evaluating cross-reactivity of T cell clones raised 
from chronically infected versus spontaneously resolved patients support the 
hypothesis that HCV-cross-reactive TCRs could have an impact on clearance of HCV 
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infection or its associated disease. Aside from therapeutic implications for HCV and its 
associated disease, this approach serves as a helpful roadmap to identify or develop 
therapeutic cross-reactive TCRs. It may also allow us to better understand our immune 
response towards diseases with genomic instability.  
TCR-pMHC Affinity Does Not Necessarily Dictate T Cell Function 
Although our structural modeling of HCV1406- and HCV1073 TCR-pMHC 
interactions helped explain altered T cell reactivity against naturally occurring mutant 
epitopes, it does not provide a true mechanism for what facilitates antigen recognition. 
It is important to consider what kinetic and/or cellular parameters help facilitate antigen 
recognition in light of altered TCR-pMHC interactions. A better understanding of what 
influences antigen recognition may help modify TCRs to specifically enhance or inhibit 
TCR cross-reactivity to improve efficacy and maximize safety. 
TCR-pMHC affinity is generally thought to play the most central role driving T cell 
specificity and reactivity [1]; therefore, it was logical to compare T cell reactivity against 
each variant pMHC with the affinity of each TCR-pMHC interaction. Because the two 
cysteine residues in NS3:1073-1081 peptides inhibited biochemical characterization, we 
proceeded with analysis of only HCV1406 TCR with WT and variant NS3:1406-1415 
epitopes. To correlate TCR-pMHC affinity with T cell function, we compared the 
equilibrium KD for each TCR-pMHC to the magnitude of IFNγ release by TCR-transduced 
CD4+ or CD8+ T cells. Measurable affinities grouped the peptides into categories of 
“moderate affinity” compared to 17 μM for WT (I1412L, V1408T, V1408L, and I1412V, 
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ranging from 32-63 μM) and “lower affinity” (A1409T, I1412L, and 8s/9G/12L, ranging 
from 120-169 μM). The TCR-pMHC affinity for mutant 8S/9S/12L/14S was unable to be 
measured but was grouped into this category based on predicted affinity from its amino 
acid substitutions and its CD8-dependent recognition. 
We found that affinity seemed to trend with antigen recognition, as WT and 
“moderate affinity” mutants were CD8-independent, and “lower affinity” variants were 
generally CD8-dependent. These observations seemed consistent with the field’s 
interpretation of affinity’s importance on antigen recognition. However, the magnitude 
of T cell responses did not completely agree with this theory. As discussed, TCR-
transduced CD4+ T cells secreted less IFNγ against V1408T and I1412L compared to 
mutants with similar affinites. Furthermore, I1412N and 8S/9G/12L have virtually 
identical affinity measurements (168 and 169 μM, respectively), but recognition of 
I1412N was CD8-dependent and 8S/9G/12L was not recognized. These functional 
observations are quite inconsistent with what would have been predicted based solely 
on affinity measurements.  
Responses by CD8- T cells should more accurately reflect affinity’s influence on 
functional recognition because SPR measurements take place in the absence of CD8. 
However, the functional avidity of HCV1406 TCR-transduced CD4+ T cells against mutant 
NS3:1406-1415 epitopes did not always correlate with the affinity of the TCR-pMHC 
interactions. This discord between TCR-pMHC affinity and T cell reactivity contradicts 
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what is accepted by many in the field and surprisingly suggests that TCR-pMHC affinity 
may not be the most important influence on T cell function.  
One potential explanation for these inconsistencies is that affinity 
measurements by SPR may not necessary necessarily reflect the true affinity of the 
physiologic TCR-pMHC interaction. SPR is performed in three-dimensional (3D) space 
with soluble TCRs and pMHCs. However, physiologically the TCR and pMHC are 
anchored on two-dimensional (2D) membranes of opposing cells [429]. One major 
caveat of 3D measurements by SPR is that soluble TCRs fail to account for the possible 
regulations imposed by the complex T-cell membrane environment. These include 
reduced spatial degrees of freedom of molecular motion and the presence of co-
receptors [430]. Consequently, affinity rates in physiologic 2D may be vastly different 
from what is measured in typical 3D assays.  
To overcome the limitation of 3D affinity measurements, methods have been 
developed to establish binding partners anchored onto 2D surfaces These include the 
mechanically based micropipette adhesion frequency assay [431], the thermal 
fluctuation assay [431], biomembrane force probes [432], as well as FRET-based single-
molecule microscopy [433]. Mechanically-based 2D binding measurements of TCR-
pMHC interactions revealed dramatically different kinetic parameters than 3D 
measurements, and 2D measurements displayed a better correlation with T cell 
responses [431, 434]. In addition, 2D techniques enable the measurement of TCR-
pMHC-CD8 tri-molecular interactions. Such analysis revealed signaling-dependent 
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cooperation between the TCR and CD8 for pMHC binding, which synergistically 
enhanced discrimination of peptides of varying potencies [435]. Implementation of 2D 
methodologies to generate refined binding data may serve as a better correlative 
marker for understanding HCV1406 TCR cross-reactivity. Additionally, 2D techniques 
should be seriously considered when evaluating all therapeutic TCRs as more evidence 
suggests 3D affinity measurements do not accurately correlate with T cell function or 
predict TCR cross-reactivity. 
It is also important to point out that differences in peptide-MHC affinity are also 
thought to have an effect on antigen recognition and the effectiveness of an immune 
response [436], but to what degree is unclear. All HCV NS3:1406-1415 peptides 
evaluated bound HLA-A2 similarly, but not identically. Additionally, thermal stability 
measurements generated by CD used to evaluate peptide-MHC binding is a proxy for 
affinity. Further studies in the field are necessary to improve the evaluation peptide-
MHC-I binding interactions and to relate small changes in peptide-MHC binding to 
differences in T cell functional responses. 
CD8 Co-Receptor Expression and Signaling, Antigen Density,  
and TCR Density Impact T Cell Function and Cross-Reactivity 
It is also possible that TCR-pMHC affinity, whether measured in 3D or 2D, is not 
the most important parameter governing T cell reactivity. Weak correlations between 
TCR-pMHC affinity and T cell function led us evaluate the importance of other 
parameters that may influence antigen recognition. Because there seemed to be a 
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cutoff in CD8-dependence relative to affinity (somewhere between 63 μM (I1412L) and 
120 μM (A1409T)), we further evaluated the influence of CD8 on antigen recognition 
and TCR cross-reactivity.  
It is generally accepted that CD8 enhances T cell sensitivity by stabilizing, or 
affinity-enhancing, the TCR-pMHC interaction [378]. However, others have shown that 
lck-recruitment to the TCR/CD3 complex by CD8 is essential for T cell function [305].  To 
test the importance of both structural stabilization and signaling by CD8, we compared 
mutant antigen recognition by TCR-transduced Jurkat cells expressing no CD8, full length 
CD8 (CD8αβ), or a truncated version (CD8α’β’) which lacks the intracellular lck-binding 
domain. Interestingly, these cell lines exhibited unanticipated cross-reactive profiles. 
Mutant epitopes characterized as CD8-independent by primary T cell functional studies 
elicited similar cytokine release in Jurkat cells regardless of the CD8 function. However, 
recognition of “lower affinity” CD8-dependent variants required both the extracellular 
portion and intracellular lck-binding domain of CD8. Thus, it is not only the TCR-pMHC 
stabilization by CD8 that dictates T cell function, but the recruitment of lck augmenting 
TCR/CD3 signaling also plays an important role. This further supports the notion that 
TCR-pMHC affinity is not necessarily the most influential parameter driving T cell 
function. 
The importance of CD8’s individual functions has been highly debated. One study 
concluded that only the extracellular domains of CD8αβ are sufficient for HLA class I-
restricted TCR-transduced CD4+ T cells to have optimal antigen recognition [437]. 
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However, others argued that CD8 signaling can be required for antigen recognition 
depending on the strength of the TCR [305]. Additionally, a gp100-reactive T cell clone 
designated T4H2 was a CD4-/CD8- T cell that efficiently recognized HLA-A2+ gp100+ 
human melanoma cells in vitro [44, 164].  However, when the T4H2 TCR was cloned and 
expressed in human T cells, it surprisingly required CD8 expression for tumor cell 
recognition [44]. Perhaps each TCR may need to be independently evaluated for its 
reliance on individual functional components of CD8 to assess its specific requirements 
for antigen recognition.  
It is important to recognize that in addition to the CD8 co-receptor, the 
sensitivity of T cells is known to be modulated by varied expression of other accessory 
and/or co-stimulatory molecules including CD28, LFA-1, ICAM-1, OX40, CD80 and TNF 
family members like 4-1BB [438]. It is also possible that upregulated expression of key 
early signal transduction molecules such as lck and ZAP70 could lower the threshold for 
T-cell triggering [384]. Alternatively, molecules such as CD45 or SHP-1 that negatively 
regulate signal transduction [439] could also alter the level of antigen density required 
for full T-cell activation [440, 441]. Thus, it is important to investigate how surface, 
adhesion, and signaling molecules other than CD8 can influence antigen recognition and 
cross-reactivity. 
In addition to CD8, we also wanted to evaluate the importance of antigen 
density on TCR cross-reactivity. Antigen density may influential because clinical reports 
of on-target/off-tumor or off-target effects by high affinity TCR-gene modified T cells 
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have been attributed to the detection of low levels of antigen [184, 211]. Additionally, 
peptide-loaded T2 cells do not represent physiologic levels of antigen a T cell would 
encounter on a tumor or virally-infected cell. To evaluate the influence of antigen 
density on TCR cross-reactivity, we arbitrarily defined three levels of antigen density. 
We consider peptide-loaded TAP- T2 cells to be the “highest” antigen density because 
exogenously loaded peptides saturate surface MHC-I in the absence of endogenously 
processed peptides. TAP+ HepG2 cells expressing HCV NS3:1406-1415 epitopes as 
minigenes require the epitopes to be expressed, minimally processed, and to compete 
for MHC-I with all other endogenously processed peptides, serving as our “lowest” 
density. Exogenously loading peptide onto TAP+ HepG2 cells eliminates any internal 
processing, but the peptide has to outcompete endogenous peptides occupying surface 
MHC-I. Peptide-loaded HepG2 cells serve as our “intermediate” density between 
peptide-loaded T2 cells and antigen-expressing HepG2 cells. Comparing reactivity 
against these three systems allows for an arbitrary evaluation of the influence of antigen 
density on TCR cross-reactivity. 
As described, cross-reactive profiles were markedly reduced against lower 
antigen levels. For example, at an “intermediate” density of antigen, CD4+ TCR-
transduced T cells secreted 100-fold less IFNγ against HepG2 cells peptide-loaded with 
V1408L compared to I1412V, despite having virtually identical TCR-pMHC affinities (60 
and 63 µM, respectively). However, there was only a consistent 2-fold difference in IFNγ 
release between V1408L and I1412V peptide-loaded T2 cells. Recognition of antigen-
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expressing HepG2 cells (our “lowest” antigen density) was reduced even more. For 
example, CD4+ TCR-transduced T cells secreted IFNγ when stimulated with the WT HCV+ 
HepG2 cells but lost reactivity against any mutant epitope; CD8+ T cells were only 
reactive against “moderate affinity” mutants that were CD8-independent in a high 
antigen density T2 cell system. These observations suggest antigen density can have a 
profound effect on antigen recognition, and that differences in IFNγ secretion are not 
always reconciled by differences in TCR-pMHC affinity. 
Because antigen density exhibited an important influence on TCR cross-
reactivity, we wanted to evaluate if TCR density has a similar impact on antigen 
recognition. We first evaluated the impact of TCR density on antigen recognition by 
taking advantage of the CD34 cassette in our retroviral vectors. CD34 expression 
represents a surrogate marker for TCR transgene expression (Foley, unpublished, [304]). 
Evaluation of IFNγ expression in high, medium, and low transgene-expressing T cells by 
flow cytometry revealed a TCR density-dependent response in CD8+ T cells. Highest TCR 
expression correlated with high expression of IFNγ, and lowest levels of TCR expression 
correlated with low, but still above background, IFNγ production. Conversely, CD4+ T 
cells were much more dependent on high levels of TCR expression to produce IFNγ 
against most CD8-independent variant peptides, which have comparable affinities to 
WT. These findings further support that affinity measurements do not predict the 
requirement for TCR expression for function. These data also suggest that TCR density 
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also plays an important role in antigen recognition, sometimes independent of TCR-
pMHC affinity. 
A potential explanation for TCR density-dependence is provided by the biology of 
a TCR-gene-modified T cell. In TCR-engineered T cells and Jurkat cells, endogenously 
expressed TCRs limit the functional expression of introduced TCRs through mismatched 
chain pairing between endogenous and introduced TCR α and β chains. Additionally, the 
introduced receptor is limited by available CD3ζ for which it competes with the 
endogenous TCR. Thus, the nature of a TCR-engineered T cells limits optimal density of 
an introduced TCR.  Because it is thought that the occupancy of a TCR may determine 
the magnitude of the T cell response [2], situations of inefficient TCR pairing may be 
detrimental to T cell function and may influence TCR cross-reactivity. So, if an altered 
peptide ligand requires a greater number of TCRs to be occupied by pMHC to generate a 
strong enough signal to induce activation, variations in TCR density may play key a role 
in its recognition.  
To test this hypothesis, we performed parallel experiments using TCR-
transduced Jurkat76 cells, which lack an endogenous TCR. This allows us to directly 
assess the impacts of TCR chain mispairing and competition for CD3 on antigen 
recognition. Jurkat76 cells were also engineered to express no CD8, full length CD8αβ, 
or truncated CD8α’β’ to simultaneously assess the importance of the co-receptor in light 
of absent chain pairing competition. Surprisingly, “lower affinity” CD8-dependent 
ligands were now recognized in the absence of CD8. This suggests that enhancing 
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introduced TCR chain pairing can alleviate the requirement of CD8 and can enhance TCR 
cross-reactivity. The most surprising observation was that CD8αβ Jurkat76 cells 
(exhibiting high TCR density and fully functional CD8) were reactive against never-
before-recognized mutant 8S/9G/12L. This key observation highlights the important 
interplay between TCR density, TCR-pMHC stabilization by CD8, and CD8-dependent 
signaling and how these factors directly influence antigen recognition irrespective of 
affinity.  
Overall, the influence of TCR density on antigen recognition suggests that affinity 
measurements measured by SPR (a system that lacks TCR pairing competition) may not 
accurately reflect TCR-pMHC interactions in TCR-gene-modified T cells. Furthermore, 
modification of TCR pairing, without altering its affinity, can have dramatic effects on 
cross-reactivity and the requirement for co-receptors. This is an important point to 
reflect on because many approaches refining TCR engineered T cells involves 
modification of the retroviral vector or the TCR itself to enhance expression, chain 
pairing, and/or association with CD3. As discussed in Chapter One, techniques used to 
enhance uniform TCR expression include introduction of 2A self-cleaving viral sequences 
to promote stoichiometric TCR chain expression or codon optimization to improve 
mRNA translation [192, 193].  Additionally, a host of approaches used to modify the TCR 
to promote chain pairing include, but are not limited to, introducing additional disulfide 
bridges into the constant regions of each chain [176], adding leucine zippers at end of 
the cytoplasmic tails [174], or murinization of the constant regions [170, 198-202]. 
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While these approaches are thought to make better effectors by enhancing the pairing 
of introduced TCRs, it has not been considered how modifying pairing efficiency could 
induce or alter the cross-reactivity of TCRs. Yet, our data suggest that enhancing the 
pairing of an introduced TCR could have a dramatic impact on the recognition of related 
antigens. Certainly, this may not be a desired result and could cause unwanted toxicities 
in patients treated with pairing-enhanced TCRs. Conversely, such strategies to enhance 
pairing that would also enhance cross-reactivity could be advantageous in diseases with 
genomic instability. Thus, the importance of TCR chain pairing on cross-reactivity should 
now be considered when designing TCRs for ACT. 
Antigen Recognition Cannot Be Assessed  
Based on a Single Functional Parameter 
As described earlier, T cells are often classified by their functional profile (type 1 
vs type 2, etc.), which have been related to therapeutic efficacy [395-399]. Specifically, T 
cells with type 1 responses are considered to facilitate better anti-tumor efficacy [395, 
396], and play an important role in T-cell mediated viral clearance [400-402]. However, 
emerging other T cell subsets have been implicated in enhancing anti-tumor and anti-
viral immunity [401-404]. In light of these generalizations, immune monitoring primarily 
evaluates one type 1 cytokine, namely IFNγ, to characterize the reactivity of bulk T cell 
cultures. In fact, up until this point, our analyses concerning the importance of affinity, 
CD8, ligand density, and TCR density on antigen recognition have been performed by 
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evaluating the release of a single cytokine. It may be important, however, to evaluate 
more than one functional parameter to appropriately characterize T cell reactivity. 
 Our simultaneously evaluation of intracellular IFNγ and surface CD107a 
revealed a much different biologic message than single cytokine release by a bulk T cell 
culture. We described that CD4+ and CD8+ T cells behave in different functional 
proportions and that changes in pMHC ligands, sometimes independently of affinity, 
disproportionately affected bi-functional IFNγ+CD107a+ populations. These preliminary 
observations suggested that the evaluation of a single cytokine might underestimate 
the complexity of T cell function and misrepresent the impact of altered TCR-pMHC 
interactions on T cell responses.  
To evaluate the importance of assessing multiple functional parameters, we 
expanded our evaluation of T cell polyfunctionality by flow cytometry to include 
CD107a and six cytokines (IFNγ, TNFα, IL-2, IL-4, IL-17A, and IL-22). The resulting multi-
dimensional datasets were immensely difficult to analyze by standard analysis 
software. Comparing combinations of seven functional parameters generated 128 
discrete functional phenotypes for a single antigen stimulation. Increasing the number 
of stimulation conditions or T cell subsets (CD4+ vs CD8+) only complicated this 
analysis. Comparisons of over half a dozen software packages enabled us to generate 
simple and interpretable graphical output using SPICE which allowed us to draw 
meaningful conclusions. While no software package is perfect, the field is continuously 
developing and evaluating new tools equipped to analyze such complex datasets [442]. 
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Initial comparisons of CD4+ and CD8+ TCR-transduced T cell reactivity against 
WT NS3:1406-1415 peptide-loaded targets revealed a much greater degree of 
phenotypic and functional complexity than is appreciated by the field, suggesting T cell 
responses have been oversimplified. Furthermore, we noticed that traditional 
functional classifications of type 1 vs type 2 responses do not always hold true. For 
example, certain populations of CD4+ or CD8+ TCR-transduced T cells produced 
unexpected combinations of cytokines, including IFNγ, IL-2, TNFα, and IL-4 in a single 
cell. Comparing T cell functional responses against altered pMHC ligands revealed that 
the frequency of polyfunctional populations did not always correlate with changes in 
affinity. Additionally, alterations in TCR-pMHC interactions seemed to preferentially 
affect higher order polyfunctional populations (≥3 simultaneous functions). 
Furthermore, we observed that higher order polyfunctional phenotypes are 
completely lost when T cells were stimulated by HCV+ tumor cells. A stark contrast in 
polyfunctional phenotypes between peptide- and naturally processed antigen-
stimulations further highlights the importance of ligand density on the quality of the T 
cell response. It would be interesting to evaluate if modifications to the TCR that 
enhanced chain pairing (increasing TCR density) could compensate for lower densities 
of antigen. This may offer a solution to restore a robust polyfunctional response 
against tumor cells expressing lower levels of antigen. It may also, however, 
inadvertently increase the risk of off-target effects.  
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Overall, these observations using human TCR-transduced T cells are intriguing 
because they represent the kinds of T cell populations we transfer into patients. 
Heterogeneity in polyfunctional populations among PBL donors demonstrated that 
different donors had different functional phenotypes as well as different ranges in 
numbers of functional parameters per cell. Expansive evaluation of T cell 
polyfunctionality in the context of individuals’ anti-viral or anti-tumor responses may 
allow for better treatment correlations or biomarkers for predictive outcomes. It might 
be predicted that a T cell performing multiple functions may provide a more effective 
immune response. However, if a T cell is performing additional functions at the expense 
of the overall magnitude of a given response, a more polyfunctional phenotype may be 
less advantageous. For instance, if a T cell is restricted to producing ten functional units 
and secretes five different cytokines, the magnitude of a response (two units of each 
cytokine) might be lower compared to a T cell secreting only two different cytokines 
(five units of each). If the strength of the response is more important than the its 
diversity, a T cell with a less diverse functional phenotype may be more therapeutic. 
However, if the diversity of a response is more important than magnitude of respective 
functions, a T cell producing more cytokines may be more therapeutic.  
In vivo modeling will be helpful in testing these hypotheses. TCR-engineered T 
cells adoptively transferred into tumor-bearing mice can be isolated from tumors or 
lymphoid compartments, assessed for functional profiles ex vivo, and compared to the 
tumor status of each animal. If T cells isolated from regressing tumors have distinctly 
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different functional phenotypes than those isolated from stable or growing tumors, this 
may indicate which functional phenotypes are providing better anti-tumor activity. 
Additionally, T cells can be isolated into individual functional phenotypes using cytokine 
affinity matrices [443-446]. T cells with certain functional phenotypes can be selectively 
adoptively transferred into tumor-bearing mice and evaluated for which functional 
phenotype(s) are most effective at reducing tumor growth. The strategies described 
above may help elucidate the importance of certain functional phenotypes and how 
they can contribute to effective immune responses.  
Together, incorporation of multiple functional parameters in immune monitoring 
may better assess the true biology of T cell cultures. This level of functional 
characterization could also allow us to isolate cells with certain polyfunctional 
phenotypes to test in vivo which functional profiles are better for anti-tumor or anti-
viral immunity. A more complete understanding of the different populations of T cells 
delivered to patients might also enable us to select for or design T cells with an 
“optimal” polyfunctional profile. This would be an immensely powerful tool to enhance 
the efficacy and safety of TCR-engineered T cells used in ACT.  
It is important to point out that these observations would have never been 
established had we limited our characterization of T cell reactivity to standard assays 
evaluating a single cytokine. While evaluation of T cell polyfunctionality by multi-
parameter flow cytometry is not necessarily a novel concept, most evaluations, 
however, have been limited to 2-4 parameters [447-451]. Very few studies have 
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assessed up to seven functional parameters, but advancement in reagents, 
instrumentation and multivariate data analysis is making this more feasible [452]. Some 
groups are evaluating larger numbers of fluorescent markers to evaluate T cell 
populations, but studies focusing on functionality are limited. A novel technology 
surpassing the practical limitations of flow cytometry, cytometry by time-of-flight 
(CyTOF), uses metal-labeled probes and mass spectrometric analysis to facilitate the 
measurement of 36 or more parameters in a single-cell with minimal crosstalk between 
channels [453]. Implementation of CyTOF has enabled researchers to evaluate 
previously unfeasible numbers of cellular parameters simultaneously. One study used 
the simultaneous detection of 16 surface markers, 6 tetramers, and 10 intracellular 
stains to evaluate  combinatorial cytokine expression in virus-specific CD8+ T cells within 
the continuum of cellular differentiation [454]. Others have used this approach to 
evaluate differential immune and drug responses across a human hematopoietic 
continuum [455]. Expansion of our functional panel using CyTOF to include lineage, 
memory, and effector markers, as well as phospho-signaling proteins or transcriptions 
factors may help provide explanations for unexpected cytokine combinations, but would 
admittedly exponentially complicate the analysis. Furthermore, scarcity of available 
instrumentation, cost of reagents, and careful optimization required make CyTOF 
analysis currently a less feasible approach. Nonetheless, our multi-parameter flow 
cytometric analysis of T cell polyfunctionality greatly alters the interpretation of antigen 
recognition compared to standard single parameter evaluations. 
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A More Complete Understanding of Antigen Recognition and TCR Cross-Reactivity  
May Rely on Structural Interpretation of the TCR-pMHC Interface 
As a whole, we have evaluated various kinetic and cellular parameters driving 
antigen recognition, TCR cross-reactivity, and T cell polyfunctionality. We have also 
come to the realization that while affinity is thought to play the most important role, it 
may be quite overvalued. In light of these observations, we still lack a complete 
understanding of (1) what is truly different about the altered ligand interactions, and (2) 
how that translates into varied polyfunctional responses.  
The concept of altered peptide ligands having  differential effects on T cell 
function was first described by Evavold and Allen [456]. In this seminal report, a 
conservative substitution (E73D), removing one methylene group of an amino acid 
anchoring side chain impaired proliferation but not IL-4 production in T cells. 
Subsequent studies involving additional T cell clones indicated that TCRs have the 
capacity of differential signaling, leading to a spectrum of functional responses and 
events [296, 457-460]. Many of the explanations of altered T cell function were initially 
rationalized by changes in affinity due to small changes in pMHC topology [461]. Yet, in 
our studies, changes in TCR-pMHC affinity (or even interactions with similar affinities) 
were not always correlative with polyfunctional responses. Others have since suggested 
that altered peptides may induce small conformational changes in the TCR engaging 
altered pMHC, leading to ranges of TCR-initiated signals, sometimes independent of 
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measurable affinity [462-464]. Thus, structural studies highlighting the TCR-pMHC 
interface may provide a better explanation for unanticipated functional outcomes. 
Efforts to better understand functional effects of altered peptide ligands have 
relied heavily on solving crystal structures of TCR-pMHC interactions. These evaluations 
provide the resolution necessary to detect important TCR contact points with peptide 
and/or MHC, identifying key hydrogen bonds or van der Waals contacts thought to 
influence antigen recognition. Comparing crystal structures of TCRs engaged with 
altered peptide ligands have revealed obvious or subtle changes in pMHC topography, 
resulting in altered TCR conformations thought to be responsible for profound biological 
effects [465-467].  
It is important to realize that the true mechanism behind altered T cell function 
lies at the origin of the interaction, the interface of the TCR-pMHC. Therefore, we 
cannot begin to fully understand how HCV1406 TCR cross-reactivity dictates functional 
outcome without evaluating structurally what happens at this TCR-pMHC interface. We 
have previously provided computational modeling of the interactions between our HCV 
TCRs and WT pMHCs to help explain changes in binary function and potency of response 
influenced by the CD8 co-receptor. Since then we have discussed at length many 
parameters other than affinity we feel are involved in dictating T cell activation and 
polyfunctionality. But as mentioned, to identify the true mechanism calls for crystal 
structure analysis. Thus, to visualize the TCR-pMHC interface and rationalize functional 
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effects upon alteration of the peptide, we turned to the solved the crystal structure of 
HCV1406 TCR with WT HCV NS3:1406-1415/HLA-A*0201. 
The crystal structure of the TCR-pMHC now allows us to highlight TCR contact 
residues important for a productive interaction. Figure 57 illustrates the crystal 
structure overview of the TCR interaction with pMHC as well as the pMHC topology with 
HCV1406 TCR’s CDR loop footprint. A closer examination of hydrogen bonds and van der 
Waals contacts with TCR and WT peptide is shown in Figure 58 and summarized in Table 
14. Interestingly, only CDRα loops are involved in hydrogen bond-mediated recognition 
of the peptide itself (Fig. 58). CDR1α loop residue S33 interacts strongly with the lysine 
residue at position one, which explains why an alanine substitution at this position 
abrogated functional responses by TCR-transduced PBL and Jurkat cells (See Appendix). 
Additionally, CDR3α loop residue D102 forms hydrogen bonds with peptide positions 4, 
6, and 7 (A1409T, G1411, and I1412, respectively). The importance of these interactions 
may help resolve differences in recognition of mutants A1409T, I1412L, I1412V, and 
I1412N. If this S33-p4 interaction is important for TCR recognition of pMHC, an amino 
acid class substitution from a nonpolar alanine to a polar threonine (A1409T) could 
require TCR and/or peptide rearrangements to resolve atomic clashes. If this were to  
only weaken the TCR-pMHC interaction, CD8-dependence would only require the 
extracellular domain stabilizing TCR-pMHC. But because recognition of A1409T also 
requires the lck-binding domain of CD8, perhaps an interface rearrangement induces a 
conformational change in the TCR leads to differential TCR/CD3 signaling requirements.   
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Figure 57. Crystal structure overview of HCV1406 TCR : WT HCV NS3:1406-1415 / HLA-
A2. (a) Side view of the TCR-pMHC complex (ribbond diagram). TCRα chain (orange); 
TCRβ chain (purple); HLA-A2 heavy chain (gray); β2m chain (blue); WT peptide is drawn 
in stick representation with carbon atoms in yellow, nitrogen atoms in blue, and oxygen 
atoms in red. (b) Footprint of the HCV1406 TCR CDR loops over the WT HCV NS3:1406-
1415 peptide. Same color scheme as part a. Crystal structure data was kindly provided 
by Yuan Wang in the Baker Lab (University of Notre Dame). 
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Figure 58. Hydrogen bonds and van der Waals contacts between HCV1406 TCR CDR loops and WT HCV NS3:1406-1415 / HLA-A2. 
(a) Hydrogen bonds between TCR and pMHC. Only CDRα loops are involved into peptide recognition. CDR1α (orange), CDR3α 
(purple); hydrogen bonds are represented by red dotted lines; TCR residues are identified by a one-letter amino acid designation 
followed by position number and chain designation. (b) van der Waals contacts (purpled dotted lines) between HCV1406 TCR CDR 
loops with pA4 (A1409). Same color scheme as in part a. (c) van der Waals contacts (purple dotted lines) between HCV1406 TCR CD$ 
loops with pI7 (I1412L). Same color scheme as in part a. Red arrows highlight altered residues in naturally occurring mutant 
epitopes. Crystal structure data was kindly provided by Yuan Wang in the Baker Lab (University of Notre Dame).
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Table 14. Interactions between HCV1406 TCR CDR loops and WT HCV NS3:1406-1415 
peptide in the TCR-pMHC complex. 
TCR CDR loop residue 
Hydrogen bonds/ 
salt bridges (bold) 
van der Waals 
contacts 
CDR1α S33 O:pK1(Nζ) 
Oγ:pK1(Nζ) 
pK1 
E34  pK1 
pA4 
D36  pA4 
Y37  pL5 
Y38  pL5 
CDR3α D102 N:pA4(O) 
Oδ1:pG6(N) 
Oδ2:pG6(N) 
Oδ2:pI7(N) 
pA4 
pA5 
pG6 
pI7 
CDR3β G96  pN8 
P97  pL5 
pN8 
Crystal structure data was kindly provided by Yuan Wang in the Baker Lab (University of 
Notre Dame). 
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That being said, in the absence of receptor pairing competition, CD8- Jurkat76 cells can 
recognize this mutant, suggesting that augmentation of TCR density can overcome or 
accommodate for any structural changes associated with this substitution. 
Similarly, we studied three altered pMHC ligands with substitutions at position 7. 
I1412L and I1412V are both CD8-independent with similar KD measurements and 
conservative substitutions. Yet I1412L, with a 2-fold higher affinity, consistently blunted 
CD4+ T cell responses.  It is less clear how the subtraction of a single methyl group 
(I1412V) could have a greater detrimental affect than the same number of hydrocarbons 
but in different branching orientation (I1412L) despite similar (yet two-fold higher) 
affinity. As these residues are hydrophobic and buried in the binding groove of HLA-A2, 
it is plausible that the orientation of the hydrocarbon side chains could alter the overall 
topology of the pMHC. Because hydrogen bonds’ energetic dependence on the 
stereochemistry and geometry of the bond is crucial [468], a minor change in a single 
hydrocarbon side chain orientation could have a significant effect on TCR 
conformational change. Thus, identification of important TCR-peptide hydrogen bonds 
helps rationalize differential antigen recognition, but a complete explanation is not yet 
clear. 
TCR and peptide interactions are also influenced by van der Waals contacts 
between CDR3α loop residue D102 with peptide positions 4-7 (Fig. 58b-c). While 
individually weaker compared to hydrogen bonds, van der Waals interactions when 
presented in large numbers across broad interfaces “sum” to substantial binding 
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energies between TCR and pMHC [469]. Thus, variants with substitutions at positions 4 
(A1409) and 7 (I1412) could disrupt the integrity of van der Waals forces, leading to 
conformational changes and differences in functional responses without a large impact 
on affinity. Similarly, while variants I1412N and 8S/9G/12L have essentially the same 
affinity, 8S/9G/12L remains unrecognized by HCV1406 TCR-transduced T cells. Perhaps 
despite identical affinities, the number of mutations or the position in which they occur 
could dramatically alter the conformation of the pMHC topography, not predicted by 3D 
affinity. In fact, it is reasonable to predict an altered conformation could affect the 
efficiency of TCR signaling, or require a greater threshold of TCR contacts or number of 
occupied TCR for functional recognition. This might explain why CD8αβ Jurkat76 cells 
(enhancing introduced TCR chain pairing and TCR signaling) could overcome structural 
perturbations and mediate T cell recognition of 8S/9G/12L. 
Additionally, TCR interactions with HLA-A2, including hydrogen bonds, salt 
bridges, and van der Waals contacts are also important (summarized in Table 15). Two 
CDRs of the α chain and all three CDRs of the β chain contact a myriad of residues 
throughout HLA-A2. It is plausible that variant peptides could alter pMHC conformation 
and disrupt TCR interaction with MHC independently of peptide contacts. Taken 
together, information gathered from crystal structure analysis offer us the opportunity 
to explain the structural importance of certain residues’ influence on downstream 
function.  
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Table 15. Interactions between HCV1406 TCR CDR loops and HLA-A2 in the TCR-pMHC 
complex. 
TCR CDR loop residue 
Hydrogen bonds/ 
salt bridges (bold) 
van der waals  
contacts 
CDR1α E34 Oξ1:K66(Nζ) 
Oξ2:K66(Nζ) 
K66α1 
S35  T163α2 
D36 Oδ1:T163(Oγ) 
Oδ2:T163(Oγ) 
Y159α2 
T163α2 
Y38  Q155α2 
CDR2α Y59  E154α2 
Q155α2 
A158α2 
 K60 Nζ:E154(Oξ2) E154α2 
CDR2α D103  R65α1 
CDR1β D30 Oδ1:K146(Nζ) K146α2 
CDR2β Y50  A69α1 
Q72α1 
G51  V76α1 
V52    V76α1 
N53  R75α1 
S54  V76α1 
 E56  Q72α1 
CDR3β R95 Nη1:A149(O)  
P97  Q155α2 
Y98 Oη:A150(O) 
Oη:Q155(Nζ2) 
A150α2 
H151α2 
Q155α2 
Crystal structure data was kindly provided by Yuan Wang in the Baker Lab (University of 
Notre Dame). 
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However, it is still not clear how conservative (i.e. I1412L vs I1412V) or more 
radical (I1412N vs 8S/9G/12L) mutations resulting in similarly paired affinities can 
induce modestly or starkly different polyfunctional outcomes. To confirm our 
predictions, comparison of crystal structures of HCV1406 TCR with each mutant peptide 
bound to HLA-A2 is required. While out of the scope of this dissertation, this is a logical 
next step to discern any true conformational changes that might induce differential T 
cell functions. Even so, based on some mutants’ minor and conservative amino acid 
changes (some with merely the addition or change in place of a single hydrocarbon), 
such conformational changes might be so subtle that a crystal structure may not provide 
enough resolution to detect them. But combining a series of crystal structures with 
alternative 2D kinetic and thermodynamic analyses may help determine what changes 
at the TCR-pMHC interface influence TCR cross-reactivity and ultimately T cell function. 
Nonetheless, structure-function studies like the ones outlined here are important to 
better understand the principles behind antigen recognition and the consequences of 
alterations in TCR-pMHC. Appreciation of important TCR-pMHC contact points and their 
impact on downstream function might allow for structure-guided design of TCRs 
enhancing or limiting contacts with peptide or MHC in order to enhance or limit a T cells 
specificity [266, 270, 470]. 
Concluding Remarks 
To improve T cell-based immunotherapy, we need to better understand the 
basic requirements for antigen recognition and what parameters govern antigen 
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specificity, TCR cross-reactivity, and T cell function. Experimental questions addressed in 
this dissertation utilized traditional and novel approaches to characterize (1) the 
requirements for cross-reactive antigen recognition by HCV1406 TCR gene-modified T 
cells and (2) the functional consequences of altered TCR-pMHC interactions. The 
characterization of HCV1406 TCR cross-reactivity against naturally occurring mutant HCV 
NS3:1406-1415 epitopes fundamentally serves as a model to study antigen recognition. 
While it is important to acknowledge that because HCV1406 TCR was allo-restricted, it 
was by definition cross-reactive. But this should not limit any value from the work as a 
whole because in a sense all T cells are inherently cross-reactive. As thymic education 
requires antigen recognition by a T cell for positive selection, certainly pathogenic 
peptides with which TCRs engage in the periphery are not presented in the thymus. The 
principles behind thymic education as well as the existence of allo-specific T cells [471, 
472] would suggest that TCRs must be cross-reactive to some extent and that the lock-
and-key principle of TCR-specificity is outdated. Aside from characterization of TCR 
cross-reactivity, this dissertation examines the basic principles behind antigen 
recognition and how TCRs can facilitate drastically different functional responses against 
naturally occurring mutant peptides.  
Overall, contrary to what is generally accepted in the field, we found that TCR-
pMHC affinity is not necessarily the most important role dictating antigen recognition 
and T cell function. Other cellular parameters, including ligand density, TCR density, and 
co-receptor signaling greatly influenced recognition of altered ligands, providing a new 
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working model for antigen recognition (Fig. 59). Additionally, modifying any of these 
parameters could dramatically change functional responses, sometimes independently 
of affinity. We also found that the field’s interpretation of TCR cross-reactivity or 
antigen recognition may be narrowed and misguided when evaluation of T cell function 
is limited to a single cytokine. Functional phenotyping by seven-parameter flow 
cytometry revealed that T cell functional profiles are more complex than were 
previously believed. Evaluation of a single functional phenotype, such as IFNγ, also does 
not accurately reflect the functional behavior of a T cell culture, especially when 
comparing altered TCR-pMHC interactions. But as the technology improves, the 
evaluation of seven functional parameters for any immune cell type will be inadequate. 
While more information may be learned from multi-parameter analyses, its analysis will 
inherently be more complex, but it will more accurately reflect the true nature of the 
immune response. 
Together, these studies suggest that the field is grossly oversimplifying the 
biology of T cells and the fundamentals of antigen recognition. It is important to note, 
however, that the data presented in this dissertation challenge longstanding 
assumptions not because the field is ignorant of them, but rather that no one has 
evaluated these questions in as much detail as is presented here. A sound explanation 
of our observations may depend on a clearer understanding of what is happening 
structurally at the TCR-pMHC interface combined with novel, emerging strategies   
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Figure 59. A new working model for kinetic and cellular parameters influencing 
antigen recognition and T cell function. Schematic diagram illustrating factors involved 
in T cell activation upon TCR-pMHC ligation. While (a) affinity of the TCR-pMHC 
interaction is thought be the most influential factor governing antigen recognition, 
studies in this dissertation suggest that is not the case. (b) Antigen and (c) TCR densities 
also play important roles, and augmentation of either one can modulate TCR cross-
reactivity. Additionally, (d) CD8 co-receptor has been shown to stabilize the TCR-pMHC 
interaction, but its (e) ability to augment TCR/CD3 signaling by recruiting lck is essential 
for low affinity interactions. A complex interplay of these, and other factors, play a role 
in dictating the (f) polyfunctional output of T cells which facilitate anti-tumor and anti-
viral immune responses. Evaluating single-cell polyfunctional response, rather than 
single cytokine release by a bulk T cell culture greatly enhances biologic interpretation.
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evaluating TCR-pMHC binding. Only then can we truly rationalize how single amino acid 
substitutions relay such substantial changes in functional output. Once resolved, such 
comprehension will not only help steer rational, structure-guided design of TCRs to 
generate better functioning T cells, but it will also impact the way in which we study 
other immune cell and receptor types, approach epitope discovery, and evaluate 
vaccine design. In this way, we have provided a new foundation in which to evaluate the 
design and implementation of novel immunotherapies.  
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Figure 60.  Rosetta score vs. modeling stage for modeling the HCV1406 (top) and 
HCV1073 (bottom) TCR-pMHC complexes. 
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Figure 61. Comparison of TCR density and HCV NS3:1406-1415 (WT) tetramer staining 
by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for 
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for 
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used 
to stain 1x106 cells.  
  
a) 
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Figure 62. Comparison of TCR density and HCV NS3:1406-1415 (I1412L) tetramer 
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for 
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for 
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used 
to stain 1x106 cells. 
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Figure 63. Comparison of TCR density and HCV NS3:1406-1415 (V1408T) tetramer 
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for 
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for 
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used 
to stain 1x106 cells. 
  
b) 
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Figure 64. Comparison of TCR density and HCV NS3:1406-1415 (V1408L) tetramer 
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for 
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for 
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used 
to stain 1x106 cells. 
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Figure 65. Comparison of TCR density and HCV NS3:1406-1415 (I1412V) tetramer 
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for 
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for 
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used 
to stain 1x106 cells. 
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Figure 66. Comparison of TCR density and HCV NS3:1406-1415 (A1409T) tetramer 
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for 
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for 
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used 
to stain 1x106 cells. 
  
b) 
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Figure 67. Comparison of TCR density and HCV NS3:1406-1415 (I1412N) tetramer 
staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate marker for 
HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate marker for 
HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of tetramer used 
to stain 1x106 cells. 
  
b) 
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Figure 68. Comparison of TCR density and HCV NS3:1406-1415 (8S/9S/12L/14S) 
tetramer staining by HCV1406 Jurkat and Jurkat76 cells. (a) CD3 serves as a surrogate 
marker for HCV1406 TCR expression in Jurkat76 cells. (b) CD34 serves as a surrogate 
marker for HCV1406 TCR exprssion in Jurkat cells. Concentrations indicate amount of 
tetramer used to stain 1x106 cells. 
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Figure 69. Evaluation of CD107a and intracellular IFNγ expression by CD4+ HCV1406 
TCR-transduced T cells stimulated with variant HCV NS3:1406-1415 peptides. HCV1406 
TCR-transduced PBL were co-cultured for 5 hr with T2 cells loaded with WT and mutant 
HCV NS3:1406-1415 or tyrosinase:368-376 peptides and stained for 
immunofluorescence. CD3+CD34+CD4+CD8- T cells were identified and evaluated for 
CD107a vs IFNγ expression. These data were used to create pie charts displayed in 
Figures 39. 
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Figure 70. Evaluation of CD107a and intracellular IFNγ expression by CD8+ HCV1406 
TCR-transduced T cells stimulated with variant HCV NS3:1406-1415 peptides. HCV1406 
TCR-transduced PBL were co-cultured for 5 hr with T2 cells loaded with WT and mutant 
HCV NS3:1406-1415 or tyrosinase:368-376 peptides and stained for 
immunofluorescence. CD3+CD34+CD4-CD8+ T cells were identified and evaluated for 
CD107a vs IFNγ expression. These data were used to create pie charts displayed in 
Figures 39-40. 
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Figure 71. Evaluation of CD107a and intracellular IFNγ expression by CD4+ HCV1406 
TCR-transduced T cells stimulated with variant naturally processed HCV NS3. COS cells 
were transfected to express full length WT HCV NS3 and COS/A2 cells were transfected 
to express full length HCV NS3 with WT or variant 1406-1415 epitopes. HCV1406 TCR-
transduced PBL were co-cultured with transfected COS cells for 5 hr and stained for 
immunofluorescence. CD3+CD34+CD4+CD8- T cells were identified and evaluated for 
CD107a vs IFNγ expression. These data were used to create pie charts displayed in 
Figure 41. 
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Figure 72. Evaluation of CD107a and intracellular IFNγ expression by CD8+ HCV1406 
TCR-transduced T cells stimulated with variant naturally processed HCV NS3. COS cells 
were transfected to express full length WT HCV NS3 and COS/A2 cells were transfected 
to express full length HCV NS3 with WT or variant 1406-1415 epitopes. HCV1406 TCR-
transduced PBL were co-cultured with transfected COS cells for 5 hr and stained for 
immunofluorescence. CD3+CD34+CD4-CD8+ T cells were identified and evaluated for 
CD107a vs IFNγ expression. These data were used to create pie charts displayed in 
Figures 41-42. 
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Figure 73. FlowJo-generated seven-parameter pairwise matrix displaying how gates 
are set against tyrosinase:368-376 peptide stimulation. Gates were set for non-specific 
(tyrsoinase) peptide stimulation and applied to HCV1406 TCR-transduced T cells 
stimulated WT HCV NS3:1405-1415 peptide-loaded T2 cells. Compare to Figure 44. 
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Figure 74. Polyfunctional profiles of CD4+ vs CD8+ HCV1406 TCR-transduced T cells after stimulation with WT HCV NS3:1405-1415 
peptide-loaded T2 cells. Compare to Figure 46 for condensed SPICE-generated bar graph. Percentages represent frequencies after 
background subtraction from tyronsiase peptide stimulation.  
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Figure 75. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV 
NS3:1405-1415 peptide-loaded T2 cells (Donor 1). Compare to Figures 48-49 for condensed cool plots. Percentages represent 
frequencies after background subtraction from tyronsiase peptide stimulation.  
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Figure 76. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV 
NS3:1405-1415 peptide-loaded T2 cells (Donor 2). Compare to Figure 49 for condensed cool plot. Percentages represent 
frequencies after background subtraction from tyronsiase peptide stimulation. 
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Figure 77. Polyfunctional profiles of CD8+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV 
NS3:1405-1415 peptide-loaded T2 cells (Donor 2). Compare to Figures 50-51 for condensed cool plots. Percentages represent 
frequencies after background subtraction from tyronsiase peptide stimulation. 
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Figure 78. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV NS3 
expressing HepG2 cells (Donor 2). T cells are non-reactive above background. Percentages represent frequencies after background 
subtraction from HCV- HepG2 peptide stimulation. 
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Figure 79. Polyfunctional profiles of CD8+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV NS3 
expressing HepG2 cells (Donor 2). Compare to Figure 52 for condensed cool plot. Percentages represent frequencies after 
background subtraction from HCV- HepG2 peptide stimulation.  [2
7
5
] 
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Figure 80. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV 
NS3:1405-1415 peptide-loaded T2 cells (Donor 3). Percentages represent frequencies after background subtraction from tyronsiase 
peptide stimulation.  
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Figure 81. Polyfunctional profiles of CD8+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV 
NS3:1405-1415 peptide-loaded T2 cells (Donor 3). Percentages represent frequencies after background subtraction from tyronsiase 
peptide stimulation.  
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Figure 82. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV NS3 
expressing HepG2 cells (Donor 3). Percentages represent frequencies after background subtraction from HCV- HepG2 peptide 
stimulation.  
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Figure 83. Polyfunctional profiles of CD8+ HCV1406 TCR-transduced T cells after stimulation with WT and various mutant HCV NS3 
expressing HepG2 cells (Donor 3). Percentages represent frequencies after background subtraction from HCV- HepG2 peptide 
stimulation. 
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Figure 84. Polyfunctional profiles of CD4+ HCV1406 TCR-transduced T cells after stimulation with a peptide titration of WT HCV 
NS3:1406-1415 (Donor 3). Compare to Figure 53. Percentages represent frequencies after background subtraction from tyronsiase 
peptide stimulation. 
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Figure 85. Polyfunctional profiles of CD8+ HCV1406 TCR-transduced T cells after stimulation with a peptide titration of WT HCV 
NS3:1406-1415 (Donor 3). Compare to Figure 49. Percentages represent frequencies after background subtraction from tyronsiase 
peptide stimulation. 
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Figure 86. Comparison of CD4+ T cell polyfunctional profiles between TCR-independent and TCR-dependent T cell activation 
(Donor 2). HCV1406 TCR-transduced CD4+ T cells were stimulated with peptide-loaded T2 cells or PMA/Ionomycin. Percentages 
represent frequencies after background subtraction from tyronsiase peptide stimulation. 
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Figure 87. Comparison of CD8+ T cell polyfunctional profiles between TCR-independent and TCR-dependent T cell activation 
(Donor 2). HCV1406 TCR-transduced CD8+ T cells were stimulated with peptide-loaded T2 cells or PMA/Ionomycin. Percentages 
represent frequencies after background subtraction from tyronsiase peptide stimulation. 
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Figure 88. Hierarchical clustering of peptide-stimulated responses of TCR-transduced 
CD8+ T cells (Donor 1). 
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Figure 89. Hierarchical clustering of peptide-stimulated repsonses of TCR-transduced 
CD4+ T cells (Donor 1). 
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Figure 90.  Hierarchical clustering of peptide-stimulated responses of TCR-transduced 
CD8+ T cells (Donor 2). 
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Figure 91. Hierarchical clustering of peptide-stimulated responses of TCR-transduced 
CD4+ T cells (Donor 2). 
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Figure 92. Hierarchical clustering of tumor-stimulated responses of TCR-transduced 
CD8+ T cells (Donor 2). 
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Figure 93. Hierarchical clustering of tumor-stimulated responses of TCR-transduced 
CD4+ T cells (Donor 2). 
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Figure 94. Cross-reactivity against alanine-substituted HCV NS3:1406-1415 peptides by 
HCV1406 TCR-transduced PBL-derived T cells. PBL from two normal donors were 
transduced with the HCV1406 TCR retroviral vector and were enriched for CD34-
expressing cells. T2 cells were loaded with 10 µg/mL HCV NS3:1406-1415, alanine 
substituted peptides (isoleucine substitutions at positions 4 and 9), or tyrosinase:368-
376. IFNγ release was determined by ELISA. Mean and standard deviation of triplicate 
measurements are shown. These data are a representative of two independent 
experiments using two donors each. 
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Figure 95. HCV1406 TCR-transduced Jurkat and Jurkat76 cells exhibit similar cross-
reactive profiles against alanine-substituted HCV NS3:1406-1415 peptides. (a) Jurkat or 
(b) Jurkat76 cells were transduced with the HCV1406 TCR retroviral vector. Transduced 
cells were enriched for CD34-expression. T2 cells were loaded with 10 µg/mL HCV 
NS3:1406-1415, alanine substituted peptides (isoleucine substitutions at positions 4 and 
9), or tyrosinase:368-376. IFNγ release was determined by ELISA. Mean and standard 
deviation of triplicate measurements are shown. These data are representative of two 
independent experiments. 
  
a) 
b) 
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Table 16. Comparison of cross-reactive profiles against alanine-substituted HCV 
NS3:1406-1415 peptides.  
Epitope Sequence PBL* 
WT Jurkat Jurkat76 
CD8– CD8+ CD8– CD8+ 
Tyrosinase YMDGTMSQV    - -   -   - 
HCV1406wt KLVALGINAV +++ +++ +++   +++   +++ 
K1406A ALVALGINAV - - -   -   - 
L1407A KAVALGINAV ++ +++ +++   ++   ++ 
V1408A KLAALGINAV ++ ++ +++   +   + 
A1409I KLVILGINAV ++ + ++   +   ++ 
L1410A KLVAAGINAV ++ + ++   +   ++ 
G1411A KLVALAINAV - - -   -   - 
I1412A KLVALGANAV  + - +   -   - 
N1413A KLVALGIAAV  +++ +++ +++   +++   +++ 
A1414I KLVALGINIV  +++ +++ +++   +++   +++ 
V1415A KLVALGINAA  +++ +++ +++   +++   +++ 
*Two donor average 
+++ = >75% WT reactivity; ++ = 25-75% WT reactivity; + = 25-5% WT reactivity; - <5% WT 
reactivity 
These data portray comparisons of cytokine release shown in Figures 94-95 and are a 
representative of two independent experiments.
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